<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REYATAZÂ - atazanavir sulfateÂ capsule, gelatin coatedÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use REYATAZ safely and effectively. See full prescribing information for REYATAZ.<br>REYATAZ<span class="Sup">Â®</span> (atazanavir sulfate) Capsules<br> Initial U.S. Approval: 2003</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta">Dosage and Administration <a href="#Section_2.2">(2.2)</a>Â Â Â Â  10/2011 </p>
<p class="Highlighta">Dosage and Administration <a href="#Section_2.3">(2.3)</a>Â Â Â Â  02/2011 </p>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">REYATAZ is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. <a href="#Section_1">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Treatment-naive patients: </span>REYATAZ 300 mg with ritonavir 100 mg once daily with food or REYATAZ 400 mg once daily with food.  When coadministered with tenofovir, the recommended dose is REYATAZ 300 mg with ritonavir 100 mg. <a href="#Section_2.1">(2.1)</a>
</li>
<li>
<span class="Italics">Treatment-experienced patients:</span> REYATAZ 300 mg with ritonavir 100 mg once daily with food. <a href="#Section_2.1">(2.1)</a>
</li>
<li>
<span class="Italics">Pediatric patients (6 to less than 18 years of age):</span> Dosage is based on body weight not to exceed the adult dose. <a href="#Section_2.2">(2.2)</a>
</li>
<li>
<span class="Italics">Pregnancy:</span> REYATAZ 300 mg with ritonavir 100 mg once daily with food, with dosing modifications for some concomitant medications. <a href="#Section_2.3">(2.3)</a>
</li>
<li>
<span class="Italics">Concomitant therapy:</span> Dosing modifications may be required. <a href="#Section_2.1">(2.1</a>, <a href="#Section_7">7)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Dosing modifications may be required. <a href="#Section_2.4">(2.4)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> Dosing modifications may be required. <a href="#Section_2.5">(2.5)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Capsules: 100 mg, 150 mg, 200 mg, 300 mg. <a href="#Section_3">(3</a>, <a href="#Section_16">16)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>REYATAZ is contraindicated in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (eg, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span>) to any of the components of this product. <a href="#Section_4">(4)</a>
</li>
<li>Coadministration with alfuzosin, triazolam, orally administered midazolam, ergot derivatives, rifampin, irinotecan, lovastatin, simvastatin, indinavir, cisapride, pimozide, St. Johnâ€™s wort, and sildenafil when dosed as REVATIO<span class="Sup">Â®</span>. <a href="#Section_4">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Cardiac conduction abnormalities:</span> PR interval prolongation may occur in some patients. Use with caution in patients with preexisting conduction system disease or when administered with other drugs that may prolong the PR interval. <a href="#Section_5.2">(5.2</a>, <a href="#Section_6.4">6.4</a>, <a href="#Section_7.3">7.3</a>, <a href="#Section_12.2">12.2</a>, <a href="#Section_17.3">17.3)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>:</span> Discontinue if severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> develops. <a href="#Section_5.3">(5.3</a>, <a href="#Section_6.4">6.4</a>, <a href="#Section_17.4">17.4)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span>:</span> Most patients experience asymptomatic increases in indirect bilirubin, which is reversible upon discontinuation. Do not dose reduce. If a concomitant transaminase increase occurs, evaluate for alternative etiologies. <a href="#Section_5.4">(5.4</a>, <a href="#Section_6.2">6.2)</a>
</li>
<li>
<span class="Italics">Hepatotoxicity:</span> REYATAZ should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> <a href="#Section_5.5">(5.5)</a>. Patients with <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> are at risk of increased transaminases or hepatic decompensation. Monitor hepatic laboratory tests prior to therapy and during treatment. <a href="#Section_2.5">(2.5</a>, <a href="#Section_5.5">5.5</a>, <a href="#Section_6.3">6.3</a>, <a href="#Section_6.4">6.4</a>, <a href="#Section_8.8">8.8)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span></span> has been reported. Consider temporary interruption or discontinuation. <a href="#Section_5.6">(5.6</a>, <a href="#Section_6.4">6.4)</a>
</li>
<li>Patients receiving REYATAZ may develop new onset or exacerbations of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> <a href="#Section_5.7">(5.7</a>, <a href="#Section_6.4">6.4)</a>, <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span> <a href="#Section_5.8">(5.8)</a>, and redistribution/accumulation of body fat. <a href="#Section_5.9">(5.9)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span>:</span> Spontaneous <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> may occur and additional factor VIII may be required. <a href="#Section_5.10">(5.10)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (â‰¥2%) are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>/<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, peripheral <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. <a href="#Section_6.1">(6.1</a>, <a href="#Section_6.2">6.2)</a> </p>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Coadministration of REYATAZ can alter the concentration of other drugs and other drugs may alter the concentration of atazanavir. The potential drug-drug interactions must be considered prior to and during therapy. <a href="#Section_4">(4</a>, <a href="#Section_5.1">5.1</a>, <a href="#Section_7">7</a>, <a href="#Section_12.3">12.3)</a> </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>
<span class="Italics">Pregnancy:</span>  Use only if the potential benefit justifies the potential risk. Physicians are encouraged to register patients in the Antiretroviral Pregnancy Registry. <a href="#Section_8.1">(8.1)</a>
</li>
<li>
<span class="Italics">Nursing mothers</span> should be instructed not to breast-feed due to the potential for postnatal HIV transmission. <a href="#Section_8.3">(8.3)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B or C co-<span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>:</span> Monitor liver enzymes. <a href="#Section_5.5">(5.5</a>, <a href="#Section_6.3">6.3)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Do not use in treatment-experienced
patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> managed with hemodialysis. <a href="#Section_2.4">(2.4</a>, <a href="#Section_8.7">8.7)</a>
</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> REYATAZ should be used with caution in patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Do not use REYATAZ in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. REYATAZ/ritonavir is not recommended. <a href="#Section_2.5">(2.5</a>, <a href="#Section_8.8">8.8)</a>
</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 2/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Adult Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Recommended Pediatric Dosage</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Pregnancy</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-3" class="toc">3  DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Drug Interactions</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Cardiac Conduction Abnormalities</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Hepatotoxicity</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Fat Redistribution</a></h2>
<h2><a href="#section-5.10" class="toc">5.10 <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11 Resistance/Cross-Resistance</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trial Experience in Adults</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Trial Experience in Pediatric Patients</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Patients Co-infected With <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus</a></h2>
<h2><a href="#section-6.4" class="toc">6.4 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potential for REYATAZ to Affect Other Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Potential for Other Drugs to Affect Atazanavir</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Established and Other Potentially Significant Drug Interactions</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Drugs with No Observed or Predicted Interactions with REYATAZ</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Age/Gender</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Impaired Hepatic Function</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology </a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Adult Patients Without Prior Antiretroviral Therapy</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Adult Patients With Prior Antiretroviral Therapy</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Pediatric Patients</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1 Dosing Instructions</a></h2>
<h2><a href="#section-15.2" class="toc">17.2 Drug Interactions </a></h2>
<h2><a href="#section-15.3" class="toc">17.3 Cardiac Conduction Abnormalities</a></h2>
<h2><a href="#section-15.4" class="toc">17.4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></a></h2>
<h2><a href="#section-15.5" class="toc">17.5 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></a></h2>
<h2><a href="#section-15.6" class="toc">17.6 Fat Redistribution</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">REYATAZ<span class="Sup">Â®</span> (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age.</p>
<p>The following points should be considered when initiating therapy with REYATAZ:</p>
<ul class="Disc">
<li>In Study AI424-045, REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and  lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection [see <span class="Italics">Clinical Studies <a href="#Section_14.2">(14.2)</a></span>].</li>
<li>The number of baseline primary protease inhibitor mutations affects the virologic response to REYATAZ/ritonavir [see <span class="Italics">Clinical Pharmacology <a href="#Section_12.4">(12.4)</a></span>].</li>
</ul>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<p class="First">General Dosing Recommendations:</p>
<ul class="Disc">
<li>REYATAZ Capsules must be taken with food.</li>
<li>Do not open the capsules.</li>
<li>The recommended oral dosage of REYATAZ depends on the treatment history of the patient and the use of other coadministered drugs. When coadministered with  H<span class="Sub">2</span>-receptor antagonists or proton-pump inhibitors, dose separation may be required [see <span class="Italics">Dosage and Administration <a href="#Section_2.1">(2.1)</a></span>].</li>
<li>When coadministered with didanosine buffered or enteric-coated formulations, REYATAZ should be given (with food) 2 hours before or 1 hour after didanosine.</li>
<li>REYATAZ without ritonavir is not recommended for treatment-experienced adult or pediatric patients with prior virologic failure [see <span class="Italics">Clinical Studies <a href="#Section_14">(14)</a></span>].</li>
<li>Efficacy and safety of REYATAZ with ritonavir in doses greater than 100 mg once daily have not been established. The use of higher ritonavir doses might alter the safety profile of atazanavir (cardiac effects, <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>) and, therefore, is not recommended. Prescribers should consult the complete prescribing information for NORVIR<span class="Sup">Â®</span> (ritonavir) when using this agent.</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Adult Dosage</h2>
<p class="First">Table 1 summarizes the recommended REYATAZ dosing regimen in adults. All REYATAZ dosing regimens are to be administered as a single dose with food.</p>
<a name="i1c141bff-ef87-4e90-8684-2fae7638cdcd"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 1: REYATAZ Dosing Regimens</span></caption>
<colgroup>
<col width="46%">
<col width="54%">
</colgroup>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" colspan="1"><span class="Bold">Treatment-Naive Patients</span></td>
<td class="Botrule Toprule" align="left" colspan="1"><span class="Bold">REYATAZ 300 mg with ritonavir 100 mg once daily
														</span></td>
</tr>
<tr>
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â If unable to tolerate ritonavir</td>
<td class="Botrule" align="left" colspan="1" rowspan="1"><span class="Bold">REYATAZ 400 mg once daily</span></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â When combined with any of the following:<br>Â Â Â Tenofovir<br>Â Â Â H<span class="Sub">2</span>-receptor antagonist<br>Â Â Â Proton-pump inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="Bold">REYATAZ 300 mg with ritonavir 100 mg once daily</span></td>
</tr>
<tr><td class="Botrule" align="left" colspan="2" rowspan="1">Â Â Â â€¢Â The H<span class="Sub">2</span>-receptor antagonist dose should not exceed a dose comparable to famotidine 40 mg twice daily.<br>Â Â Â Â  Administer REYATAZ and ritonavir simultaneously with, and/or at least 10 hours after the H<span class="Sub">2</span>-receptor<br>Â Â Â Â  antagonist.<br>Â Â Â â€¢Â If unable to tolerate ritonavir, administer REYATAZ 400 mg once daily at least 2 hours before and at least<br>Â Â Â Â  10 hours after the H<span class="Sub">2</span>-receptor antagonist. No single dose of the H<span class="Sub">2</span>-receptor antagonist should exceed a dose<br>Â Â Â Â  comparable to famotidine 20 mg and the total daily dose should not exceed a dose comparable to famotidine <br>Â Â Â Â  40 mg.<br>Â Â Â â€¢Â The proton-pump inhibitor dose should not exceed a dose comparable to omeprazole 20 mg daily and must <br>Â Â Â Â   be taken approximately 12 hours prior to REYATAZ and ritonavir.</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â Â When combined with efavirenz</td>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="Bold">REYATAZ 400 mg with ritonavir 100 mg once daily</span></td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Â Â Â â€¢Â Efavirenz should be administered on an empty stomach, preferably at bedtime.</td></tr>
<tr>
<td class="Botrule Toprule" align="left" colspan="1"><span class="Bold">Treatment-Experienced Patients</span></td>
<td class="Botrule Toprule" align="left" colspan="1"><span class="Bold">REYATAZ 300 mg with ritonavir 100 mg once daily</span></td>
</tr>
<tr><td class="Botrule" align="left" colspan="2" rowspan="1">Â Â Â Do not coadminister with proton-pump inhibitors or efavirenz in treatment-experienced patients.</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â Â When given with an H<span class="Sub">2</span>-receptor antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="Bold">REYATAZ 300 mg with ritonavir 100 mg once daily</span></td>
</tr>
<tr><td class="Botrule" align="left" colspan="2" rowspan="1">Â Â Â â€¢Â The H<span class="Sub">2</span>-receptor antagonist dose should not exceed a dose comparable to famotidine 20 mg twice daily.<br>Â Â Â Â  Administer REYATAZ and ritonavir simultaneously with, and/or at least 10 hours after the H<span class="Sub">2</span>-receptor<br>Â Â Â Â  antagonist.</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Â Â Â When given with both tenofovir<span class="Italics">and</span> an H<span class="Sub">2</span>-receptor antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top"><span class="Bold">REYATAZ 400 mg with ritonavir 100 mg once daily</span></td>
</tr>
<tr class="Last"><td align="left" colspan="2" rowspan="1">Â Â Â â€¢Â The H<span class="Sub">2</span>-receptor antagonist dose should not exceed a dose comparable to famotidine 20 mg twice daily.<br>Â Â Â Â  Administer REYATAZ and ritonavir simultaneously with, and/or at least 10 hours after the H<span class="Sub">2</span>-receptor<br>Â Â Â Â  antagonist.</td></tr>
</tbody>
</table>
<p>[For these drugs and other antiretroviral agents for which dosing modification may be appropriate, see <span class="Italics"> Drug Interactions <a href="#Section_7">(7)</a></span>.]
										</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Recommended Pediatric Dosage</h2>
<p class="First" style="border-left:1px solid;">The recommended <span class="XmChange">daily</span> dosage of REYATAZ for pediatric patients (6 to less than 18 years of age) is based on body weight and should not exceed the recommended adult dosage. REYATAZ Capsules must be taken with food. The data are insufficient to recommend dosing of REYATAZ for any of the following: (1) patients less than 6 years of age, (2) <span class="Underline">without ritonavir</span> in <span class="XmChange">any pediatric</span> patient less than 13 years of age, and (3) patients less than 40 kg receiving concomitant tenofovir, H<span class="Sub">2</span>-receptor antagonists, or proton-pump inhibitors.
								</p>
<p style="border-left:1px solid;">The recommended dosage of REYATAZ with ritonavir in <span class="XmChange">pediatric</span> patients at least 6 years of age is shown in Table 2.</p>
<a name="i6817e1b9-a82d-473f-8f7b-98e55bc028a3"></a><table border="0" cellpadding="2" width="100%">
<caption><span>Table 2: Dosage for Pediatric Patients (6 to less than 18 years of age) for REYATAZ Capsules with ritonavir<span class="Sup">a</span></span></caption>
<thead><tr class="First Last">
<th class="Toprule" align="center"><span class="Bold"><span class="XmChange">Body Weight</span></span></th>
<th class="Toprule" align="center"><span class="Bold"><span class="XmChange">REYATAZ dose</span></span></th>
<th class="Toprule" align="center"><span class="Bold"><span class="XmChange">ritonavir dose</span></span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Toprule" align="left" colspan="3" rowspan="1"><span class="XmChange"><span class="Sup">a</span> The REYATAZ and ritonavir dose should be taken once daily with food.</span></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center" colspan="1" rowspan="1"><span class="XmChange">15 kg to less than 20 kg</span></td>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">150 mg</span></td>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">100 mg</span></td>
</tr>
<tr>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">20 kg to less than 40 kg</span></td>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">200 mg</span></td>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">100 mg</span></td>
</tr>
<tr class="Last">
<td align="center" colspan="1" rowspan="1"><span class="XmChange">at least 40 kg</span></td>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">300 mg</span></td>
<td align="center" colspan="1" rowspan="1"><span class="XmChange">100 mg</span></td>
</tr>
</tbody>
</table>
<p>For treatment-naive patients at least 13 years of age and at least 40 kg, who are unable to tolerate ritonavir, the recommended dose is REYATAZ 400 mg (without ritonavir) once daily with food. For patients at least 13 years of age and at least 40 kg receiving concomitant tenofovir, H<span class="Sub">2</span>-receptor antagonists, or proton-pump inhibitors, REYATAZ should not be administered without ritonavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Pregnancy</h2>
<p class="First" style="border-left:1px solid;"><span class="Italics" style="border-left:1px solid;"><span class="XmChange">Dosing During Pregnancy and the Postpartum Period:</span></span></p>
<ul>
<li style="border-left:1px solid;"><span class="XmChange">REYATAZ should not be administered without ritonavir.</span></li>
<li style="border-left:1px solid;"><span class="XmChange">REYATAZ should only be administered to pregnant women with HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> susceptible to atazanavir.</span></li>
<li style="border-left:1px solid;">
<span class="XmChange">For pregnant patients, no dose adjustment is required for REYATAZ with the following exceptions:</span><ul><li style="border-left:1px solid;">
<span class="XmChange">For treatment-experienced pregnant women during the second or third trimester, when REYATAZ is</span><br><span class="XmChange">coadministered with either an H<span class="Sub">2</span>-receptor antagonist <span class="Bold">or</span> tenofovir, REYATAZ 400 mg with ritonavir</span><br><span class="XmChange"> 100 mg once daily is recommended. There are insufficient data to recommend a REYATAZ dose</span><br><span class="XmChange"> for use with both an H<span class="Sub">2</span>-receptor antagonist <span class="Italics">and</span> tenofovir in treatment-experienced pregnant</span><br><span class="XmChange"> women.</span>
</li></ul>
</li>
<li style="border-left:1px solid;">
<span class="XmChange">No dose adjustment is required for postpartum patients. However, patients should be closely monitored for</span><br><span class="XmChange"> adverse events because atazanavir exposures could be higher during the first 2 months after delivery. [See</span><br><span class="XmChange"><span class="Italics"> Use in Specific Populations <a href="#Section_8.1">(8.1)</a></span> and <span class="Italics"> Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span>.]</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">For patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, including those with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who are not managed with hemodialysis, no dose adjustment is required for REYATAZ. Treatment-naive patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> managed with hemodialysis should receive REYATAZ 300 mg with ritonavir 100 mg. <span class="Underline">REYATAZ should not be administered to HIV-treatment-experienced patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> managed with hemodialysis.</span> [See <span class="Italics">Use in Specific Populations <a href="#Section_8.7">(8.7)</a></span>.]
								</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">REYATAZ should be used with caution in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.  For patients with moderate
<span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class B) who have not experienced prior virologic failure, a dose reduction to 300 mg once daily should be considered.  REYATAZ should not be used in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh Class C). REYATAZ/ritonavir has not been studied in subjects with hepatic
impairment and is not recommended. [See <span class="Italics">Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span> and <span class="Italics">Use in Specific Populations <a href="#Section_8.8">(8.8)</a>.</span>]
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3  DOSAGE FORMS AND STRENGTHS</h1>
<ul class="Disc">
<li>100 mg capsule with blue cap and white body, printed with white ink â€œBMS 100 mgâ€? on the cap and with blue ink â€œ3623â€? on the body.</li>
<li>150 mg capsule with blue cap and powder blue body, printed with white ink â€œBMS 150 mgâ€? on the cap and with blue ink â€œ3624â€? on the body.</li>
<li>200 mg capsule with blue cap and blue body, printed with white ink â€œBMS 200 mgâ€? on the cap and with white ink â€œ3631â€? on the body.</li>
<li>300 mg capsule with red cap and blue body, printed with white ink â€œBMS 300 mgâ€? on the cap and with white ink â€œ3622â€? on the body.</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">REYATAZ (atazanavir sulfate) is contraindicated:</p>
<ul class="Disc">
<li>in patients with previously demonstrated clinically significant <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (eg, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, or <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span>) to any of the components of this product.</li>
<li>when coadministered with drugs that are highly dependent on CYP3A or UGT1A1 for clearance, and for which elevated plasma concentrations are associated with serious and/or life-threatening events. These and other contraindicated drugs are listed in Table 3.</li>
</ul>
<a name="iebb43964-3086-4307-8ed8-f24f992b2ca0"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 3: Drugs That Are Contraindicated with REYATAZ (atazanavir) (Information in the table applies to REYATAZ with or without ritonavir, unless otherwise indicated)</span></caption>
<colgroup>
<col width="19%">
<col width="21%">
<col width="60%">
</colgroup>
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Drug Class</span></th>
<th class="Botrule Toprule" align="left" valign="bottom"><span class="Bold">Drugs within class that are contraindicated with REYATAZ</span></th>
<th class="Botrule Toprule" align="center" valign="bottom"><span class="Bold">Clinical Comment</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="3" valign="top">
<span class="Sup">a</span> See <span class="Italics"><a href="#Section_7">Drug Interactions, Table 13 (7)</a></span> for parenterally administered midazolam.</td></tr>
<tr class="Last"><td class="Botrule" colspan="3" valign="top">
<span class="Sup">b</span> See <span class="Italics"><a href="#Section_7">Drug Interactions, Table 13 (7)</a></span> for sildenafil when dosed as VIAGRA<span class="Sup">Â®</span> for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1" valign="top">Alpha 1-Adrenoreceptor Antagonist</td>
<td align="left" colspan="1" rowspan="1" valign="top">Alfuzosin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for increased alfuzosin concentrations, which can result in <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span>Antimycobacterials</span></td>
<td align="left" colspan="1" rowspan="1" valign="top">Rifampin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Rifampin substantially decreases plasma concentrations of atazanavir, which may result in loss of therapeutic effect and development of resistance.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span>Antineoplastics</span></td>
<td align="left" colspan="1" rowspan="1" valign="top">Irinotecan</td>
<td align="left" colspan="1" rowspan="1" valign="top">Atazanavir inhibits UGT1A1 and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top"><span>Benzodiazepines</span></td>
<td align="left" colspan="1" rowspan="1" valign="top">Triazolam, orally administered midazolam<span class="Sup">a</span>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">Triazolam and orally administered midazolam are extensively metabolized by CYP3A4. Coadministration of triazolam or orally administered midazolam with REYATAZ may cause large increases in the concentration of these benzodiazepines. Potential for serious and/or life-threatening events such as prolonged or increased sedation or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Ergot Derivatives</td>
<td align="left" colspan="1" rowspan="1" valign="top">Dihydroergotamine, ergotamine, ergonovine, methylergonovine</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for serious and/or life-threatening events such as acute ergot toxicity characterized by peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> and <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities and other tissues.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GI Motility Agent</td>
<td align="left" colspan="1" rowspan="1" valign="top">Cisapride</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Herbal Products</td>
<td align="left" colspan="1" rowspan="1" valign="top">St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>)</td>
<td align="left" colspan="1" rowspan="1" valign="top">Patients taking REYATAZ should not use products containing St. Johnâ€™s wort because coadministration may be expected to reduce plasma concentrations of atazanavir. This may result in loss of therapeutic effect and development of resistance.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">HMG-CoA Reductase Inhibitors</td>
<td align="left" colspan="1" rowspan="1" valign="top">Lovastatin, simvastatin</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for serious reactions such as <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">Neuroleptic</td>
<td align="left" colspan="1" rowspan="1" valign="top">Pimozide</td>
<td align="left" colspan="1" rowspan="1" valign="top">Potential for serious and/or life-threatening reactions such as <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">PDE5 Inhibitor</td>
<td align="left" colspan="1" rowspan="1" valign="top">Sildenafil<span class="Sup">b</span> when dosed as REVATIO<span class="Sup">Â®</span> for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span></td>
<td align="left" colspan="1" rowspan="1" valign="top">A safe and effective dose in combination with REYATAZ has not been established for sildenafil (REVATIO<span class="Sup">Â®</span>) when used for the treatment of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>. There is increased potential for sildenafil-associated adverse events (which include <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>).</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1" valign="top">Protease Inhibitors</td>
<td class="Botrule" align="left" colspan="1" rowspan="1" valign="top">Indinavir</td>
<td class="Botrule" align="left" colspan="1" rowspan="1" valign="top">Both REYATAZ and indinavir are associated with indirect (unconjugated) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span>.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Drug Interactions</h2>
<p class="First">See Table 3 for a listing of drugs that are contraindicated for use with REYATAZ due to potentially life-threatening
adverse events, significant drug interactions, or loss of virologic activity. [See <span class="Italics">Contraindications <a href="#Section_4">(4)</a></span>.] Please refer to Table 13 for established and other potentially significant drug interactions [see <span class="Italics">Drug Interactions <a href="#Section_7.3">(7.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Cardiac Conduction Abnormalities</h2>
<p class="First">Atazanavir has been shown to prolong the PR interval of the electrocardiogram in some patients. In healthy volunteers and in patients, abnormalities in atrioventricular (AV) conduction were asymptomatic and generally limited to first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. There have been reports of second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> and other conduction abnormalities [see <span class="Italics">Adverse Reactions <a href="#Section_6.4">(6.4)</a></span> and <span class="Italics">Overdosage <a href="#Section_10">(10)</a></span>]. In clinical trials that included electrocardiograms, asymptomatic first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> was observed in 5.9% of atazanavir-treated patients (n=920), 5.2% of lopinavir/ritonavir-treated patients (n=252), 10.4% of nelfinavir-treated patients (n=48), and 3.0% of efavirenz-treated patients (n=329). In Study AI424-045, asymptomatic first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> was observed in 5% (6/118) of atazanavir/ritonavir-treated patients and 5% (6/116) of lopinavir/ritonavir-treated patients who had on-study electrocardiogram measurements. Because of limited clinical experience in patients with preexisting conduction system disease (eg, marked first-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span> or second- or third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>), atazanavir should be used with caution in these patients. [See <span class="Italics">Clinical Pharmacology <a href="#Section_12.2">(12.2)</a></span>.]</p>
<p>Atazanavir in combination with diltiazem increased diltiazem plasma concentration by 2-fold with an additive effect on the PR interval. When used in combination with atazanavir, a dose reduction of diltiazem by one-half should be considered and ECG monitoring is recommended. In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, no clinically significant additive effect of atazanavir and atenolol on the PR interval was observed. Dose adjustment of atenolol is not required when used in combination with atazanavir. [See <span class="Italics">Drug Interactions <a href="#Section_12.5">(7)</a></span> and <span class="Italics">Clinical Pharmacology <a href="#Section_12.2">(12.2)</a></span>.] Pharmacokinetic studies between atazanavir and other drugs that prolong the PR interval including beta blockers [other than atenolol, see <span class="Italics">Drug Interactions <a href="#Section_7">(7)</a></span>], verapamil, and digoxin have not been performed. An additive effect of atazanavir and these drugs cannot be excluded; therefore, caution should be exercised when atazanavir is given concurrently with these drugs, especially those that are metabolized by CYP3A (eg, verapamil).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">In controlled clinical trials, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (all grades, regardless of causality) occurred in approximately 20% of patients
treated with REYATAZ. The median time to onset of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in clinical studies was 7.3 weeks and the median duration of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> was 1.4 weeks. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> were generally mild-to-moderate maculopapular <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin eruptions</span>. Treatment-emergent adverse reactions of moderate or severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (occurring at a rate of â‰¥2%) are presented for the individual clinical studies [see <span class="Italics">Adverse Reactions <a href="#Section_6.1">(6.1)</a></span>]. Dosing with REYATAZ was often continued without interruption in patients who developed <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. The discontinuation rate for <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in clinical trials was &lt;1%. REYATAZ should be discontinued if severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> develops. Cases of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span> have been reported in patients receiving REYATAZ. [See <span class="Italics">Contraindications <a href="#Section_4">(4)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></h2>
<p class="First">Most patients taking REYATAZ experience asymptomatic elevations in indirect (unconjugated) bilirubin related to inhibition
of UDP-glucuronosyl transferase (UGT). This <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> is reversible upon discontinuation of REYATAZ. Hepatic transaminase elevations that occur
with <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> should be evaluated for alternative etiologies. No long-term safety data are available for patients experiencing persistent elevations
in total bilirubin &gt;5 times ULN. Alternative antiretroviral therapy to REYATAZ may be considered if <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or <span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span> associated with bilirubin
elevations presents cosmetic concerns for patients. Dose reduction of atazanavir is not recommended since long-term efficacy of reduced doses has not been
established. [See <span class="Italics">Adverse Reactions <a href="#Section_6.1">(6.1</a>, <a href="#Section_6.2">6.2)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Hepatotoxicity</h2>
<p class="First">Caution should be exercised when administering REYATAZ to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> because atazanavir concentrations may be increased. [See <span class="Italics">Dosage and Administration <a href="#Section_2.5">(2.5)</a></span>.]
 Patients with underlying <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> or marked elevations in transaminases before treatment may be at increased risk for developing
further transaminase elevations or hepatic decompensation. In these patients, hepatic laboratory testing should be conducted prior to initiating therapy
with REYATAZ and during treatment. [See <span class="Italics">Adverse Reactions <a href="#Section_6.3">(6.3)</a></span> and <span class="Italics">Use in Specific Populations <a href="#Section_8.8">(8.8)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Nephrolithiasis</span></h2>
<p class="First">Cases of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> were reported during postmarketing surveillance in HIV-infected patients receiving REYATAZ
therapy. Because these events were reported voluntarily during clinical practice, estimates of frequency cannot be made. If signs or symptoms of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span>
occur, temporary interruption or discontinuation of therapy may be considered. [See <span class="Italics">Adverse Reactions <a href="#Section_6.4">(6.4)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus/<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></h2>
<p class="First">New-onset <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, exacerbation of preexisting <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> have been reported during
postmarketing surveillance in HIV-infected patients receiving protease inhibitor therapy.  Some patients required either initiation or dose adjustments of
insulin or oral hypoglycemic agents for treatment of these events. In some cases, <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> has occurred. In those patients who discontinued
protease inhibitor therapy, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> persisted in some cases.  Because these events have been reported voluntarily during clinical practice, estimates
of frequency cannot be made and a causal relationship between protease inhibitor therapy and these events has not been established. [See <span class="Italics">Adverse Reactions <a href="#Section_6.4">(6.4)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune Reconstitution Syndrome</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">Immune reconstitution syndrome</span> has been reported in patients treated with combination antiretroviral therapy, including
REYATAZ.  During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response
to indolent or residual <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> (such as <span class="Italics">Mycobacterium avium</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, cytomegalovirus, <span class="Italics">Pneumocystis jiroveci</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, or <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>), which may necessitate further evaluation and treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Fat Redistribution</h2>
<p class="First">Redistribution/accumulation of body fat including <span class="product-label-link" type="condition" conceptid="4087487" conceptname="Central obesity">central obesity</span>, dorsocervical fat enlargement (<span class="product-label-link" type="condition" conceptid="4032559" conceptname="Buffalo hump">buffalo hump</span>), peripheral
<span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, facial <span class="product-label-link" type="condition" conceptid="134765" conceptname="Cachexia">wasting</span>, <span class="product-label-link" type="condition" conceptid="78474" conceptname="Hypertrophy of breast">breast enlargement</span>, and â€œcushingoid appearanceâ€? have been observed in patients receiving antiretroviral therapy.  The mechanism
and long-term consequences of these events are currently unknown.  A causal relationship has not been established. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10 <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">Hemophilia</span></h2>
<p class="First">There have been reports of increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including spontaneous skin <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> and <span class="product-label-link" type="condition" conceptid="76784" conceptname="Hemarthrosis">hemarthrosis</span>, in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> type A and B treated with protease inhibitors. In some patients additional factor VIII was given. In more than half of the reported cases, treatment
with protease inhibitors was continued or reintroduced. A causal relationship between protease inhibitor therapy and these events has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11 Resistance/Cross-Resistance</h2>
<p class="First">Various degrees of cross-resistance among protease inhibitors have been observed. Resistance to atazanavir may not preclude the subsequent use of other protease inhibitors. [See <span class="Italics">Clinical Pharmacology <a href="#Section_12.4">(12.4)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul class="Disc">
<li>cardiac conduction abnormalities [see <span class="Italics">Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.3">(5.3)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.4">(5.4)</a></span>]</li>
<li><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.6">(5.6)</a></span>]</li>
</ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug
cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trial Experience in Adults</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.1"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold">Treatment-Emergent Adverse Reactions in Treatment-Naive Patients</span></p>
<p>The safety profile of REYATAZ in treatment-naive adults is based on 1625 HIV-1 infected patients in clinical trials. 536 patients received REYATAZ 300 mg with ritonavir 100 mg and 1089 patients received REYATAZ 400 mg or higher (without ritonavir).</p>
<p>The most common adverse reactions are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>/<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>Selected clinical adverse reactions of moderate or severe intensity reported in â‰¥2% of treatment-naive patients receiving combination therapy including REYATAZ 300 mg with ritonavir 100 mg and REYATAZ 400 mg (without ritonavir) are presented in Tables 4 and 5, respectively.</p>
<a name="i38635136-7867-4f02-8d51-530eb550757f"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 4: Selected Treatment-Emergent Adverse Reactions<span class="Sup">a</span> of Moderate or Severe Intensity Reported in â‰¥2% of Adult Treatment-Naive Patients,<span class="Sup">b</span> Study AI424-138</span></caption>
<colgroup>
<col width="30%">
<col width="35%">
<col width="35%">
</colgroup>
<thead>
<tr class="First">
<th class="Toprule">Â </th>
<th class="Toprule" align="center"><span class="Bold">96 weeks<span class="Sup">c</span></span></th>
<th class="Toprule" align="center"><span class="Bold">96 weeks<span class="Sup">c</span></span></th>
</tr>
<tr>
<th>Â </th>
<th align="center"><span class="Bold">REYATAZ 300Â mg with ritonavir<br>100 mg (once daily) and tenofovir<br>with emtricitabine<span class="Sup">d</span></span></th>
<th align="center"><span class="Bold">lopinavir 400Â mg with ritonavir<br>100 mg (twice daily)
and tenofovir<br>with emtricitabine<span class="Sup">d</span></span></th>
</tr>
<tr class="Last">
<th class="Botrule">Â </th>
<th class="Botrule" align="center"><span class="Bold">(n=441)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=437)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="3">* None reported in this treatment arm.</td></tr>
<tr><td colspan="3">
<span class="Sup">a</span> Includes events of possible, probable, certain, or unknown relationship to treatment regimen.</td></tr>
<tr><td colspan="3">
<span class="Sup">b</span> Based on the regimen containing REYATAZ.</td></tr>
<tr><td colspan="3">
<span class="Sup">c</span> Median time on therapy.</td></tr>
<tr class="Last"><td class="Botrule" colspan="3">
<span class="Sup">d</span> As a fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td><span class="Bold">Digestive System</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr>
<td>Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">4%</td>
<td align="center">8%</td>
</tr>
<tr>
<td>Â Â Â <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span>/<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span></td>
<td align="center">5%</td>
<td align="center">*</td>
</tr>
<tr>
<td>Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">2%</td>
<td align="center">12%</td>
</tr>
<tr>
<td><span class="Bold">Skin and Appendages</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr class="Last">
<td>Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">3%</td>
<td align="center">2%</td>
</tr>
</tbody>
</table>
<a name="i65cd8582-b7ea-488a-80cd-6d561ec1f5f1"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 5: Selected Treatment-Emergent Adverse Reactions<span class="Sup">a</span> of Moderate or Severe Intensity Reported in â‰¥2% of Adult Treatment-Naive Patients,<span class="Sup">b</span> Studies AI424-034, AI424-007, and AI424-008</span></caption>
<colgroup>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" rowspan="3">Â </th>
<th class="Toprule" align="center" colspan="2"><span class="Bold">Study AI424-034</span></th>
<th class="Toprule" align="center" colspan="2"><span class="Bold">Studies AI424-007, -008</span></th>
</tr>
<tr>
<th align="center" valign="bottom"><span class="Bold">64 weeks<span class="Sup">c</span><br>REYATAZ 400 mg once daily + lamivudine + zidovudine<span class="Sup">e</span></span></th>
<th align="center" valign="bottom"><span class="Bold">64 weeks<span class="Sup">c</span><br>efavirenz 600 mg once daily + lamivudine + zidovudine<span class="Sup">e</span></span></th>
<th align="center" valign="bottom"><span class="Bold">120 weeks<span class="Sup">c,d</span><br>REYATAZ 400 mg once daily + stavudine + lamivudine or didanosine</span></th>
<th align="center" valign="bottom"><span class="Bold">73 weeks<span class="Sup">c,d</span><br>nelfinavir 750 mg TID or 1250 mg BID + stavudine + lamivudine or  didanosine</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center"><span class="Bold">(n=404)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=401)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=279) </span></th>
<th class="Botrule" align="center"><span class="Bold">(n=191)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="5" rowspan="1">* None reported in this treatment arm.</td></tr>
<tr><td align="left" colspan="5" rowspan="1">
<span class="Sup">a</span> Includes events of possible, probable, certain, or unknown relationship to treatment regimen.</td></tr>
<tr><td align="left" colspan="5" rowspan="1">
<span class="Sup">b</span> Based on regimens containing REYATAZ.</td></tr>
<tr><td align="left" colspan="5" rowspan="1">
<span class="Sup">c</span> Median time on therapy.</td></tr>
<tr><td align="left" colspan="5" rowspan="1">
<span class="Sup">d</span> Includes long-term follow-up.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" rowspan="1">
<span class="Sup">e</span> As a fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.</td></tr>
</tfoot>
<tbody>
<tr class="First"><td class="Toprule" align="left" colspan="5" rowspan="1"><span class="Bold">Body as a Whole</span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
</tr>
<tr><td align="left" colspan="5" rowspan="1"><span class="Bold">Digestive System</span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" colspan="1" rowspan="1">14%</td>
<td align="center" colspan="1" rowspan="1">12%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span>/scleral<br>Â Â Â 
<span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">icterus</span></td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">*</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">*</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">16%</td>
</tr>
<tr><td align="left" colspan="5" rowspan="1"><span class="Bold">Nervous System</span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">*</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">*</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Peripheral neurologic<br>Â Â Â symptoms</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr><td align="left" colspan="5" rowspan="1"><span class="Bold">Skin and Appendages</span></td></tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">10%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">1%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.2"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold">Treatment-Emergent Adverse Reactions in Treatment-Experienced Patients</span></p>
<p>The safety profile of REYATAZ in treatment-experienced adults is based on 119 HIV-1 infected patients in clinical trials.</p>
<p>The most common adverse reactions are <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>/<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span> and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>.</p>
<p>Selected clinical adverse reactions of moderate or severe intensity reported in â‰¥2% of treatment-experienced patients receiving REYATAZ/ritonavir are presented in Table 6.</p>
<a name="ice56bfda-fb0b-4da6-8d20-3266a9237021"></a><table border="0" cellpadding="2" cellspacing="1" frame="above" width="100%">
<caption><span>Table 6: Selected Treatment-Emergent Adverse Reactions<span class="Sup">a</span> of Moderate or Severe Intensity Reported in â‰¥2% of Adult Treatment-Experienced Patients,<span class="Sup">b</span> Study AI424-045</span></caption>
<colgroup>
<col width="28%">
<col width="36%">
<col width="35%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" rowspan="2">Â </th>
<th class="Toprule" align="center"><span class="Bold">48 weeks<span class="Sup">c</span><br>REYATAZ/ritonavir 300/100 mg<br>once daily + tenofovir + NRTI</span></th>
<th class="Toprule" align="center"><span class="Bold">48 weeks<span class="Sup">c</span><br>lopinavir/ritonavir 400/100 mg<br>twice daily<span class="Sup">d</span> + tenofovir + NRTI</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center"><span class="Bold">(n=119) </span></th>
<th class="Botrule" align="center"><span class="Bold">(n=118)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1">* None reported in this treatment arm.</td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">a</span> Includes events of possible, probable, certain, or unknown relationship to treatment regimen.</td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">b</span> Based on the regimen containing REYATAZ.</td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">c</span> Median time on therapy.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" rowspan="1">
<span class="Sup">d</span> As a fixed-dose combination.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top"><td class="Toprule" align="left" colspan="3" rowspan="1"><span class="Bold">Body as a Whole</span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">*</td>
</tr>
<tr valign="top"><td align="left" colspan="3" rowspan="1"><span class="Bold">Digestive System</span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">Jaundice</span>/<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span></td>
<td align="center" colspan="1" rowspan="1">9%</td>
<td align="center" colspan="1" rowspan="1">*</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">11%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
</tr>
<tr valign="top"><td align="left" colspan="3" rowspan="1"><span class="Bold">Nervous System</span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
</tr>
<tr valign="top"><td align="left" colspan="3" rowspan="1"><span class="Bold">Musculoskeletal System</span></td></tr>
<tr class="Last" valign="top">
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule" align="center" colspan="1" rowspan="1">4%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">*</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.3"></a><a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Abnormalities in Treatment-Naive Patients</span></p>
<p>The percentages of adult treatment-naive patients treated with combination therapy including REYATAZ (atazanavir sulfate) 300 mg with ritonavir 100 mg and REYATAZ 400 mg (without ritonavir) with Grade 3â€“4 laboratory abnormalities are presented in Tables 7 and 8, respectively.</p>
<a name="i084adf93-c117-4e41-823d-88db54a77e7d"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 7: Grade 3â€“4 Laboratory Abnormalities Reported in â‰¥2% of Adult Treatment-Naive Patients,<span class="Sup">a</span> Study AI424-138 </span></caption>
<colgroup>
<col width="22%">
<col width="16%">
<col width="31%">
<col width="31%">
</colgroup>
<tfoot>
<tr class="First"><td class="Toprule" colspan="4">
<span class="Sup">a</span> Based on the regimen containing REYATAZ.</td></tr>
<tr><td colspan="4">
<span class="Sup">b</span> Median time on therapy.</td></tr>
<tr><td colspan="4">
<span class="Sup">c</span> ULN = upper limit of normal.</td></tr>
<tr class="Last"><td class="Botrule" colspan="4">
<span class="Sup">d</span> As a fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily.</td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Toprule" align="left" rowspan="3" valign="bottom"><span class="Bold">Variable</span></td>
<td class="Botrule Toprule" align="center" rowspan="3" valign="bottom"><span class="Bold"> Limit<span class="Sup">c</span></span></td>
<td class="Toprule" align="center"><span class="Bold">96 weeks<span class="Sup">b</span></span></td>
<td class="Toprule" align="center"><span class="Bold">96 weeks<span class="Sup">b</span></span></td>
</tr>
<tr>
<td align="center"><span class="Bold">REYATAZ 300 mg<br>with ritonavir 100 mg<br>(once daily) and tenofovir<br>with emtricitabine<span class="Sup">d</span></span></td>
<td align="center"><span class="Bold">lopinavir 400 mg<br>with ritonavir 100 mg<br>(twice daily) and tenofovir<br>with emtricitabine<span class="Sup">d</span></span></td>
</tr>
<tr>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">(n=441)</span></td>
<td class="Botrule" align="center" valign="bottom"><span class="Bold">(n=437)</span></td>
</tr>
<tr>
<td>Chemistry</td>
<td align="center"><span class="Underline">High</span></td>
<td>Â </td>
<td>Â </td>
</tr>
<tr>
<td>Â Â Â <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST</td>
<td align="center">â‰¥5.1 x ULN</td>
<td align="center">3%</td>
<td align="center">1%</td>
</tr>
<tr>
<td>Â Â Â SGPT/ALT</td>
<td align="center">â‰¥5.1 x ULN</td>
<td align="center">3%</td>
<td align="center">2%</td>
</tr>
<tr>
<td>Â Â Â Total Bilirubin</td>
<td align="center">â‰¥2.6 x ULN</td>
<td align="center">44%</td>
<td align="center">&lt;1%</td>
</tr>
<tr>
<td>Â Â Â Lipase</td>
<td align="center">â‰¥2.1 x ULN</td>
<td align="center">2%</td>
<td align="center">2%</td>
</tr>
<tr>
<td>Â Â Â Creatine Kinase</td>
<td align="center">â‰¥5.1 x ULN</td>
<td align="center">8%</td>
<td align="center">7%</td>
</tr>
<tr>
<td>Â Â Â Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center">â‰¥240 mg/dL</td>
<td align="center">11%</td>
<td align="center">25%</td>
</tr>
<tr>
<td>Hematology</td>
<td align="center"><span class="Underline">Low</span></td>
<td align="center">Â </td>
<td align="center">Â </td>
</tr>
<tr class="Last">
<td>Â Â Â <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td align="center">&lt;750 cells/mm<span class="Sup">3</span>
</td>
<td align="center">5%</td>
<td align="center">2%</td>
</tr>
</tbody>
</table>
<a name="ica7b3a29-9829-4cd3-81e3-0f5867f52ab1"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 8: Grade 3â€“4 Laboratory Abnormalities Reported in â‰¥2% of Adult Treatment-Naive Patients,<span class="Sup">a</span> Studies AI424-034, AI424-007, and AI424-008</span></caption>
<colgroup>
<col width="19%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="18%">
<col width="18%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" align="left" rowspan="4" valign="bottom"><span class="Bold">Variable</span></th>
<th class="Botrule Toprule" rowspan="4" valign="bottom"><span class="Bold"> Limit<span class="Sup">d</span></span></th>
<th class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold"><span class="Bold">Study AI424-034</span></span></th>
<th class="Toprule" align="center" colspan="2" valign="bottom"><span class="Bold"><span class="Bold">Studies AI424-007, -008</span></span></th>
</tr>
<tr>
<th align="center" valign="bottom"><span class="Bold">64 weeks<span class="Sup">b</span></span></th>
<th align="center" valign="bottom"><span class="Bold">64 weeks<span class="Sup">b</span></span></th>
<th align="center" valign="bottom"><span class="Bold">120 weeks<span class="Sup">b,c</span></span></th>
<th align="center" valign="bottom"><span class="Bold">73 weeks<span class="Sup">b,c</span></span></th>
</tr>
<tr>
<th align="center" valign="top"><span class="Bold">REYATAZ<br>400 mg<br>once daily<br>+ lamivudine<br>+ zidovudine<span class="Sup">e</span></span></th>
<th align="center" valign="top"><span class="Bold">efavirenz<br>600 mg<br>once daily<br>+ lamivudine<br>+ zidovudine<span class="Sup">e</span></span></th>
<th align="center" valign="top"><span class="Bold">REYATAZ<br>400 mg<br>once daily<br>+ stavudine<br>+ lamivudine or<br>+ stavudine<br>+ didanosine</span></th>
<th align="center" valign="top"><span class="Bold">nelfinavir<br>750 mg TID or<br>1250 mg BID<br>+ stavudine<br>+ lamivudine or<br>+ stavudine<br>+ didanosine</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=404)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=401)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=279) </span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=191)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="6" rowspan="1">* None reported in this treatment arm.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">a</span> Based on regimen(s) containing REYATAZ.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">b</span> Median time on therapy.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">c</span> Includes long-term follow-up.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">d</span> ULN = upper limit of normal.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="6" rowspan="1">
<span class="Sup">e</span> As a fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1">Chemistry</td>
<td align="center" colspan="1" rowspan="1"><span class="Underline">High</span></td>
<td align="left" colspan="4" rowspan="1">Â </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST</td>
<td align="center" colspan="1" rowspan="1">â‰¥5.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â SGPT/ALT</td>
<td align="center" colspan="1" rowspan="1">â‰¥5.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">9%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Total Bilirubin</td>
<td align="center" colspan="1" rowspan="1">â‰¥2.6 x ULN</td>
<td align="center" colspan="1" rowspan="1">35%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">47%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Amylase</td>
<td align="center" colspan="1" rowspan="1">â‰¥2.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">*</td>
<td align="center" colspan="1" rowspan="1">*</td>
<td align="center" colspan="1" rowspan="1">14%</td>
<td align="center" colspan="1" rowspan="1">10%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Lipase</td>
<td align="center" colspan="1" rowspan="1">â‰¥2.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Creatine Kinase</td>
<td align="center" colspan="1" rowspan="1">â‰¥5.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">11%</td>
<td align="center" colspan="1" rowspan="1">9%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center" colspan="1" rowspan="1">â‰¥240 mg/dL</td>
<td align="center" colspan="1" rowspan="1">6%</td>
<td align="center" colspan="1" rowspan="1">24%</td>
<td align="center" colspan="1" rowspan="1">19%</td>
<td align="center" colspan="1" rowspan="1">48%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Triglycerides</td>
<td align="center" colspan="1" rowspan="1">â‰¥751 mg/dL</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">2%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hematology</td>
<td align="center" colspan="1" rowspan="1"><span class="Underline">Low</span></td>
<td align="left" colspan="4" rowspan="1">Â </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Hemoglobin</td>
<td align="center" colspan="1" rowspan="1">&lt;8.0 g/dL</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">4%</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td align="center" colspan="1" rowspan="1">&lt;750 cells/mm<span class="Sup">3</span>
</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">9%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.4"></a><a name="section-6.1.4"></a><p></p>
<p class="First"><span class="Bold">Laboratory Abnormalities in Treatment-Experienced Patients</span></p>
<p>The percentages of adult treatment-experienced patients treated with combination therapy including REYATAZ/ritonavir with Grade 3â€“4 laboratory abnormalities are presented in Table 9.</p>
<a name="ib35f2524-befa-4dcb-82e4-f265eaf8188c"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 9: Grade 3â€“4 Laboratory Abnormalities Reported in â‰¥2% of Adult Treatment-Experienced Patients, Study AI424-045<span class="Sup">a</span></span></caption>
<colgroup>
<col width="25%">
<col width="21%">
<col width="27%">
<col width="27%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="left" rowspan="3"><span class="Bold">Variable</span></th>
<th class="Botrule Toprule" align="center" rowspan="3"><span class="Bold">Limit<span class="Sup">c</span></span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">48 weeks<span class="Sup">b</span></span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">48 weeks<span class="Sup">b</span></span></th>
</tr>
<tr valign="bottom">
<th align="center" colspan="1" rowspan="1"><span class="Bold">REYATAZ/ritonavir<br>300/100Â mg once daily<br>+ tenofovir + NRTI</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">lopinavir/ritonavir<br>400/100Â mg twice daily<span class="Sup">d</span><br>+ tenofovirÂ +Â NRTI</span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=119)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=118)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="4" rowspan="1">
<span class="Sup">a</span> Based on regimen(s) containing REYATAZ.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">b</span> Median time on therapy.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">c</span> ULN = upper limit of normal.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" rowspan="1">
<span class="Sup">d</span> As a fixed-dose combination.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1">Chemistry</td>
<td align="center" colspan="1" rowspan="1"><span class="Underline">High</span></td>
<td align="left" colspan="2" rowspan="1">Â </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>/AST</td>
<td align="center" colspan="1" rowspan="1">â‰¥5.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â SGPT/ALT</td>
<td align="center" colspan="1" rowspan="1">â‰¥5.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">4%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Total Bilirubin</td>
<td align="center" colspan="1" rowspan="1">â‰¥2.6 x ULN</td>
<td align="center" colspan="1" rowspan="1">49%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Lipase</td>
<td align="center" colspan="1" rowspan="1">â‰¥2.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">6%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Creatine Kinase</td>
<td align="center" colspan="1" rowspan="1">â‰¥5.1 x ULN</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">8%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center" colspan="1" rowspan="1">â‰¥240 mg/dL</td>
<td align="center" colspan="1" rowspan="1">25%</td>
<td align="center" colspan="1" rowspan="1">26%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Triglycerides</td>
<td align="center" colspan="1" rowspan="1">â‰¥751 mg/dL</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">12%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Glucose</td>
<td align="center" colspan="1" rowspan="1">â‰¥251 mg/dL</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Hematology</td>
<td align="center" colspan="1" rowspan="1"><span class="Underline">Low</span></td>
<td align="left" colspan="2" rowspan="1">Â </td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Platelets</td>
<td align="center" colspan="1" rowspan="1">&lt;50,000 cells/mm<span class="Sup">3</span>
</td>
<td align="center" colspan="1" rowspan="1">2%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">Neutrophils</span></td>
<td class="Botrule" align="center" colspan="1" rowspan="1">&lt;750 cells/mm<span class="Sup">3</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">7%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">8%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.5"></a><a name="section-6.1.5"></a><p></p>
<p class="First"><span class="Bold">Lipids, Change from Baseline in Treatment-Naive Patients</span></p>
<p>For Study AI424-138 and Study AI424-034, changes from baseline in LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides are shown in Tables 10 and 11, respectively. </p>
<a name="ifa09946a-01bf-4981-8c90-cf5d1f5d3ca3"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 10: Lipid Values, Mean Change from Baseline, Study AI424-138</span></caption>
<colgroup>
<col width="20%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
<col width="8%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" rowspan="5">Â </th>
<th class="Toprule" align="center" colspan="5"><span class="Bold">REYATAZ/ritonavir<span class="Sup">a,b</span></span></th>
<th class="Toprule" align="center" colspan="5"><span class="Bold">lopinavir/ritonavir<span class="Sup">b,c</span></span></th>
</tr>
<tr>
<th align="center"><span class="Bold">Baseline</span></th>
<th align="center" colspan="2"><span class="Bold">Week 48</span></th>
<th align="center" colspan="2"><span class="Bold">Week 96</span></th>
<th align="center"><span class="Bold">Baseline</span></th>
<th align="center" colspan="2"><span class="Bold">Week 48</span></th>
<th align="center" colspan="2"><span class="Bold">Week 96</span></th>
</tr>
<tr>
<th align="center"><span class="Bold">mg/dL</span></th>
<th align="center"><span class="Bold">mg/dL</span></th>
<th align="center"><span class="Bold">Change<span class="Sup">d</span></span></th>
<th align="center"><span class="Bold">mg/dL</span></th>
<th align="center"><span class="Bold">Change<span class="Sup">d</span></span></th>
<th align="center"><span class="Bold">mg/dL</span></th>
<th align="center"><span class="Bold">mg/dL</span></th>
<th align="center"><span class="Bold">Change<span class="Sup">d</span></span></th>
<th align="center"><span class="Bold">mg/dL</span></th>
<th align="center"><span class="Bold">Change<span class="Sup">d</span></span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center"><span class="Bold">(n=428<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=372<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=372<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=342<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=342<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=424<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=335<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=335<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=291<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=291<span class="Sup">e</span>)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="11">
<span class="Sup">a</span> REYATAZ 300 mg with ritonavir 100 mg once daily with the fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily. </td></tr>
<tr><td colspan="11">
<span class="Sup">b</span> Values obtained after initiation of serum lipid-reducing agents were not included in these analyses. At baseline, serum lipid-reducing agents were used in 1% in the lopinavir/ritonavir treatment arm and 1% in the REYATAZ/ritonavir arm. Through Week 48, serum lipid-reducing agents were used in 8% in the lopinavir/ritonavir treatment arm and 2% in the REYATAZ/ritonavir arm. Through Week 96, serum lipid-reducing agents were used in 10% in the lopinavir/ritonavir treatment arm and 3% in the REYATAZ/ritonavir arm.</td></tr>
<tr><td colspan="11">
<span class="Sup">c</span> Lopinavir 400 mg with ritonavir 100 mg twice daily with the fixed-dose combination 300 mg tenofovir, 200 mg emtricitabine once daily.</td></tr>
<tr><td colspan="11">
<span class="Sup">d</span> The change from baseline is the mean of within-patient changes from baseline for patients with both baseline and Week 48 or Week 96 values and is not a simple difference of the baseline and Week 48 or Week 96 mean values, respectively.</td></tr>
<tr><td colspan="11">
<span class="Sup">e</span> Number of patients with LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> measured.</td></tr>
<tr class="Last"><td class="Botrule" colspan="11">
<span class="Sup">f</span> Fasting.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td>LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span><span class="Sup">f</span>
</td>
<td align="center">92</td>
<td align="center">105</td>
<td align="center">+14%</td>
<td align="center">105</td>
<td align="center">+14%</td>
<td align="center">93</td>
<td align="center">111</td>
<td align="center">+19%</td>
<td align="center">110</td>
<td align="center">+17%</td>
</tr>
<tr>
<td>HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span><span class="Sup">f</span>
</td>
<td align="center">37</td>
<td align="center">46</td>
<td align="center">+29%</td>
<td align="center">44</td>
<td align="center">+21%</td>
<td align="center">36</td>
<td align="center">48</td>
<td align="center">+37%</td>
<td align="center">46</td>
<td align="center">+29%</td>
</tr>
<tr>
<td>Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span><span class="Sup">f</span>
</td>
<td align="center">149</td>
<td align="center">169</td>
<td align="center">+13%</td>
<td align="center">169</td>
<td align="center">+13%</td>
<td align="center">150</td>
<td align="center">187</td>
<td align="center">+25%</td>
<td align="center">186</td>
<td align="center">+25%</td>
</tr>
<tr class="Last">
<td>Triglycerides<span class="Sup">f</span>
</td>
<td align="center">126</td>
<td align="center">145</td>
<td align="center">+15%</td>
<td align="center">140</td>
<td align="center">+13%</td>
<td align="center">129</td>
<td align="center">194</td>
<td align="center">+52%</td>
<td align="center">184</td>
<td align="center">+50%</td>
</tr>
</tbody>
</table>
<a name="ie885c557-38e8-4b64-80d8-aac2a9be2597"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 11: Lipid Values, Mean Change from Baseline, Study AI424-034</span></caption>
<colgroup>
<col width="22%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="left" rowspan="4"></th>
<th class="Toprule" align="center" colspan="3" rowspan="1"><span class="Bold">REYATAZ<span class="Sup">a,b</span></span></th>
<th class="Toprule" align="center" colspan="3" rowspan="1"><span class="Bold">efavirenz<span class="Sup">b,c</span></span></th>
</tr>
<tr valign="bottom">
<th align="center" colspan="1" rowspan="1"><span class="Bold">Baseline</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Week 48</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Week 48</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Baseline</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Week 48</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Week 48</span></th>
</tr>
<tr valign="bottom">
<th align="center" colspan="1" rowspan="1"><span class="Bold">mg/dL</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">mg/dL</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Change<span class="Sup">d</span></span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">mg/dL</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">mg/dL</span></th>
<th align="center" colspan="1" rowspan="1"><span class="Bold">Change<span class="Sup">d</span></span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=383<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=283<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=272<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=378<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=264<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=253<span class="Sup">e</span>)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="7" rowspan="1">
<span class="Sup">a</span> REYATAZ 400 mg once daily with the fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">b</span> Values obtained after initiation of serum lipid-reducing agents were not included in these analyses. At baseline, serum lipid-reducing agents were used in 0% in the efavirenz treatment arm and &lt;1% in the REYATAZ arm. Through Week 48, serum lipid-reducing agents were used in 3% in the efavirenz treatment arm and 1% in the REYATAZ arm.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">c</span> Efavirenz 600 mg once daily with the fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">d</span> The change from baseline is the mean of within-patient changes from baseline for patients with both baseline and Week 48 values and is not a simple difference of the baseline and Week 48 mean values.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">e</span> Number of patients with LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> measured.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="7" rowspan="1">
<span class="Sup">f</span> Fasting.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" colspan="1" rowspan="1">LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span><span class="Sup">f</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">98</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">98</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">+1%</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">98</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">114</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">+18%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="center" colspan="1" rowspan="1">43</td>
<td align="center" colspan="1" rowspan="1">+13%</td>
<td align="center" colspan="1" rowspan="1">38</td>
<td align="center" colspan="1" rowspan="1">46</td>
<td align="center" colspan="1" rowspan="1">+24%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center" colspan="1" rowspan="1">164</td>
<td align="center" colspan="1" rowspan="1">168</td>
<td align="center" colspan="1" rowspan="1">+2%</td>
<td align="center" colspan="1" rowspan="1">162</td>
<td align="center" colspan="1" rowspan="1">195</td>
<td align="center" colspan="1" rowspan="1">+21%</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">Triglycerides<span class="Sup">f</span>
</td>
<td align="center" colspan="1" rowspan="1">138</td>
<td align="center" colspan="1" rowspan="1">124</td>
<td align="center" colspan="1" rowspan="1">-9%</td>
<td align="center" colspan="1" rowspan="1">129</td>
<td align="center" colspan="1" rowspan="1">168</td>
<td align="center" colspan="1" rowspan="1">+23%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1.6"></a><a name="section-6.1.6"></a><p></p>
<p class="First"><span class="Bold">Lipids, Change from Baseline in Treatment-Experienced Patients</span></p>
<p>For Study AI424-045, changes from baseline in LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and triglycerides
are shown in Table 12. The observed magnitude of <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> was less with REYATAZ/ritonavir than with lopinavir/ritonavir. However, the clinical impact
of such findings has not been demonstrated. </p>
<a name="i9f6cfbe2-0ae4-432d-8037-f3d2bcbcd45d"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 12: Lipid Values, Mean Change from Baseline, Study AI424-045</span></caption>
<colgroup>
<col width="22%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
<col width="13%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" rowspan="4">Â </th>
<th class="Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">REYATAZ/ritonavir<span class="Sup">a,b</span></span></th>
<th class="Toprule" align="center" colspan="3" valign="bottom"><span class="Bold">lopinavir/ritonavir<span class="Sup">b,c</span></span></th>
</tr>
<tr>
<th align="center" valign="bottom"><span class="Bold">Baseline</span></th>
<th align="center" valign="bottom"><span class="Bold">Week 48</span></th>
<th align="center" valign="bottom"><span class="Bold">Week 48</span></th>
<th align="center" valign="bottom"><span class="Bold">Baseline</span></th>
<th align="center" valign="bottom"><span class="Bold">Week 48</span></th>
<th align="center" valign="bottom"><span class="Bold">Week 48</span></th>
</tr>
<tr>
<th align="center" valign="bottom"><span class="Bold">mg/dL</span></th>
<th align="center" valign="bottom"><span class="Bold">mg/dL</span></th>
<th align="center" valign="bottom"><span class="Bold">Change<span class="Sup">d</span></span></th>
<th align="center" valign="bottom"><span class="Bold">mg/dL</span></th>
<th align="center" valign="bottom"><span class="Bold">mg/dL</span></th>
<th align="center" valign="bottom"><span class="Bold">Change<span class="Sup">d</span></span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=111<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=75<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=74<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=108<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=76<span class="Sup">e</span>)</span></th>
<th class="Botrule" align="center" valign="bottom"><span class="Bold">(n=73<span class="Sup">e</span>)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="7" rowspan="1">
<span class="Sup">a</span> REYATAZ 300 mg once daily + ritonavir + tenofovir + 1 NRTI.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">b</span> Values obtained after initiation of serum lipid-reducing agents were not included in these analyses.  At baseline, serum lipid-reducing agents were used in 4% in the lopinavir/ritonavir treatment arm and 4% in the REYATAZ/ritonavir arm. Through Week 48, serum lipid-reducing agents were used in 19% in the lopinavir/ritonavir treatment arm and 8% in the REYATAZ/ritonavir arm.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">c</span> Lopinavir/ritonavir (400/100 mg) BID + tenofovir + 1 NRTI.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">d</span> The change from baseline is the mean of within-patient changes from baseline for patients with both baseline and Week 48 values and is not a simple difference of the baseline and Week 48 mean values.</td></tr>
<tr><td align="left" colspan="7" rowspan="1">
<span class="Sup">e</span> Number of patients with LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> measured.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="7" rowspan="1">
<span class="Sup">f</span> Fasting.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" colspan="1" rowspan="1">LDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span><span class="Sup">f</span>
</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">108</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">98</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">-10%</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">104</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">103</td>
<td class="Toprule" align="center" colspan="1" rowspan="1">+1%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HDL-<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center" colspan="1" rowspan="1">40</td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="center" colspan="1" rowspan="1">-7%</td>
<td align="center" colspan="1" rowspan="1">39</td>
<td align="center" colspan="1" rowspan="1">41</td>
<td align="center" colspan="1" rowspan="1">+2%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span></td>
<td align="center" colspan="1" rowspan="1">188</td>
<td align="center" colspan="1" rowspan="1">170</td>
<td align="center" colspan="1" rowspan="1">-8%</td>
<td align="center" colspan="1" rowspan="1">181</td>
<td align="center" colspan="1" rowspan="1">187</td>
<td align="center" colspan="1" rowspan="1">+6%</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">Triglycerides<span class="Sup">f</span>
</td>
<td align="center" colspan="1" rowspan="1">215</td>
<td align="center" colspan="1" rowspan="1">161</td>
<td align="center" colspan="1" rowspan="1">-4%</td>
<td align="center" colspan="1" rowspan="1">196</td>
<td align="center" colspan="1" rowspan="1">224</td>
<td align="center" colspan="1" rowspan="1">+30%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Trial Experience in Pediatric Patients</h2>
<p class="First">The safety and tolerability of REYATAZ Capsules with and without ritonavir have been established in pediatric patients
at least 6 years of age from the open-label, multicenter clinical trial PACTG 1020A. Use of REYATAZ in pediatric patients less than 6 years of age is under
investigation.</p>
<p>The safety profile of REYATAZ in pediatric patients (6 to less than 18 years of age) was generally similar to that observed
in clinical studies of REYATAZ in adults. The most common Grade 2â€“4 adverse events (â‰¥5%, regardless of causality) reported in pediatric patients were <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> (21%), <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (18%), <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>/<span class="product-label-link" type="condition" conceptid="4081004" conceptname="Scleral icterus">scleral icterus</span> (15%), <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (14%), <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (12%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (9%), <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (8%), <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> (7%), extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (6%), <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span> (6%), oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (6%), <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span> (6%), and <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span> (6%). Asymptomatic second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span> was reported in &lt;2% of patients. The most common Grade 3â€“4 laboratory abnormalities occurring in pediatric patients were elevation of total bilirubin (â‰¥3.2 mg/dL, 58%), <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (9%), and <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (4%). All other Grade 3â€“4 laboratory abnormalities occurred with a frequency of less than 3%. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Patients Co-infected With <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B and/or <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> C Virus</h2>
<p class="First">Liver function tests should be monitored in patients with a history of <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C.</p>
<p>In study AI424-138, 60 patients treated with REYATAZ/ritonavir 300 mg/100 mg once daily, and 51 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, each with fixed dose tenofovir-emtricitabine, were seropositive for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C at study entry. ALT levels &gt;5 times ULN developed in 10% (6/60) of the REYATAZ/ritonavir-treated patients and 8% (4/50) of the lopinavir/ritonavir-treated patients. AST levels &gt;5 times ULN developed in 10% (6/60) of the REYATAZ/ritonavir-treated patients and none (0/50) of the lopinavir/ritonavir-treated patients.</p>
<p> In study AI424-045, 20 patients treated with REYATAZ/ritonavir 300 mg/100 mg once daily, and 18 patients treated with lopinavir/ritonavir 400 mg/100 mg twice daily, were seropositive for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C at study entry. ALT levels &gt;5 times ULN developed in 25% (5/20) of the REYATAZ/ritonavir-treated patients and 6% (1/18) of the lopinavir/ritonavir-treated patients. AST levels &gt;5 times ULN developed in 10% (2/20) of the REYATAZ/ritonavir-treated patients and 6% (1/18) of the lopinavir/ritonavir-treated patients.</p>
<p>In studies AI424-008 and AI424-034, 74 patients treated with 400 mg of REYATAZ (atazanavir sulfate) once daily, 58 who received efavirenz, and 12 who received nelfinavir were seropositive for <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B and/or C at study entry. ALT levels &gt;5 times the upper limit of normal (ULN) developed in 15% of the REYATAZ-treated patients, 14% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. AST levels &gt;5 times ULN developed in 9% of the REYATAZ-treated patients, 5% of the efavirenz-treated patients, and 17% of the nelfinavir-treated patients. Within atazanavir and control regimens, no difference in frequency of bilirubin elevations was noted between seropositive and seronegative patients. [See <span class="Italics">Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4 Postmarketing Experience</h2>
<p class="First">The following events have been identified during postmarketing use of REYATAZ. Because these reactions are reported
voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug
exposure. </p>
<p><span class="Italics">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></p>
<p><span class="Italics">Cardiovascular System: </span>second-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, third-degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, left bundle
branch block, QTc prolongation [see <span class="Italics">Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span>] </p>
<p><span class="Italics">Gastrointestinal System: </span><span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span></p>
<p><span class="Italics">Hepatic System: </span>hepatic function abnormalities </p>
<p><span class="Italics">Hepatobiliary Disorders: </span><span class="product-label-link" type="condition" conceptid="4098112" conceptname="Biliary sludge">cholelithiasis</span>, <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span></p>
<p><span class="Italics">Metabolic System and Nutrition Disorders: </span><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.7">(5.7)</a></span>]</p>
<p><span class="Italics">Musculoskeletal System:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span></p>
<p><span class="Italics">Renal System: </span><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> [see <span class="Italics">Warnings and Precautions <a href="#Section_5.6">(5.6)</a></span>]</p>
<p><span class="Italics">Skin and Appendages: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span> [see <span class="Italics">Contraindications <a href="#Section_4">(4)</a></span> and <span class="Italics">Warnings and Precautions <a href="#Section_5.3">(5.3)</a></span>], <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">See also <span class="Italics">Contraindications <a href="#Section_4">(4)</a></span> and <span class="Italics">Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potential for REYATAZ to Affect Other Drugs</h2>
<p class="First">Atazanavir is an inhibitor of CYP3A and UGT1A1. Coadministration of REYATAZ and drugs primarily metabolized by CYP3A
or UGT1A1 may result in increased plasma concentrations of the other drug that could increase or prolong its therapeutic and adverse effects.</p>
<p>Atazanavir is a weak inhibitor of CYP2C8. Caution should be used when REYATAZ without ritonavir is coadministered with drugs highly dependent on CYP2C8 with narrow therapeutic indices (eg, paclitaxel, repaglinide). When REYATAZ with ritonavir is coadministered with substrates of CYP2C8, clinically significant interactions are not expected. [See <span class="Italics">Clinical Pharmacology, Table 14
										<a href="#Section_12.3"> (12.3)</a></span>.]</p>
<p>The magnitude of CYP3A-mediated drug interactions on coadministered drug may change when REYATAZ is coadministered
with ritonavir. See the complete prescribing information for NORVIR<span class="Sup">Â®</span> (ritonavir) for information on drug interactions with ritonavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Potential for Other Drugs to Affect Atazanavir</h2>
<p class="First">Atazanavir is a CYP3A4 substrate; therefore, drugs that induce CYP3A4 may decrease atazanavir plasma concentrations and reduce REYATAZâ€™s therapeutic effect.</p>
<p>Atazanavir solubility decreases as pH increases. Reduced plasma concentrations of atazanavir are expected if proton-pump inhibitors, antacids, buffered medications, or H<span class="Sub">2</span>-receptor antagonists are administered with atazanavir.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Established and Other Potentially Significant Drug Interactions</h2>
<p class="First">Table 13 provides dosing recommendations as a result of drug interactions with REYATAZ. These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious events or loss of efficacy.</p>
<a name="i0ac74f10-d457-44cd-8e84-987dbd92248c"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 13: Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies<span class="Sup">a</span> or Predicted Interactions (Information in the table applies to REYATAZ with or without ritonavir, unless otherwise indicated)</span></caption>
<colgroup>
<col width="25%">
<col width="20%">
<col width="55%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<th class="Botrule Toprule" align="left" colspan="1" rowspan="1"><span class="Bold"><span class="Bold Italics">Concomitant Drug Class:</span><br>Specific Drugs</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Effect on Concentration of Atazanavir or Concomitant Drug</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Clinical Comment</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1">
<span class="Sup">a</span> For magnitude of interactions see <span class="Italics">Clinical Pharmacology, Tables 17</span> and <span class="Italics">18<a href="#Section_12.3"> (12.3)</a></span>.</td></tr>
<tr><td colspan="3">
<span class="Sup">b</span> See <span class="Italics">Contraindications<a href="#Section_4"> (4)</a>, Table 3</span> for orally administered midazolam.</td></tr>
<tr><td colspan="3">
<span class="Sup">c</span> In combination with atazanavir 300 mg and ritonavir 100 mg once daily.</td></tr>
<tr class="Last"><td class="Botrule" colspan="3">
<span class="Sup">d</span> In combination with atazanavir 400 mg once daily.</td></tr>
</tfoot>
<tbody>
<tr class="First"><td class="Botrule" align="left" colspan="3" rowspan="1"><span class="Bold"><span class="Bold Italics">HIV Antiviral Agents</span></span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Nucleoside Reverse Transcriptase Inhibitors (NRTIs):</span><br>didanosine buffered formulations enteric-coated (EC) capsules</td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir<br>â†“Â didanosine</td>
<td align="left" colspan="1" rowspan="1">Coadministration of REYATAZ with didanosine buffered tablets resulted in a marked decrease in atazanavir exposure.
It is recommended that REYATAZ be given (with food) 2 h before or 1 h after didanosine buffered formulations.  Simultaneous administration of didanosine
EC and REYATAZ with food results in a decrease in didanosine exposure.  Thus, REYATAZ and didanosine EC should be administered at different times.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Nucleotide Reverse Transcriptase
Inhibitors:</span> tenofovir disoproxil fumarate</td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir<br>â†‘Â tenofovir</td>
<td align="left" colspan="1" rowspan="1">Tenofovir may decrease the AUC and C<span class="Sub">min</span> of atazanavir. When coadministered with tenofovir, it is recommended that REYATAZ 300 mg be given with ritonavir 100 mg and tenofovir 300 mg (all as a single daily dose with food). <span class="Bold">REYATAZ without ritonavir should not be coadministered with tenofovir.</span> REYATAZ increases tenofovir concentrations. The mechanism of this interaction is unknown. Higher tenofovir concentrations could potentiate tenofovir-associated adverse events, including <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disorders</span>. Patients receiving REYATAZ and tenofovir should be monitored for tenofovir-associated adverse events. For pregnant women taking REYATAZ with ritonavir <span class="Italics">and</span> tenofovir, see <span class="Italics">Dosage and Administration <a href="#Section_2.3">(2.3)</a></span>.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs):</span> efavirenz</td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir</td>
<td align="left" colspan="1" rowspan="1">Efavirenz decreases atazanavir exposure.<br><span class="Italics"><span class="Bold Italics">In treatment-naive patients:</span></span><br>If REYATAZ is combined with efavirenz, REYATAZ 400 mg (two 200-mg capsules) with ritonavir 100 mg should be administered once daily all as a single dose with
food, and efavirenz 600 mg should be administered once daily on an empty stomach, preferably at bedtime.<br><span class="Bold"><span class="Bold Italics">In treatment-experienced patients:</span></span><br>Do not coadminister REYATAZ with efavirenz in treatment-experienced patients due to decreased atazanavir exposure.<br>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Non-nucleoside Reverse Transcriptase Inhibitors:</span> nevirapine</td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir<br>â†‘Â nevirapine</td>
<td align="left" colspan="1" rowspan="1">Do not coadminister REYATAZ with
nevirapine because:<ul class="Disc">
<li>Nevirapine substantially decreases atazanavir exposure.</li>
<li>Potential risk for nevirapine associated toxicity due to increased nevirapine exposures.</li>
</ul>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Protease Inhibitors: </span>saquinavir
(soft gelatin capsules)</td>
<td align="center" colspan="1" rowspan="1">â†‘Â saquinavir</td>
<td align="left" colspan="1" rowspan="1">Appropriate dosing recommendations for this combination, with or without ritonavir, with respect to efficacy and safety have not been established. In a clinical study, saquinavir 1200 mg coadministered with REYATAZ 400 mg and tenofovir 300 mg (all given once daily) plus nucleoside analogue reverse transcriptase inhibitors did not provide adequate efficacy [see <span class="Italics">Clinical Studies <a href="#Section_14.2">(14.2)</a></span>].</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Protease Inhibitors: </span>ritonavir</td>
<td align="center" colspan="1" rowspan="1">â†‘Â atazanavir</td>
<td align="left" colspan="1" rowspan="1">If REYATAZ is coadministered with ritonavir, it is recommended that REYATAZ 300 mg once daily be given with ritonavir 100 mg once daily with food. See the complete prescribing information for NORVIR<span class="Sup">Â®</span> (ritonavir) for information on drug interactions with ritonavir.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Protease Inhibitors: </span>others</td>
<td align="center" colspan="1" rowspan="1">â†‘Â other protease inhibitor</td>
<td align="left" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold Italics">REYATAZ/ritonavir:
 </span></span>Although not studied, the coadministration of REYATAZ/ritonavir and other protease inhibitors would be expected to increase exposure to the other protease inhibitor. Such coadministration is not recommended.</td>
</tr>
<tr valign="top"><td class="Botrule Toprule" align="left" colspan="3" rowspan="1"><span class="Bold"><span class="Bold Italics">Other Agents</span></span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"><span class="Italics">Antacids and buffered medications</span></td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir</td>
<td align="left" colspan="1" rowspan="1">Reduced plasma concentrations of atazanavir are expected if antacids, including buffered medications, are administered with REYATAZ.  REYATAZ should be administered 2 hours before or 1 hour after these medications.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Antiarrhythmics:</span> amiodarone, bepridil, lidocaine (systemic), quinidine</td>
<td align="center" colspan="1" rowspan="1">â†‘Â amiodarone, bepridil, lidocaine (systemic), quinidine</td>
<td align="left" colspan="1" rowspan="1">Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied.  Caution is warranted and therapeutic concentration monitoring of these drugs is recommended if they are used concomitantly with REYATAZ (atazanavir sulfate). </td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Anticoagulants:</span> 
warfarin</td>
<td align="center" colspan="1" rowspan="1">â†‘Â warfarin</td>
<td align="left" colspan="1" rowspan="1">Coadministration with REYATAZ has the potential to produce serious and/or life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and has not been studied. It is recommended that INR (International Normalized Ratio) be monitored.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Antidepressants: </span> tricyclic antidepressants</td>
<td align="center" colspan="1" rowspan="1">â†‘Â tricyclic antidepressants</td>
<td align="left" colspan="1" rowspan="1">Coadministration with REYATAZ has the potential to produce serious and/or life-threatening adverse events and has not been studied.  Concentration monitoring of these drugs is recommended if they are used concomitantly with REYATAZ.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">trazodone</td>
<td align="center" colspan="1" rowspan="1">â†‘Â trazodone</td>
<td align="left" colspan="1" rowspan="1">Concomitant use of trazodone and REYATAZ with or without ritonavir may increase plasma concentrations of trazodone. Adverse events of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as REYATAZ, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Antifungals: </span> ketoconazole, itraconazole</td>
<td align="center" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold Italics">REYATAZ/ritonavir:</span></span><br> â†‘Â ketoconazole<br> â†‘Â itraconazole</td>
<td align="left" colspan="1" rowspan="1">Coadministration of  ketoconazole has only been studied with REYATAZ without ritonavir (negligible increase in atazanavir AUC and C<span class="Sub">max</span>).  Due to the effect of ritonavir on ketoconazole, high doses of ketoconazole and itraconazole (&gt;200 mg/day) should be used cautiously with REYATAZ/ritonavir.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Antifungals: </span> voriconazole</td>
<td align="center" colspan="1" rowspan="1">Effect is unknown</td>
<td align="left" colspan="1" rowspan="1">Coadministration of voriconazole with REYATAZ, with or without ritonavir, has not been studied. Administration of voriconazole with ritonavir 100 mg every 12 hours decreased voriconazole steady-state AUC by an average of 39%. Voriconazole should not be administered to patients receiving REYATAZ/ritonavir, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole. Coadministration of voriconazole with REYATAZ (without ritonavir) may increase atazanavir concentrations; however, no data are available.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Antigout: </span> colchicine</td>
<td align="center" colspan="1" rowspan="1">â†‘Â colchicine</td>
<td align="left" colspan="1" rowspan="1">REYATAZ should not be coadministered with colchicine to patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.<br><span class="Bold Italics">Recommended dosage of colchicine when administered with REYATAZ:<br>Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>:</span><dl>
<dt></dt>
<dd>0.6 mg (1 tablet) for 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Not to be repeated before 3 days.</dd>
</dl>
<span class="Bold Italics">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>:</span><dl>
<dt></dt>
<dd>If the original regimen was 0.6 mg <span class="Italics">twice</span> a day, the regimen should be adjusted to 0.3 mg <span class="Italics">once a day</span>.<br><br>
												If the original regimen was 0.6 mg <span class="Italics">once</span> a day, the regimen should be adjusted to 0.3 mg <span class="Italics">once every other day</span>.</dd>
</dl>
<span class="Bold Italics">Treatment of familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (FMF):</span><dl>
<dt></dt>
<dd>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).</dd>
</dl>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Antimycobacterials: </span> rifabutin</td>
<td align="center" colspan="1" rowspan="1">â†‘Â rifabutin</td>
<td align="left" colspan="1" rowspan="1">A rifabutin dose reduction of up to 75% (eg, 150 mg every other day or 3 times per week) is recommended. Increased monitoring for rifabutin-associated adverse reactions including <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is warranted.</td>
</tr>
<tr>
<td valign="top">
<span class="Italics">Benzodiazepines: </span>parenterally administered midazolam<span class="Sup">b</span>
</td>
<td align="center" valign="top">â†‘Â midazolam</td>
<td valign="top">Concomitant use of parenteral midazolam with REYATAZ may increase plasma concentrations of midazolam. Coadministration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Coadministration of oral midazolam with REYATAZ is CONTRAINDICATED. </td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Calcium channel blockers: </span>diltiazem</td>
<td align="center" colspan="1" rowspan="1">â†‘Â diltiazem and desacetyl-diltiazem</td>
<td align="left" colspan="1" rowspan="1">Caution is warranted. A dose reduction of diltiazem by 50% should be considered. ECG monitoring is recommended. Coadministration of REYATAZ/ritonavir with diltiazem has not been studied.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">eg, felodipine, nifedipine, nicardipine, and verapamil</td>
<td align="center" colspan="1" rowspan="1">â†‘Â calcium channel blocker</td>
<td align="left" colspan="1" rowspan="1">Caution is warranted. Dose titration of the calcium channel blocker should be considered. ECG monitoring is recommended.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Endothelin receptor antagonists: </span> bosentan</td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir<br>â†‘Â bosentan</td>
<td align="left" colspan="1" rowspan="1">Plasma concentrations of atazanavir may be decreased when bosentan is administered with REYATAZ without ritonavir. Coadministration of bosentan and REYATAZ without ritonavir is not recommended.<br><span class="Bold Italics">Coadministration of bosentan in patients on REYATAZ/ritonavir:</span><dl>
<dt></dt>
<dd>For patients who have been receiving REYATAZ/ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based on individual tolerability.</dd>
</dl>
<span class="Bold Italics">Coadministration of REYATAZ/ritonavir in patients on bosentan:</span><dl>
<dt></dt>
<dd>Discontinue bosentan at least 36 hours before starting REYATAZ/ritonavir. At least 10 days after starting REYATAZ/ritonavir, resume bosentan at 62.5 mg once daily or every other day based on individual tolerability.</dd>
</dl>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">HMG-CoA reductase inhibitors:
 </span>atorvastatin, rosuvastatin</td>
<td align="center" colspan="1" rowspan="1">â†‘Â atorvastatin <br>â†‘Â rosuvastatin</td>
<td align="left" colspan="1" rowspan="1">Use the lowest possible dose of atorvastatin or rosuvastatin with careful monitoring, or consider other HMG-CoA reductase inhibitors such as pravastatin or fluvastatin in combination with REYATAZ (with or without ritonavir). The risk of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span>, may be increased when HIV protease inhibitors, including REYATAZ, are used in combination with these drugs.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"><span class="Italics">H<span class="Sub">2</span>-Receptor antagonists</span></td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir</td>
<td align="left" colspan="1" rowspan="1">Plasma concentrations of atazanavir were substantially decreased when REYATAZ 400 mg once daily was administered simultaneously with famotidine 40 mg twice daily, which may result in loss of therapeutic effect and development of resistance. </td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">Â </td>
<td colspan="1" rowspan="1">
<span class="Bold"><span class="Bold Italics">In treatment-naive patients:</span></span><br>REYATAZ 300 mg with ritonavir 100 mg once daily with food should be administered simultaneously with, and/or at
least 10 hours after, a dose of the H<span class="Sub">2</span>-receptor antagonist. An H<span class="Sub">2</span>-receptor antagonist dose comparable to famotidine
20 mg once daily up to a dose comparable to famotidine 40 mg twice daily can be used with REYATAZ 300 mg with ritonavir 100 mg in treatment-naive patients.<br>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â OR<br>For patients unable to tolerate ritonavir, REYATAZ 400 mg once daily with food should be administered at least 2 hours before and at least 10 hours after a dose of the H<span class="Sub">2</span>-receptor antagonist. No single dose of the H<span class="Sub">2</span>-receptor antagonist should exceed a dose comparable to famotidine 20 mg, and the total daily dose should not exceed a dose comparable to famotidine 40 mg. However, REYATAZ should not be used without ritonavir in pregnant women.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold Italics">In treatment-experienced patients:</span></span><br>Whenever an H<span class="Sub">2</span>-receptor antagonist is given to a patient receiving REYATAZ with ritonavir, the H<span class="Sub">2</span>-receptor antagonist dose should not exceed a dose comparable to famotidine 20 mg twice daily, and the REYATAZ and ritonavir doses should be administered simultaneously with, and/or at least 10 hours after, the dose of the H<span class="Sub">2</span>-receptor antagonist.
												<ul class="Disc">
<li>REYATAZ 300 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with an H<span class="Sub">2</span>-receptor antagonist. For pregnant women taking REYATAZ with ritonavir and an H<span class="Sub">2</span>-receptor antagonist, see <span class="Italics">Dosage and Administration <a href="#Section_2.3">(2.3)</a></span>.</li>
<li>REYATAZ 400 mg with ritonavir 100 mg once daily (all as a single dose with food) if taken with both tenofovir and an H<span class="Sub">2</span>-receptor antagonist. For pregnant women taking REYATAZ with ritonavir and both tenofovir and an H<span class="Sub">2</span>-receptor antagonist, see <span class="Italics">Dosage and Administration <a href="#Section_2.3">(2.3)</a></span>.</li>
</ul>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Hormonal contraceptives: </span>ethinyl estradiol and norgestimate or norethindrone</td>
<td align="center" colspan="1" rowspan="1">â†“Â ethinyl estradiol <br>â†‘Â norgestimate<span class="Sup">c</span><br>â†‘Â ethinyl estradiol<br>â†‘Â norethindrone<span class="Sup">d</span>
</td>
<td align="left" colspan="1" rowspan="1">Use with caution if coadministration of REYATAZ or REYATAZ/ritonavir with oral contraceptives is considered. If an oral contraceptive is administered with REYATAZ plus ritonavir, it is recommended that the oral contraceptive contain at least
35 mcg of ethinyl estradiol. If REYATAZ is administered without ritonavir, the oral contraceptive should contain no more than 30 mcg of ethinyl estradiol.<br>Â Â Â Â Â Potential safety risks include substantial increases in progesterone exposure. The long-term effects of increases in concentration of the progestational agent are unknown and could increase the risk of <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>, <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span>, and <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">acne</span>. <br>Â Â Â Â Â Coadministration of REYATAZ or REYATAZ/ritonavir with other hormonal contraceptives (eg, contraceptive patch, contraceptive vaginal ring, or injectable contraceptives) or oral contraceptives containing progestogens other than norethindrone or norgestimate, or less
than 25 mcg of ethinyl estradiol, has not been studied; therefore, alternative methods of contraception are recommended.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Immunosuppressants: </span>cyclosporin, sirolimus, tacrolimus</td>
<td align="center" colspan="1" rowspan="1">â†‘Â immunosuppressants</td>
<td align="left" colspan="1" rowspan="1">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with REYATAZ (atazanavir sulfate).</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Inhaled beta agonist:</span> salmeterol</td>
<td align="center" colspan="1" rowspan="1">
														â†‘Â salmeterol</td>
<td align="left" colspan="1" rowspan="1">Coadministration of salmeterol with REYATAZ is not recommended. Concomitant use of salmeterol and REYATAZ may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">sinus tachycardia</span>. </td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Inhaled/nasal steroid:</span> fluticasone</td>
<td align="center" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold"><span class="Bold Italics">REYATAZ</span></span><br></span>â†‘Â fluticasone</td>
<td align="left" colspan="1" rowspan="1">Concomitant use of fluticasone propionate and REYATAZ (without ritonavir) may increase plasma concentrations of fluticasone propionate.  Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold"><span class="Bold Italics">REYATAZ/ritonavir</span></span><br></span>â†‘Â fluticasone</td>
<td align="left" colspan="1" rowspan="1">Concomitant use of fluticasone propionate and REYATAZ/ritonavir may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations. Systemic corticosteroid effects, including Cushingâ€™s syndrome and adrenal suppression, have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone propionate. Coadministration of fluticasone propionate and REYATAZ/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see <span class="Italics">Warnings and Precautions <a href="#Section_5">(5.1)</a></span>].</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Macrolide antibiotics:</span> clarithromycin</td>
<td align="center" colspan="1" rowspan="1">â†‘Â clarithromycin <br>â†“Â 14-OH clarithromycin <br>â†‘Â atazanavir</td>
<td align="left" colspan="1" rowspan="1">Increased concentrations of clarithromycin may cause QTc prolongations; therefore, a dose reduction of clarithromycin by 50% should be considered when it is coadministered with REYATAZ. In addition, concentrations of the active metabolite 14-OH clarithromycin are significantly reduced; consider alternative therapy for indications other than <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Mycobacterium avium</span> complex. Coadministration of REYATAZ/ritonavir with clarithromycin has not been studied.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Opioids:</span> Buprenorphine</td>
<td align="center" colspan="1" rowspan="1">â†‘Â buprenorphine<br>â†‘Â norbuprenorphine</td>
<td align="left" colspan="1" rowspan="1">Coadministration of buprenorphine and REYATAZ with or without ritonavir increases the plasma concentration of buprenorphine and norbuprenorphine. Coadministration of REYATAZ plus ritonavir with buprenorphine warrants clinical monitoring for sedation and cognitive effects. A dose reduction of buprenorphine may be considered. Coadministration of buprenorphine and REYATAZ with ritonavir is not expected to decrease atazanavir plasma concentrations. Coadministration of buprenorphine and REYATAZ without ritonavir may decrease atazanavir plasma concentrations. REYATAZ without ritonavir should not be coadministered with buprenorphine.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">PDE5 inhibitors:</span> sildenafil, tadalafil, vardenafil</td>
<td align="center" colspan="1" rowspan="1">â†‘Â sildenafil<br>â†‘Â tadalafil<br>â†‘Â vardenafil</td>
<td align="left" colspan="1" rowspan="1">Coadministration with REYATAZ has not been studied but may result in an increase in PDE5 inhibitor-associated adverse events, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>.<br><br><span class="Bold Italics">Use of PDE5 inhibitors for <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH):</span><dl class="Disc">
<dt></dt>
<dd>Use of REVATIO<span class="Sup">Â®</span> (sildenafil) for the treatment of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> (PAH) is contraindicated with REYATAZ [see <span class="Italics">Contraindications <a href="#Section_4">(4)</a></span>].<br><br>
</dd>
<dt></dt>
<dd>The following dose adjustments are recommended for the use of ADCIRCA<span class="Sup">Â®</span> (tadalafil) with REYATAZ:<br><br><dl>
<dt></dt>
<dd>Coadministration of ADCIRCA<span class="Sup">Â®</span> in patients on REYATAZ (with or without ritonavir):<br><ul><li>For patients receiving REYATAZ (with or without ritonavir) for at least one week, start ADCIRCA<span class="Sup">Â®</span> at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.<br><br>
</li></ul>
</dd>
</dl>
<dl>
<dt></dt>
<dd>Coadministration of REYATAZ (with or without ritonavir) in patients on ADCIRCA<span class="Sup">Â®</span>:<br><ul><li>Avoid the use of ADCIRCA<span class="Sup">Â®</span> when starting REYATAZ (with or without ritonavir). Stop ADCIRCA<span class="Sup">Â®</span> at least 24 hours before starting REYATAZ (with or without ritonavir). At least one week after starting REYATAZ (with or without ritonavir), resume ADCIRCA<span class="Sup">Â®</span> at 20 mg once daily. Increase to 40 mg once daily based on individual tolerability.</li></ul>
</dd>
</dl>
</dd>
</dl>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1"><span class="Bold"><span class="Bold"><span class="Bold Italics"></span></span></span></td>
<td align="left" colspan="1" rowspan="1">
<span class="Bold Italics"> Use of PDE5 inhibitors for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>:</span><p class="First">Â Â Â Â Â Â Â Â Use VIAGRA<span class="Sup">Â®</span> (sildenafil) with caution at reduced doses of 25 mg every 48 hours with increased monitoring for adverse events.<br></p>
<p>Â Â Â Â Â Â Â Â Use CIALIS<span class="Sup">Â®</span> (tadalafil) with caution at reduced doses of 10 mg every 72 hours with increased monitoring for adverse events.<br></p>
<p>Â Â Â Â Â Â Â Â <span class="Bold Italics">REYATAZ/ritonavir:</span> Use LEVITRA<span class="Sup">Â®</span> (vardenafil) with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring for adverse events.<br></p>
<p>Â Â Â Â Â Â Â Â <span class="Bold Italics">REYATAZ:</span> Use LEVITRA<span class="Sup">Â®</span> (vardenafil) with caution at reduced doses of no more than 2.5 mg every 24 hours with increased monitoring for adverse events.<br></p>
</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">
<span class="Italics">Proton-pump inhibitors: </span>omeprazole</td>
<td align="center" colspan="1" rowspan="1">â†“Â atazanavir</td>
<td align="left" colspan="1" rowspan="1">Plasma concentrations of atazanavir were substantially decreased when REYATAZ 400 mg or REYATAZ 300 mg/ritonavir 100 mg once daily was administered with omeprazole 40 mg once daily, which may result in loss of therapeutic effect and development of resistance.</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold Italics">In treatment-naive patients:</span></span><br>The proton-pump inhibitor dose should not exceed a dose comparable to omeprazole 20 mg and must be taken approximately 12 hours prior to the REYATAZ 300 mg with ritonavir 100 mg dose.</td>
</tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="left" colspan="1" rowspan="1">
<span class="Bold"><span class="Bold Italics">In treatment-experienced patients:</span></span><br>Proton-pump inhibitors should not be used in treatment-experienced patients receiving REYATAZ.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Drugs with No Observed or Predicted Interactions with REYATAZ</h2>
<p class="First">Clinically significant interactions are not expected between atazanavir and substrates of CYP2C19, CYP2C9, CYP2D6,
CYP2B6, CYP2A6, CYP1A2, or CYP2E1. Clinically significant interactions are not expected between atazanavir when administered with ritonavir and substrates
of CYP2C8. See the complete prescribing information for NORVIR<span class="Sup">Â®</span> for information on other potential drug interactions with ritonavir.</p>
<p>Based on known metabolic profiles, clinically significant drug interactions are not expected between REYATAZ (atazanavir sulfate) and fluvastatin, pravastatin, dapsone, trimethoprim/sulfamethoxazole, azithromycin, or erythromycin.  REYATAZ does not interact with substrates of CYP2D6 (eg, nortriptyline, desipramine, metoprolol). Additionally, no clinically significant drug interactions were observed when REYATAZ was coadministered with methadone, fluconazole, acetaminophen, or atenolol. [See <span class="Italics">Clinical Pharmacology, Tables 17</span> and <span class="Italics">18 <a href="#Section_12.3">(12.3)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_8.1.1"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category B</span></p>
<p><span class="Bold Italics">Antiretroviral Pregnancy Registry:</span> To monitor maternal-fetal outcomes of pregnant women exposed to REYATAZ, an Antiretroviral Pregnancy Registry has been established. Physicians are encouraged to register patients by calling 1-800-258-4263.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_8.1.2"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">Risk Summary</span></p>
<p>Atazanavir has been evaluated in a limited number of women during pregnancy and postpartum. Available human and animal data suggest that atazanavir does not increase the risk of major <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> overall compared to the background rate. However, because the studies in humans cannot rule out the possibility of harm, REYATAZ should be used during pregnancy only if clearly needed.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis syndrome</span>, sometimes fatal, and symptomatic hyperlactatemia have occurred in pregnant women using REYATAZ in combination with nucleoside analogues. Nucleoside analogues are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis syndrome</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> occurs frequently in patients who take REYATAZ, including pregnant women. All infants, including neonates exposed to REYATAZ <span class="Italics">in-utero</span>, should be monitored for the development of severe <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> during the first few days of life.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_8.1.4"></a><a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Bold">Clinical Considerations</span></p>
<p><span class="Italics">Dosing During Pregnancy and the Postpartum Period:</span></p>
<ul>
<li>REYATAZ should not be administered without ritonavir.</li>
<li>REYATAZ should only be administered to pregnant women with HIV-1 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> susceptible to atazanavir.</li>
<li>For pregnant patients, no dose adjustment is required for REYATAZ with the following exceptions:
											<ul><li>For treatment-experienced pregnant women during the second or third trimester, when REYATAZ is coadministered with either an H<span class="Sub">2</span>-receptor antagonist <span class="Bold">or</span> tenofovir, REYATAZ 400 mg with ritonavir 100 mg once daily is recommended. There are insufficient data to recommend a REYATAZ dose for use with both an H<span class="Sub">2</span>-receptor antagonist <span class="Italics">and</span> tenofovir in treatment-experienced pregnant women.</li></ul>
</li>
<li>No dose adjustment is required for postpartum patients. However, patients should be closely monitored for adverse events because atazanavir exposures could be higher during the first 2 months after delivery. [See <span class="Italics"> Dosage and Administration <a href="#Section_2">(2,</a><a href="#Section_2.3"> 2.3</a>)</span> and <span class="Italics"> Clinical Pharmacology <a href="#Section_23.3">(12.3)</a></span>.]</li>
</ul>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_8.1.5"></a><a name="section-8.1.4"></a><p></p>
<p class="First"><span class="Bold">Human Data</span></p>
<p><span class="Bold Italics">Clinical Trials:</span> In clinical trial AI424-182, REYATAZ/ritonavir (300/100 mg or 400/100 mg) in combination with zidovudine/lamivudine was administered to 41 HIV-infected pregnant women during the second or third trimester. Among the 39 women who completed the study, 38 women achieved an HIV RNA &lt;50 copies/mL at time of delivery. Six of 20 (30%) women on REYATAZ/ritonavir 300/100 mg and 13 of 21 (62%) women on REYATAZ/ritonavir 400/100 mg experienced <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> (total bilirubin greater than or equal to 2.6 times the upper limit of normal). There were no cases of <span class="product-label-link" type="condition" conceptid="4239233" conceptname="Lactic acidosis">lactic acidosis</span> observed in clinical trial AI424-182.</p>
<p>Atazanavir drug concentrations in fetal umbilical cord blood were approximately 12â€“19% of maternal concentrations. Among the 40 infants born to 40 HIV-infected pregnant women, all had test results that were negative for HIV-1 DNA at the time of delivery and/or during the first 6 months postpartum. All 40 infants received antiretroviral <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment containing zidovudine. No evidence of severe <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> (total bilirubin levels greater than 20 mg/dL) or acute or chronic bilirubin <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> was observed among neonates in this study. However, 10/36 (28%) infants (6 greater than or equal to 38 weeks gestation and 4 less than 38 weeks gestation) had bilirubin levels of 4 mg/dL or greater within the first day of life.</p>
<p>Lack of ethnic diversity was a study limitation. In the study population, 33/40 (83%) infants were Black/African American, who have a lower incidence of neonatal <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> than Caucasians and Asians. In addition, women with Rh incompatibility were excluded, as well as women who had a previous infant who developed hemolytic disease and/or had neonatal pathologic <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> (requiring phototherapy).</p>
<p>Additionally, of the 38 infants who had glucose samples collected in the first day of life, 3 had adequately collected serum glucose samples with values of &lt;40 mg/dL that could not be attributed to maternal <span class="product-label-link" type="condition" conceptid="44808385" conceptname="Pre-diabetes">glucose intolerance</span>, difficult delivery, or <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>.</p>
<p><span class="Bold Italics Underline">Antiretroviral Pregnancy Registry Data</span><span class="Bold Italics">:</span>  As of January 2010, the Antiretroviral Pregnancy Registry (APR) has received prospective reports of 635 exposures to atazanavir-containing regimens (425 exposed in the first trimester and 160 and 50 exposed in second and third trimester, respectively). <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">Birth defects</span> occurred in 9 of 393 (2.3%) live births (first trimester exposure) and 5 of 212 (2.4%) live births (second/third trimester exposure). Among pregnant women in the U.S. reference population, the background rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> is 2.7%. There was no association between atazanavir and overall <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> observed in the APR.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_8.1.6"></a><a name="section-8.1.5"></a><p></p>
<p class="First"><span class="Bold">Pharmacokinetics of Atazanavir in Pregnancy</span></p>
<p>[See <span class="Italics">Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="Section_8.1.7"></a><a name="section-8.1.6"></a><p></p>
<p class="First"><span class="Bold">Animal Data</span></p>
<p>In animal reproduction studies, there was no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> in offspring born to animals at systemic drug exposure levels (AUC) 0.7 (in rabbits) to 1.2 (in rats) times those observed at the human clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir). In pre- and post-natal development studies in the rat, atazanavir caused body <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> or <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> suppression in the animal offspring with maternal drug exposure (AUC) 1.3 times the human exposure at this clinical dose. However, maternal toxicity also occurred at this exposure level.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><span class="Bold">The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breast-feed their infants to avoid risking postnatal transmission of HIV.</span> It is not known whether atazanavir is present in human milk. Because of both the potential for HIV transmission and the potential for serious adverse reactions in nursing infants, <span class="Bold">mothers should be instructed not to breast-feed if they are taking REYATAZ</span>.
								</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">REYATAZ should not be administered to pediatric patients below the age of 3 months due to the risk of <span class="product-label-link" type="condition" conceptid="4326231" conceptname="Kernicterus">kernicterus</span>.</p>
<p>The safety, activity, and pharmacokinetic profiles of REYATAZ in pediatric patients ages 3 months to less than 6 years have not been established.</p>
<p>The safety, pharmacokinetic profile, and virologic response of REYATAZ were evaluated in pediatric patients in an open-label, multicenter clinical trial PACTG 1020A [see <span class="Italics">Clinical Pharmacology <a href="#Section_12.3">(12.3)</a></span> and <span class="Italics">Clinical Studies <a href="#Section_14.3">(14.3)</a></span>]. The safety profile in pediatric patients was generally similar to that observed in adults [see <span class="Italics">Adverse Reactions <a href="#Section_6.2">(6.2)</a></span>].  Please see <span class="Italics">Dosage and Administration <a href="#Section_2.2">(2.2)</a></span> for dosing recommendations for pediatric patients 6 years of age and older.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies of REYATAZ did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.  Based on a comparison of mean single-dose pharmacokinetic values for C<span class="Sub">max</span> and AUC, a dose adjustment based upon age is not recommended.  In general, appropriate caution should be exercised in the administration and monitoring of REYATAZ
in elderly patients reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Age/Gender</h2>
<p class="First">A study of the pharmacokinetics of atazanavir was performed in young (n=29; 18â€“40 years) and elderly (n=30; â‰¥65 years) healthy subjects. There were no clinically important pharmacokinetic differences observed due to age or gender.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">In healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose. REYATAZ has been studied in adult subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (n=20), including those on hemodialysis, at multiple doses of 400 mg once daily. The mean atazanavir C<span class="Sub">max</span> was 9% lower, AUC was 19% higher, and C<span class="Sub">min</span> was 96% higher in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> not undergoing hemodialysis (n=10), than in age, weight, and gender matched subjects with normal renal function. Atazanavir was not appreciably cleared during hemodialysis. In a 4-hour dialysis session, 2.1% of the administered dose was removed. When atazanavir was administered either prior to, or following hemodialysis (n=10), the geometric means for C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> were approximately 25 to 43% lower compared to subjects with normal renal function. The mechanism of this decrease is unknown. REYATAZ should not be administered to HIV-treatment-experienced patients with end stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> managed with hemodialysis. [See <span class="Italics">Dosage and Administration <a href="#Section_2.4">(2.4)</a></span>.]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Impaired Hepatic Function</h2>
<p class="First">Atazanavir is metabolized and eliminated primarily by the liver.  REYATAZ (atazanavir sulfate) has been studied in
adult subjects with moderate to severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (14 Child-Pugh B and 2 Child-Pugh C subjects) after a single 400-mg dose.  The mean AUC<span class="Sub">(0-âˆž)</span> was 42% greater in subjects with impaired hepatic function than in healthy volunteers. The mean half-life of atazanavir in hepatically impaired subjects was 12.1 hours compared to 6.4 hours in healthy volunteers.  Increased concentrations of atazanavir are expected in patients with moderately or severely impaired hepatic function. The pharmacokinetics of REYATAZ in combination with ritonavir have not been studied in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. REYATAZ should not be administered to patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. REYATAZ/ritonavir is not recommended for use in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. [See <span class="Italics">Dosage and Administration <a href="#Section_2.5">(2.5)</a></span> and <span class="Italics">Warnings and Precautions <a href="#Section_5.5">(5.5)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Human experience of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> with REYATAZ is limited.  Single doses up to 1200 mg have been taken by healthy volunteers without symptomatic untoward effects. A single self-administered <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of 29.2 g of REYATAZ in an HIV-infected patient (73 times the 400-mg
recommended dose) was associated with asymptomatic bifascicular block and PR interval prolongation. These events resolved spontaneously. At high doses
that lead to high drug exposures, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> due to indirect (unconjugated) <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">hyperbilirubinemia</span> (without associated liver function test changes) or PR interval prolongation may be observed. [See <span class="Italics">Warnings and Precautions <a href="#Section_5.2">(5.2</a>, <a href="#Section_5.4">5.4)</a></span> and <span class="Italics">Clinical Pharmacology <a href="#Section_12.2">(12.2)</a></span>.]</p>
<p>Treatment of overdosage with REYATAZ should consist of general supportive measures, including monitoring of vital signs and ECG, and observations of the patientâ€™s clinical status. If indicated, elimination of unabsorbed atazanavir should be achieved by <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or gastric lavage. Administration of activated charcoal may also be used to aid removal of unabsorbed drug. There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with REYATAZ.  Since atazanavir is extensively metabolized by the liver and is highly protein bound, dialysis is unlikely to be beneficial in significant removal of this medicine.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">REYATAZ<span class="Sup">Â®</span> (atazanavir sulfate) is an azapeptide inhibitor of HIV-1 protease.</p>
<p>The chemical name for atazanavir sulfate is (3<span class="Italics">S</span>,8<span class="Italics">S</span>,9<span class="Italics">S</span>,12<span class="Italics">S</span>)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioic
acid dimethyl ester, sulfate (1:1). Its molecular formula is C<span class="Sub">38</span>H<span class="Sub">52</span>N<span class="Sub">6</span>O<span class="Sub">7</span>â€¢H<span class="Sub">2</span>SO<span class="Sub">4</span>, which corresponds to a molecular weight of 802.9 (sulfuric acid salt). The free base molecular weight is 704.9.  Atazanavir sulfate has the following structural formula:</p>
<div class="Figure"><img alt="atazanavir sulfate chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=025876b6-f031-43ea-967a-b1d95b4685a6&amp;name=reyataz-structure.jpg"></div>
<p>Atazanavir sulfate is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow crystalline powder.  It is slightly soluble in water (4â€“5 mg/mL, free base equivalent) with the pH of a saturated solution in water being about 1.9 at 24 Â± 3Â° C.</p>
<p>REYATAZ Capsules are available for oral administration in strengths containing the equivalent of 100 mg, 150 mg, 200 mg, or 300 mg of atazanavir as atazanavir sulfate and the following inactive ingredients: crospovidone, lactose monohydrate, and magnesium stearate. The capsule shells contain the following inactive ingredients: gelatin, FD&amp;C Blue #2, titanium dioxide, black iron oxide, red iron oxide, and yellow iron oxide. The capsules are printed with ink containing shellac, titanium dioxide, FD&amp;C Blue #2, isopropyl alcohol, ammonium hydroxide, propylene glycol, n-butyl alcohol, simethicone, and dehydrated alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Atazanavir is an antiviral drug [see <span class="Italics">Clinical Pharmacology <a href="#Section_12.4">(12.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.2.1"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Effects on Electrocardiogram</span></p>
<p>Concentration- and dose-dependent prolongation of the PR interval in the electrocardiogram has been observed in healthy volunteers receiving atazanavir. In a placebo-controlled study (AI424-076), the mean (Â±SD) maximum change in PR interval from the predose value was 24 (Â±15) msec following oral dosing with 400 mg of atazanavir (n=65) compared to 13 (Â±11) msec following dosing with placebo (n=67). The PR interval prolongations in this study were asymptomatic. There is limited information on the potential for a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span> in humans between atazanavir and other drugs that prolong the PR interval of the electrocardiogram. [See <span class="Italics">Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span>.]</p>
<p>Electrocardiographic effects of atazanavir were determined in a clinical pharmacology study of 72 healthy subjects. Oral doses of 400 mg and 800 mg were compared with placebo; there was no concentration-dependent effect of atazanavir on the QTc interval (using Fridericiaâ€™s correction). In 1793 HIV-infected patients receiving antiretroviral regimens, QTc prolongation was comparable in the atazanavir and comparator regimens. No atazanavir-treated healthy subject or HIV-infected patient in clinical trials had a QTc interval &gt;500 msec. [See <span class="Italics">Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span>.]</p>
<p>In a pharmacokinetic study between atazanavir 400 mg once daily and diltiazem 180 mg once daily, a CYP3A substrate, there was a 2-fold increase in the diltiazem plasma concentration and an additive effect on the PR interval. In a pharmacokinetic study between atazanavir 400 mg once daily and atenolol 50 mg once daily, there was no substantial additive effect of atazanavir and atenolol on the PR interval. [See <span class="Italics">Warnings and Precautions <a href="#Section_5.2">(5.2)</a></span>.]</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of atazanavir were evaluated in healthy adult volunteers and in HIV-infected patients after administration of REYATAZ 400 mg once daily and after administration of REYATAZ 300 mg with ritonavir 100 mg once daily (see Table 14).</p>
<a name="i2089856e-e456-4a56-841e-2a5587d0c5aa"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 14: Steady-State Pharmacokinetics of Atazanavir in Healthy Subjects or HIV-Infected Patients in the Fed State</span></caption>
<colgroup>
<col width="32%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Toprule" align="left" colspan="1" rowspan="1"></th>
<th class="Botrule Toprule" align="center" colspan="2" rowspan="1"><span class="Bold">400 mg once daily </span></th>
<th class="Botrule Toprule" align="center" colspan="2" rowspan="1"><span class="Bold">300 mg with ritonavir<br>100 mg once daily</span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="left" colspan="1" rowspan="1"><span class="Bold">Parameter</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">Healthy<br>Subjects<br> (n=14)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">HIV-Infected Patients<br>(n=13)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">Healthy<br>Subjects<br>(n=28)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">HIV-Infected Patients<br>(n=10)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="5" rowspan="1">
<span class="Sup">a</span> n=26.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="5" rowspan="1">
<span class="Sup">b</span> n=12.</td></tr>
</tfoot>
<tbody>
<tr class="First"><td align="left" colspan="5" rowspan="1">C<span class="Sub">max</span> (ng/mL)</td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Geometric mean (CV%)</td>
<td align="center" colspan="1" rowspan="1">5199 (26)</td>
<td align="center" colspan="1" rowspan="1">2298 (71)</td>
<td align="center" colspan="1" rowspan="1">6129 (31)</td>
<td align="center" colspan="1" rowspan="1">4422 (58)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Mean (SD)</td>
<td align="center" colspan="1" rowspan="1">5358 (1371)</td>
<td align="center" colspan="1" rowspan="1">3152 (2231)</td>
<td align="center" colspan="1" rowspan="1">6450 (2031)</td>
<td align="center" colspan="1" rowspan="1">5233 (3033)</td>
</tr>
<tr valign="top"><td align="left" colspan="5" rowspan="1">T<span class="Sub">max</span> (h)</td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Median</td>
<td align="center" colspan="1" rowspan="1">2.5</td>
<td align="center" colspan="1" rowspan="1">2.0</td>
<td align="center" colspan="1" rowspan="1">2.7</td>
<td align="center" colspan="1" rowspan="1">3.0</td>
</tr>
<tr valign="top"><td align="left" colspan="5" rowspan="1">AUC (ngâ€¢h/mL)</td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Geometric mean (CV%)</td>
<td align="center" colspan="1" rowspan="1">28132 (28)</td>
<td align="center" colspan="1" rowspan="1">14874 (91)</td>
<td align="center" colspan="1" rowspan="1">57039 (37)</td>
<td align="center" colspan="1" rowspan="1">46073 (66)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Mean (SD)</td>
<td align="center" colspan="1" rowspan="1">29303 (8263)</td>
<td align="center" colspan="1" rowspan="1">22262 (20159)</td>
<td align="center" colspan="1" rowspan="1">61435 (22911)</td>
<td align="center" colspan="1" rowspan="1">53761 (35294)</td>
</tr>
<tr valign="top"><td align="left" colspan="5" rowspan="1">T-half (h)</td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Mean (SD)</td>
<td align="center" colspan="1" rowspan="1">7.9 (2.9)</td>
<td align="center" colspan="1" rowspan="1">6.5 (2.6)</td>
<td align="center" colspan="1" rowspan="1">18.1 (6.2)<span class="Sup">a</span>
</td>
<td align="center" colspan="1" rowspan="1">8.6 (2.3)</td>
</tr>
<tr><td align="left" colspan="5" rowspan="1">C<span class="Sub">min</span> (ng/mL)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Geometric mean (CV%)</td>
<td align="center" colspan="1" rowspan="1">159 (88)</td>
<td align="center" colspan="1" rowspan="1">120 (109)</td>
<td align="center" colspan="1" rowspan="1">1227 (53)</td>
<td align="center" colspan="1" rowspan="1">636 (97)</td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â Mean (SD)</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">218 (191)</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">273 (298)<span class="Sup">b</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">1441 (757)</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">862 (838)</td>
</tr>
</tbody>
</table>
<p>Figure 1 displays the mean plasma concentrations of atazanavir at steady state after REYATAZ 400 mg once daily (as two 200-mg capsules) with a light meal and after REYATAZ 300 mg (as two 150-mg capsules) with ritonavir 100 mg once daily with a light meal in HIV-infected adult patients.</p>
<p><span class="Bold">Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for HIV-Infected Adult Patients</span></p>
<div class="Figure"><img alt="Figure 1: Mean (SD) Steady-State Plasma Concentrations of Atazanavir 400 mg (n=13) and 300 mg with Ritonavir (n=10) for HIV-Infected Adult Patients" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=025876b6-f031-43ea-967a-b1d95b4685a6&amp;name=reyataz-figure1.jpg"></div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.1"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Absorption</span></p>
<p>Atazanavir is rapidly absorbed with a T<span class="Sub">max</span> of approximately 2.5 hours. Atazanavir demonstrates nonlinear pharmacokinetics with greater than dose-proportional increases in AUC and C<span class="Sub">max</span> values over the dose range of 200â€“800 mg once daily. Steady state is achieved between Days 4 and 8, with an accumulation of approximately 2.3-fold.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.2"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Food Effect</span></p>
<p>Administration of REYATAZ with food enhances bioavailability and reduces pharmacokinetic variability.  Administration of a single 400-mg dose of REYATAZ with a light meal (357 kcal, 8.2 g fat, 10.6 g protein) resulted in a 70% increase in AUC and 57% increase in C<span class="Sub">max</span> relative to the fasting state. Administration of a single 400-mg dose of REYATAZ with a high-fat meal (721 kcal, 37.3 g fat, 29.4 g protein) resulted in a mean increase in AUC of 35% with no change in C<span class="Sub">max</span> relative to the fasting state.  Administration of REYATAZ (atazanavir sulfate) with either a light meal or high-fat meal decreased the coefficient of variation of AUC and C<span class="Sub">max</span> by approximately one-half compared
to the fasting state. </p>
<p>Coadministration of a single 300-mg dose of REYATAZ and a 100-mg dose of ritonavir with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 33% increase in the AUC and a 40% increase in both the C<span class="Sub">max</span> and the 24-hour concentration of atazanavir relative to the fasting state. Coadministration with a high-fat meal (951 kcal, 54.7 g fat, 35.9 g protein) did not affect the AUC of atazanavir relative to fasting conditions and the C<span class="Sub">max</span> was within 11% of fasting values. The 24-hour concentration following a high-fat meal was increased by approximately 33% due to delayed absorption; the median T<span class="Sub">max</span> increased from 2.0 to 5.0 hours. Coadministration of REYATAZ with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and C<span class="Sub">max</span> by approximately 25% compared to the fasting state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.3"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Distribution</span></p>
<p>Atazanavir is 86% bound to human serum proteins and protein binding is independent of concentration.  Atazanavir
binds to both alpha-1-acid glycoprotein (AAG) and albumin to a similar extent (89% and 86%, respectively). In a multiple-dose study in HIV-infected patients
dosed with REYATAZ 400 mg once daily with a light meal for 12 weeks, atazanavir was detected in the cerebrospinal fluid and semen.  The cerebrospinal fluid/plasma ratio for atazanavir (n=4) ranged between 0.0021 and 0.0226 and seminal fluid/plasma ratio (n=5) ranged between 0.11 and 4.42.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.4"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Metabolism</span></p>
<p>Atazanavir is extensively metabolized in humans. The major biotransformation pathways of atazanavir in humans consisted of monooxygenation and dioxygenation. Other minor biotransformation pathways for atazanavir or its metabolites consisted of glucuronidation, N-dealkylation, hydrolysis, and oxygenation with dehydrogenation. Two minor metabolites of atazanavir in plasma have been characterized. Neither metabolite demonstrated <span class="Italics">in vitro</span> antiviral activity. <span class="Italics">In vitro</span> studies using human liver microsomes suggested that atazanavir is metabolized by CYP3A.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.5"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Elimination</span></p>
<p>Following a single 400-mg dose of <span class="Sup">14</span>C-atazanavir, 79% and 13% of the total radioactivity was recovered in the feces and urine, respectively. Unchanged drug accounted for approximately 20% and 7% of the administered dose in the feces and urine, respectively. The mean elimination half-life of atazanavir in healthy volunteers (n=214) and HIV-infected adult patients (n=13) was approximately 7 hours at steady state following a dose of 400 mg daily with a light meal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6"></a><a name="section-11.3.6"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.1"></a><a name="section-11.3.6.1"></a><p></p>
<p class="First"><span class="Bold Italics">Pediatrics</span></p>
<p>The pharmacokinetic parameters for atazanavir at steady state in pediatric patients were predicted by a population pharmacokinetic model and are summarized in Table 15 by weight ranges that correspond to the recommended doses. [See <span class="Italics">Dosage and Administration <a href="#Section_2.2">(2.2)</a></span>.]
												</p>
<a name="i794201aa-8c8a-4282-832d-1414ac5ec2dc"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 15: Predicted Steady-State Pharmacokinetics of Atazanavir (capsule formulation) with ritonavir in HIV-Infected Pediatric Patients</span></caption>
<colgroup>
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<th class="Botrule Toprule" align="center" rowspan="1"><span class="Bold">Body Weight<br>(range in kg)</span></th>
<th class="Botrule Toprule" align="center" rowspan="1"><span class="Bold"> atazanavir/ritonavir<br>Dose (mg)</span></th>
<th class="Botrule Toprule" align="center" rowspan="1"><span class="Bold">C<span class="Sub">max</span> ng/mL<br>Geometric Mean<br>(CV%)</span></th>
<th class="Botrule Toprule" align="center" rowspan="1"><span class="Bold">AUC ngâ€¢h/mL<br>Geometric Mean<br>(CV%)</span></th>
<th class="Botrule Toprule" align="center" rowspan="1"><span class="Bold">C<span class="Sub">min</span> ng/mL<br>Geometric Mean<br>(CV%)</span></th>
</tr></thead>
<tbody>
<tr class="First" valign="top">
<td align="center" colspan="1" rowspan="1">15â€“&lt;20</td>
<td align="center" colspan="1" rowspan="1">150/100</td>
<td align="center" colspan="1" rowspan="1">5213 (78.7%)</td>
<td align="center" colspan="1" rowspan="1">42902 (77.0%)</td>
<td align="center" colspan="1" rowspan="1">504 (99.5%)</td>
</tr>
<tr valign="top">
<td align="center" colspan="1" rowspan="1">20â€“&lt;40</td>
<td align="center" colspan="1" rowspan="1">200/100</td>
<td align="center" colspan="1" rowspan="1">4954 (81.7%)</td>
<td align="center" colspan="1" rowspan="1">42999 (78.5%)</td>
<td align="center" colspan="1" rowspan="1">562 (98.9%)</td>
</tr>
<tr class="Last" valign="top">
<td align="center" colspan="1" rowspan="1">â‰¥40</td>
<td align="center" colspan="1" rowspan="1">300/100</td>
<td align="center" colspan="1" rowspan="1">5040 (84.6%)</td>
<td align="center" colspan="1" rowspan="1">46777 (80.6%)</td>
<td align="center" colspan="1" rowspan="1">691 (98.5%)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.6.2"></a><a name="section-11.3.7"></a><p></p>
<p class="First"><span class="Bold Italics">Pregnancy</span></p>
<p>The pharmacokinetic data from HIV-infected pregnant women receiving REYATAZ Capsules with ritonavir are presented in Table 16.</p>
<a name="i13c6be70-df74-42f0-8ce3-dc8cc5e79bae"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 16: Steady-State Pharmacokinetics of Atazanavir with ritonavir in HIV-Infected Pregnant Women in the Fed State
											</span></caption>
<colgroup>
<col width="34%">
<col width="22%">
<col width="22%">
<col width="22%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Â </span></th>
<th class="Toprule" align="center" colspan="3" rowspan="1"><span class="Bold">Atazanavir 300 mg with ritonavir 100 mg</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="left" colspan="1" rowspan="1" valign="top"><span class="Bold">Pharmacokinetic Parameter</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">2nd Trimester<br>(n=5<span class="Sup">a</span>)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">3rd Trimester<br>(n=20)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">Postpartum<span class="Sup">b</span><br>(n=34)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td align="left" colspan="4" rowspan="1">
<span class="Sup">a</span> Available data during the 2nd trimester are limited.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">b</span> Atazanavir peak concentrations and AUCs were found to be approximately 28â€“43% higher during the postpartum period (4â€“12 weeks) than those observed historically in HIV-infected, non-pregnant patients. Atazanavir plasma trough concentrations were approximately 2.2-fold higher during the postpartum period when compared to those observed historically in HIV-infected, non-pregnant patients.</td></tr>
<tr class="Last"><td align="left" colspan="4" rowspan="1">
<span class="Sup">c</span> C<span class="Sub">min</span> is concentration 24 hours post-dose.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="1" rowspan="1">C<span class="Sub">max</span> ng/mL</td>
<td align="center" colspan="1" rowspan="1">3078.85</td>
<td align="center" colspan="1" rowspan="1">3291.46</td>
<td align="center" colspan="1" rowspan="1">5721.21</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Geometric mean (CV%)</td>
<td align="center" colspan="1" rowspan="1">(50)</td>
<td align="center" colspan="1" rowspan="1">(48)</td>
<td align="center" colspan="1" rowspan="1">(31)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AUC ngâˆ™h/mL</td>
<td align="center" colspan="1" rowspan="1">27657.1</td>
<td align="center" colspan="1" rowspan="1">34251.5</td>
<td align="center" colspan="1" rowspan="1">61990.4</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Â Â Â Geometric mean (CV%)</td>
<td align="center" colspan="1" rowspan="1">(43)</td>
<td align="center" colspan="1" rowspan="1">(43)</td>
<td align="center" colspan="1" rowspan="1">(32)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">C<span class="Sub">min</span> ng/mL<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">538.70</td>
<td align="center" colspan="1" rowspan="1">668.48</td>
<td align="center" colspan="1" rowspan="1">1462.59</td>
</tr>
<tr class="Last">
<td align="left" colspan="1" rowspan="1">Â Â Â Geometric mean (CV%)</td>
<td align="center" colspan="1" rowspan="1">(46)</td>
<td align="center" colspan="1" rowspan="1">(50)</td>
<td align="center" colspan="1" rowspan="1">(45)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.3.7"></a><a name="section-11.3.8"></a><p></p>
<p class="First"><span class="Bold">Drug Interaction Data</span></p>
<p>Atazanavir is a metabolism-dependent CYP3A inhibitor, with a K<span class="Sub">inact</span> value of 0.05 to 0.06
min<span class="Sup">-1</span> and K<span class="Sub">i</span> value of 0.84 to 1.0 ÂµM.  Atazanavir is also a direct inhibitor for UGT1A1 (K<span class="Sub">i</span>=1.9 ÂµM) and CYP2C8 (K<span class="Sub">i</span>=2.1 ÂµM). </p>
<p>Atazanavir has been shown <span class="Italics">in vivo</span> not to induce its own metabolism, nor to increase the biotransformation of some drugs metabolized by CYP3A.  In a multiple-dose study, REYATAZ decreased the urinary ratio of endogenous
6Î²-OH cortisol to cortisol versus baseline, indicating that CYP3A production was not induced.</p>
<p>Drug interaction studies were performed with REYATAZ and other drugs likely to be coadministered and some drugs commonly used as probes for <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span>. The effects of coadministration of REYATAZ on the AUC, C<span class="Sub">max</span>, and C<span class="Sub">min</span> are summarized in Tables 17 and 18. For information regarding clinical recommendations, see <span class="Italics">Drug Interactions <a href="#Section_7">(7)</a></span>.</p>
<a name="i9cf65c4a-590e-4700-8ef4-7c674348ec58"></a><table border="0" cellpadding="1" cellspacing="1" width="100%">
<caption><span>Table 17: Drug Interactions: Pharmacokinetic Parameters for Atazanavir in the Presence of Coadministered Drugs<span class="Sup">a</span></span></caption>
<colgroup>
<col width="17%">
<col width="18%">
<col width="19%">
<col width="15%">
<col width="15%">
<col width="16%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Coadministered Drug</span></th>
<th class="Botrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">Coadministered Drug<br>Dose/Schedule</span></th>
<th class="Botrule Toprule" align="center" rowspan="2" valign="middle"><span class="Bold">REYATAZ<br>Dose/Schedule</span></th>
<th class="Toprule" align="center" colspan="3" rowspan="1"><span class="Bold">Ratio (90% Confidence Interval) of Atazanavir Pharmacokinetic Parameters with/without
Coadministered Drug;<br>No Effect = 1.00</span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">C<span class="Sub">max</span></span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">AUC</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1" valign="bottom"><span class="Bold">C<span class="Sub">min</span></span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="6" rowspan="1">
<span class="Sup">a</span> Data provided are under fed conditions unless otherwise noted.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">b</span> All drugs were given under fasted conditions.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">c</span> 400 mg ddI EC and REYATAZ were administered together with food on Days 8 and 19.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">d</span> REYATAZ 300 mg plus ritonavir 100 mg once daily coadministered with famotidine 40
mg twice daily resulted in atazanavir geometric mean C<span class="Sub">max</span> that was similar and AUC and C<span class="Sub">min</span> values that were 1.79-
and 4.46-fold higher relative to REYATAZ 400 mg once daily alone.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">e</span> Similar results were noted when famotidine 20 mg BID was administered 2 hours after and 10 hours before atazanavir 300 mg and ritonavir 100 mg plus tenofovir 300 mg.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">f</span> Atazanavir/ritonavir/tenofovir was administered after a light meal.</td></tr>
<tr><td colspan="6">
<span class="Sup">g </span>Study was conducted in HIV-infected individuals. </td></tr>
<tr><td colspan="6">
<span class="Sup">h </span>Compared with atazanavir 400 mg historical data without nevirapine (n=13), the ratio of geometric means
(90% confidence intervals) for C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> were 1.42 (0.98, 2.05), 1.64 (1.11, 2.42), and 1.25 (0.66, 2.36), respectively,
for atazanavir/ritonavir 300/100 mg; and 2.02 (1.42, 2.87), 2.28 (1.54, 3.38), and 1.80 (0.94, 3.45), respectively, for atazanavir/ritonavir 400/100 mg.</td></tr>
<tr><td colspan="6">
<span class="Sup">i </span>Parallel group design; n=23 for atazanavir/ritonavir plus nevirapine, n=22 for atazanavir 300 mg/ritonavir
100 mg without nevirapine. Subjects were treated with nevirapine prior to study entry. </td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">j </span>Omeprazole 40 mg was administered on an empty stomach 2 hours before REYATAZ.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">k </span>Omeprazole 20 mg was administered 30 minutes prior to a light meal in the morning and REYATAZ 300 mg plus ritonavir 100 mg in the evening after a light meal, separated by 12 hours from omeprazole.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">l</span>  REYATAZ 300 mg plus ritonavir 100 mg once daily separated by 12 hours from omeprazole
20 mg daily resulted in increases in atazanavir geometric mean AUC (10%) and C<span class="Sub">min </span>(2.4-fold), with a decrease in C<span class="Sub">max</span> (29%)
relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1âˆ’6).</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">m</span>  Omeprazole 20 mg was given 30 minutes prior to a light meal in the morning and REYATAZ
400 mg plus ritonavir 100 mg once daily after a light meal, 1 hour after omeprazole. Effects on atazanavir concentrations were similar when REYATAZ 400 mg plus ritonavir 100 mg was separated from omeprazole 20 mg by 12 hours.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">n</span> REYATAZ 400 mg plus ritonavir 100 mg once daily administered with omeprazole 20 mg
once daily resulted in increases in atazanavir geometric mean AUC (32%) and C<span class="Sub">min</span> (3.3-fold), with a decrease in C<span class="Sub">max</span> (26%)
relative to REYATAZ 400 mg once daily in the absence of omeprazole (study days 1âˆ’6).</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">o</span> Compared with atazanavir 400 mg QD historical data, administration of atazanavir/ritonavir
300/100 mg QD increased the atazanavir geometric mean values of C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> by 18%, 103%, and 671%, respectively. </td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">p</span> Note that similar results were observed in studies where administration of tenofovir
and REYATAZ was separated by 12 hours.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="6" rowspan="1">
<span class="Sup">q</span> Ratio of atazanavir plus ritonavir plus tenofovir to atazanavir plus ritonavir.
Atazanavir 300 mg plus ritonavir 100 mg results in higher atazanavir exposure than atazanavir 400 mg (see footnote <span class="Sup">o</span>). The geometric
mean values of atazanavir pharmacokinetic parameters when coadministered with ritonavir and tenofovir were: C<span class="Sub">max</span> = 3190 ng/mL, AUC
= 34459 ngâ€¢h/mL, and C<span class="Sub">min</span> = 491 ng/mL. Study was conducted in HIV-infected individuals.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">atenolol</td>
<td align="center" colspan="1" rowspan="1">50 mg QD, dÂ 7âˆ’11 (n=19) and dÂ 19âˆ’23</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’11 (n=19)</td>
<td align="center" colspan="1" rowspan="1">1.00<br>(0.89, 1.12)</td>
<td align="center" colspan="1" rowspan="1">0.93<br>(0.85, 1.01)</td>
<td align="center" colspan="1" rowspan="1">0.74<br>(0.65, 0.86)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">clarithromycin</td>
<td align="center" colspan="1" rowspan="1">500 mg BID, dÂ 7âˆ’10 (n=29) and dÂ 18âˆ’21</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’10 (n=29)</td>
<td align="center" colspan="1" rowspan="1">1.06<br>(0.93, 1.20)</td>
<td align="center" colspan="1" rowspan="1">1.28<br>(1.16, 1.43)</td>
<td align="center" colspan="1" rowspan="1">1.91<br>(1.66, 2.21)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">didanosine (ddI) (buffered tablets) plus stavudine (d4T)<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">ddI: 200 mg x 1 dose,<br>d4T: 40 mg x 1 dose (n=31)</td>
<td align="center" colspan="1" rowspan="1">400 mg x 1 dose simultaneously with ddI and d4T (n=31)</td>
<td align="center" colspan="1" rowspan="1">0.11<br>(0.06, 0.18)</td>
<td align="center" colspan="1" rowspan="1">0.13<br>(0.08, 0.21)</td>
<td align="center" colspan="1" rowspan="1">0.16<br>(0.10, 0.27)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">ddI: 200 mg x 1 dose,<br>d4T: 40 mg x 1 dose (n=32)</td>
<td align="center" colspan="1" rowspan="1">400 mg x 1 dose 1 h after ddI + d4T (n=32)</td>
<td align="center" colspan="1" rowspan="1">1.12<br>(0.67, 1.18)</td>
<td align="center" colspan="1" rowspan="1">1.03<br>(0.64, 1.67)</td>
<td align="center" colspan="1" rowspan="1">1.03<br>(0.61, 1.73)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ddI (enteric-coated [EC] capsules)<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">400 mg dÂ 8 (fed) (n=34) 400 mg dÂ 19 (fed) (n=31)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 2âˆ’8 (n=34) 300 mg/ritonavir 100 mg QD, dÂ 9âˆ’19 (n=31)</td>
<td align="center" colspan="1" rowspan="1">1.03<br>(0.93, 1.14)<br>1.04<br>(1.01, 1.07)</td>
<td align="center" colspan="1" rowspan="1">0.99<br>(0.91, 1.08)<br>1.00<br>(0.96, 1.03)</td>
<td align="center" colspan="1" rowspan="1">0.98<br>(0.89, 1.08)<br>0.87<br>(0.82, 0.92)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">diltiazem</td>
<td align="center" colspan="1" rowspan="1">180 mg QD, dÂ 7âˆ’11 (n=30) and dÂ 19âˆ’23</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’11 (n=30)</td>
<td align="center" colspan="1" rowspan="1">1.04<br>(0.96, 1.11)</td>
<td align="center" colspan="1" rowspan="1">1.00<br>(0.95, 1.05)</td>
<td align="center" colspan="1" rowspan="1">0.98<br>(0.90, 1.07)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">efavirenz</td>
<td align="center" colspan="1" rowspan="1">600 mg QD, dÂ 7âˆ’20 (n=27)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’20 (n=27)</td>
<td align="center" colspan="1" rowspan="1">0.41<br>(0.33, 0.51)</td>
<td align="center" colspan="1" rowspan="1">0.26<br>(0.22, 0.32)</td>
<td align="center" colspan="1" rowspan="1">0.07<br>(0.05, 0.10)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">600 mg QD, dÂ 7âˆ’20 (n=13)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’6 (n=23) then 300 mg/ritonavir 100 mg QD, 2Â h before efavirenz, dÂ 7âˆ’20 (n=13)</td>
<td align="center" colspan="1" rowspan="1">1.14<br>(0.83, 1.58)</td>
<td align="center" colspan="1" rowspan="1">1.39<br>(1.02, 1.88)</td>
<td align="center" colspan="1" rowspan="1">1.48<br>(1.24, 1.76)</td>
</tr>
<tr>
<td valign="top">Â </td>
<td align="center" valign="top">600Â mg QD, dÂ 11â€“24 (pm) (n=14)</td>
<td align="center" valign="top">300 mg QD/ritonavir 100Â mg QD, dÂ 1â€“10 (pm) (n=22), then 400Â mg QD/ritonavir 100 mg QD, dÂ 11â€“24 (pm), (simultaneous with efavirenz) (n=14)</td>
<td align="center" valign="top">1.17<br>(1.08, 1.27)</td>
<td align="center" valign="top">1.00<br>(0.91, 1.10)</td>
<td align="center" valign="top">0.58<br>(0.49, 0.69)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">famotidine</td>
<td align="center" colspan="1" rowspan="1">40 mg BID, dÂ 7âˆ’12 (n=15)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’6 (n=45), dÂ 7âˆ’12 (simultaneous administration) (n=15)</td>
<td align="center" colspan="1" rowspan="1">0.53<br>(0.34, 0.82)</td>
<td align="center" colspan="1" rowspan="1">0.59<br>(0.40, 0.87) </td>
<td align="center" colspan="1" rowspan="1">0.58<br>(0.37, 0.89)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, dÂ 7âˆ’12 (n=14)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD (pm), dÂ 1âˆ’6 (n=14), dÂ 7âˆ’12 (10 h after, 2 h before famotidine) (n=14)</td>
<td align="center" colspan="1" rowspan="1">1.08<br>(0.82, 1.41)</td>
<td align="center" colspan="1" rowspan="1">0.95<br>(0.74, 1.21)</td>
<td align="center" colspan="1" rowspan="1">0.79<br>(0.60, 1.04)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, dÂ 11âˆ’20 (n=14)<span class="Sup">d</span>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 1âˆ’10 (n=46), dÂ 11âˆ’20<span class="Sup">d</span> (simultaneous administration) (n=14)</td>
<td align="center" colspan="1" rowspan="1">0.86<br>(0.79, 0.94)</td>
<td align="center" colspan="1" rowspan="1">0.82<br>(0.75, 0.89)</td>
<td align="center" colspan="1" rowspan="1">0.72<br>(0.64, 0.81)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">20 mg BID, dÂ 11âˆ’17 (n=18)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ ritonavir 100 mg QD/tenofovir 300 mg QD, dÂ 1âˆ’10 (am) (n=39), dÂ 11âˆ’17 (am) (simultaneous administration with am famotidine) (n=18)<span class="Sup">e,f</span>
</td>
<td align="center" colspan="1" rowspan="1">0.91<br>(0.84, 0.99)</td>
<td align="center" colspan="1" rowspan="1">0.90<br>(0.82, 0.98)</td>
<td align="center" colspan="1" rowspan="1">0.81<br>(0.69, 0.94)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">40 mg QD (pm),<br>d 18âˆ’24 (n=20)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ ritonavir 100 mg QD/tenofovir 300 mg QD, dÂ 1âˆ’10 (am) (n=39), dÂ 18âˆ’24 (am) (12Â h after pm famotidine) (n=20)<span class="Sup">f</span>
</td>
<td align="center" colspan="1" rowspan="1">0.89<br>(0.81, 0.97)</td>
<td align="center" colspan="1" rowspan="1">0.88<br>(0.80, 0.96)</td>
<td align="center" colspan="1" rowspan="1">0.77<br>(0.63, 0.93)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, dÂ 18âˆ’24 (n=18)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD/tenofovir 300 mg QD, dÂ 1âˆ’10 (am) (n=39), dÂ 18âˆ’24 (am) (10Â h after pm famotidine and 2Â h before am famotidine) (n=18)<span class="Sup">f</span>
</td>
<td align="center" colspan="1" rowspan="1">0.74<br>(0.66, 0.84)</td>
<td align="center" colspan="1" rowspan="1">0.79<br>(0.70, 0.88)</td>
<td align="center" colspan="1" rowspan="1">0.72<br>(0.63, 0.83)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">40 mg BID, dÂ 11âˆ’20 (n=15)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 1âˆ’10 (am) (n=46), then 400 mg QD/ritonavir 100 mg QD, dÂ 11âˆ’20 (am) (n=15)</td>
<td align="center" colspan="1" rowspan="1">1.02<br>(0.87, 1.18)</td>
<td align="center" colspan="1" rowspan="1">1.03<br>(0.86, 1.22)</td>
<td align="center" colspan="1" rowspan="1">0.86<br>(0.68, 1.08)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">fluconazole</td>
<td align="center" colspan="1" rowspan="1">200 mg QD, dÂ 11âˆ’20 (n=29)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ ritonavir 100Â mg QD, dÂ 1âˆ’10 (n=19), dÂ 11âˆ’20 (n=29)</td>
<td align="center" colspan="1" rowspan="1">1.03<br>(0.95, 1.11)</td>
<td align="center" colspan="1" rowspan="1">1.04<br>(0.95, 1.13)</td>
<td align="center" colspan="1" rowspan="1">0.98<br>(0.85, 1.13)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ketoconazole</td>
<td align="center" colspan="1" rowspan="1">200 mg QD, dÂ 7âˆ’13 (n=14)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’13 (n=14)</td>
<td align="center" colspan="1" rowspan="1">0.99<br>(0.77, 1.28)</td>
<td align="center" colspan="1" rowspan="1">1.10<br>(0.89, 1.37)</td>
<td align="center" colspan="1" rowspan="1">1.03<br>(0.53, 2.01)</td>
</tr>
<tr>
<td valign="top">nevirapine<span class="Sup">g,h</span>
</td>
<td align="center" valign="top">200 mg BID, d 1â€“23 (n=23)</td>
<td align="center" valign="top">300 mg QD/ritonavir 100 mg QD, d 4â€“13, then 400 mg QD/ritonavir 100 mg QD, d 14â€“23 (n=23)<span class="Sup">i</span>
</td>
<td align="center" valign="top">0.72<br>(0.60, 0.86)<br>1.02<br>(0.85, 1.24)</td>
<td align="center" valign="top">0.58<br>(0.48, 0.71)<br>0.81<br>(0.65, 1.02)</td>
<td align="center" valign="top">0.28<br>(0.20, 0.40)<br>0.41<br>(0.27, 0.60)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">omeprazole</td>
<td align="center" colspan="1" rowspan="1">40 mg QD, dÂ 7âˆ’12 (n=16)<span class="Sup">j</span>
</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’6 (n=48), dÂ 7âˆ’12 (n=16)</td>
<td align="center" colspan="1" rowspan="1">0.04<br>(0.04, 0.05)</td>
<td align="center" colspan="1" rowspan="1">0.06<br>(0.05, 0.07)</td>
<td align="center" colspan="1" rowspan="1">0.05<br>(0.03, 0.07)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">40 mg QD, dÂ 11âˆ’20 (n=15)<span class="Sup">j</span>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100Â mg QD, dÂ 1âˆ’20 (n=15)</td>
<td align="center" colspan="1" rowspan="1">0.28<br>(0.24, 0.32)</td>
<td align="center" colspan="1" rowspan="1">0.24<br>(0.21, 0.27)</td>
<td align="center" colspan="1" rowspan="1">0.22<br>(0.19, 0.26)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">20 mg QD, dÂ 17âˆ’23 (am) (n=13)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100Â mg QD, dÂ 7âˆ’16 (pm) (n=27), dÂ 17âˆ’23 (pm) (n=13)<span class="Sup">k,l</span>
</td>
<td align="center" colspan="1" rowspan="1">0.61<br>(0.46, 0.81)</td>
<td align="center" colspan="1" rowspan="1">0.58<br>(0.44, 0.75)</td>
<td align="center" colspan="1" rowspan="1">0.54<br>(0.41, 0.71)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">20 mg QD, dÂ 17âˆ’23 (am) (n=14)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100Â mg QD, dÂ 7âˆ’16 (am) (n=27), then 400 mg QD/ritonavir 100 mg QD, dÂ 17âˆ’23 (am) (n=14)<span class="Sup">m,n</span>
</td>
<td align="center" colspan="1" rowspan="1">0.69<br>(0.58, 0.83)</td>
<td align="center" colspan="1" rowspan="1">0.70<br>(0.57, 0.86)</td>
<td align="center" colspan="1" rowspan="1">0.69<br>(0.54, 0.88)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">rifabutin</td>
<td align="center" colspan="1" rowspan="1">150 mg QD, dÂ 15âˆ’28 (n=7)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’28 (n=7)</td>
<td align="center" colspan="1" rowspan="1">1.34<br>(1.14, 1.59)</td>
<td align="center" colspan="1" rowspan="1">1.15<br>(0.98, 1.34)</td>
<td align="center" colspan="1" rowspan="1">1.13<br>(0.68, 1.87)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">rifampin</td>
<td align="center" colspan="1" rowspan="1">600 mg QD, dÂ 17âˆ’26 (n=16)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100Â mg QD, dÂ 7âˆ’16 (n=48), dÂ 17âˆ’26 (n=16)</td>
<td align="center" colspan="1" rowspan="1">0.47<br>(0.41, 0.53)</td>
<td align="center" colspan="1" rowspan="1">0.28<br>(0.25, 0.32)</td>
<td align="center" colspan="1" rowspan="1">0.02<br>(0.02, 0.03)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ritonavir<span class="Sup">o</span>
</td>
<td align="center" colspan="1" rowspan="1">100 mg QD, dÂ 11âˆ’20 (n=28)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD, dÂ 1âˆ’20 (n=28)</td>
<td align="center" colspan="1" rowspan="1">1.86<br>(1.69, 2.05)</td>
<td align="center" colspan="1" rowspan="1">3.38<br>(3.13, 3.63)</td>
<td align="center" colspan="1" rowspan="1">11.89<br>(10.23, 13.82)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">tenofovir<span class="Sup">p</span>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD, dÂ 9âˆ’16 (n=34)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 2âˆ’16 (n=34)</td>
<td align="center" colspan="1" rowspan="1">0.79<br>(0.73, 0.86)</td>
<td align="center" colspan="1" rowspan="1">0.75<br>(0.70, 0.81)</td>
<td align="center" colspan="1" rowspan="1">0.60<br>(0.52, 0.68)</td>
</tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">300 mg QD, dÂ 15âˆ’42 (n=10)</td>
<td align="center" colspan="1" rowspan="1">300 mg/ritonavir 100Â mg QD, dÂ 1âˆ’42 (n=10)</td>
<td align="center" colspan="1" rowspan="1">0.72<span class="Sup">q</span><br>(0.50, 1.05)</td>
<td align="center" colspan="1" rowspan="1">0.75<span class="Sup">q </span><br>(0.58, 0.97)</td>
<td align="center" colspan="1" rowspan="1">0.77<span class="Sup">q</span><br>(0.54, 1.10)</td>
</tr>
</tbody>
</table>
<a name="ie4de3cb6-1894-42bf-85ab-c136d6bba6e1"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 18: Drug Interactions: Pharmacokinetic Parameters for Coadministered Drugs in the Presence of REYATAZ<span class="Sup">a</span></span></caption>
<colgroup>
<col width="17%">
<col width="18%">
<col width="19%">
<col width="15%">
<col width="15%">
<col width="16%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="center" colspan="1" rowspan="2" valign="middle"><span class="Bold">Coadministered Drug</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="2" valign="middle"><span class="Bold">Coadministered Drug<br>Dose/Schedule</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="2" valign="middle"><span class="Bold">REYATAZ<br>Dose/Schedule</span></th>
<th class="Toprule" align="center" colspan="3" rowspan="1"><span class="Bold">Ratio (90% Confidence Interval) of Coadministered Drug Pharmacokinetic Parameters
with/without REYATAZ;<br>No Effect = 1.00</span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">C<span class="Sub">max</span></span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">AUC</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">C<span class="Sub">min</span></span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="6">
<span class="Sup">a</span> Data provided are under fed conditions unless otherwise noted.</td></tr>
<tr><td colspan="6">
<span class="Sup">b</span> All drugs were given under fasted conditions. </td></tr>
<tr><td colspan="6">
<span class="Sup">c</span> 400 mg ddI EC and REYATAZ were administered together with food on Days 8 and 19.</td></tr>
<tr><td colspan="6">
<span class="Sup">d</span> Upon further dose normalization of ethinyl estradiol 25 mcg with atazanavir relative to ethinyl
estradiol 35 mcg without atazanavir, the ratio of geometric means (90% confidence intervals) for C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> were
0.82 (0.73, 0.92), 1.06 (0.95, 1.17), and 1.35 (1.11, 1.63), respectively.</td></tr>
<tr><td colspan="6">
<span class="Sup">e</span> Upon further dose normalization of ethinyl estradiol 35 mcg with atazanavir/ritonavir relative
to ethinyl estradiol 25 mcg  without atazanavir/ritonavir, the ratio of geometric means (90% confidence intervals) for C<span class="Sub">max</span>, AUC, and
C<span class="Sub">min</span> were 1.17 (1.03, 1.34), 1.13 (1.05, 1.22), and 0.88 (0.77, 1.00), respectively.</td></tr>
<tr><td colspan="6">
<span class="Sup">f</span> All subjects were on a 28 day lead-in period; one full cycle of Ortho Tri-Cyclen<span class="Sup">Â®</span>.
Ortho Tri-Cyclen<span class="Sup">Â®</span> contains 35 mcg of  ethinyl estradiol. Ortho Tri-Cyclen<span class="Sup">Â®</span> LO contains 25 mcg of ethinyl
estradiol. Results were dose normalized to an ethinyl  estradiol dose of 35 mcg.</td></tr>
<tr><td colspan="6">
<span class="Sup">g</span> 17-deacetyl norgestimate is the active component of norgestimate.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">h</span> (R)-methadone is the active isomer of methadone.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">i</span> Study was conducted in HIV-infected individuals.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">j</span> Subjects were treated with nevirapine prior to study entry.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">k</span> Omeprazole was used as a metabolic probe for CYP2C19. Omeprazole was given 2 hours after
REYATAZ on DayÂ 7; and was given alone 2 hours after a light meal on Day 20.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">l</span> Not the recommended therapeutic dose of atazanavir.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">m</span> When compared to rifabutin 150 mg QD alone d1âˆ’10 (n=14). Total of Rifabutin + 25-O-desacetyl-rifabutin: AUC 2.19 (1.78, 2.69).</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">n</span> Rosiglitazone used as a probe substrate for CYP2C8.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">o</span> The combination of atazanavir and saquinavir 1200 mg QD produced daily saquinavir
exposures similar to the values produced by the standard therapeutic dosing of saquinavir at 1200 mg TID. However, the C<span class="Sub">max</span> is
about 79% higher than that for the standard dosing of saquinavir (soft gelatin capsules) alone at 1200 mg TID.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">p</span> Note that similar results were observed in a study where administration of tenofovir
and REYATAZ was separated by 12 hours.</td></tr>
<tr><td align="left" colspan="6" rowspan="1">
<span class="Sup">q</span> Administration of tenofovir and REYATAZ was temporally separated by 12 hours.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="6" rowspan="1">NA = not available.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">acetaminophen</td>
<td align="center" colspan="1" rowspan="1">1 gm BID, dÂ 1âˆ’20 (n=10)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 11âˆ’20 (n=10)</td>
<td align="center" colspan="1" rowspan="1">0.87<br>(0.77, 0.99)</td>
<td align="center" colspan="1" rowspan="1">0.97<br>(0.91, 1.03)</td>
<td align="center" colspan="1" rowspan="1">1.26<br>(1.08, 1.46)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">atenolol</td>
<td align="center" colspan="1" rowspan="1">50 mg QD, dÂ 7âˆ’11 (n=19) and dÂ 19âˆ’23</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’11 (n=19)</td>
<td align="center" colspan="1" rowspan="1">1.34<br>(1.26, 1.42)</td>
<td align="center" colspan="1" rowspan="1">1.25<br>(1.16, 1.34)</td>
<td align="center" colspan="1" rowspan="1">1.02<br>(0.88, 1.19)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">clarithromycin</td>
<td align="center" colspan="1" rowspan="1">500 mg BID, dÂ 7âˆ’10 (n=21) and dÂ 18âˆ’21</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’10 (n=21)</td>
<td align="center" colspan="1" rowspan="1">1.50<br>(1.32, 1.71)<br>OH-<br>clarithromycin:<br>0.28<br>(0.24,
0.33)</td>
<td align="center" colspan="1" rowspan="1">1.94<br>(1.75, 2.16)<br>OH-<br>clarithromycin:<br>0.30<br>(0.26,
0.34)</td>
<td align="center" colspan="1" rowspan="1">2.60<br>(2.35, 2.88)<br>OH-<br>clarithromycin:<br>0.38<br>(0.34,
0.42)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">didanosine (ddI) (buffered tablets) plus stavudine<br>(d4T)<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">ddI: 200 mg x 1 dose,<br>d4T: 40 mg x 1 dose (n=31)</td>
<td align="center" colspan="1" rowspan="1">400 mg x 1 dose simultaneous with ddI and d4T (n=31)</td>
<td align="center" colspan="1" rowspan="1">ddI: 0.92<br>(0.84, 1.02)<br>d4T: 1.08<br>(0.96, 1.22)</td>
<td align="center" colspan="1" rowspan="1">ddI: 0.98<br>(0.92, 1.05)<br>d4T: 1.00<br>(0.97, 1.03)</td>
<td align="center" colspan="1" rowspan="1">NA<br><br>d4T: 1.04<br>(0.94, 1.16)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ddI (enteric-coated [EC] capsules)<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">400 mg dÂ 1 (fasted), dÂ 8 (fed) (n=34)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 2âˆ’8 (n=34)</td>
<td align="center" colspan="1" rowspan="1">0.64<br>(0.55, 0.74)</td>
<td align="center" colspan="1" rowspan="1">0.66<br>(0.60, 0.74)</td>
<td align="center" colspan="1" rowspan="1">1.13<br>(0.91, 1.41)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">400 mg dÂ 1 (fasted), dÂ 19 (fed) (n=31)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 9âˆ’19 (n=31)</td>
<td align="center" colspan="1" rowspan="1">0.62<br>(0.52, 0.74)</td>
<td align="center" colspan="1" rowspan="1">0.66<br>(0.59, 0.73)</td>
<td align="center" colspan="1" rowspan="1">1.25<br>(0.92, 1.69)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">diltiazem</td>
<td align="center" colspan="1" rowspan="1">180 mg QD, dÂ 7âˆ’11 (n=28) and dÂ 19âˆ’23</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’11 (n=28)</td>
<td align="center" colspan="1" rowspan="1">1.98<br>(1.78, 2.19)<br>desacetyl-<br>diltiazem:<br>2.72<br>(2.44,
3.03)</td>
<td align="center" colspan="1" rowspan="1">2.25<br>(2.09, 2.16)<br>desacetyl-<br>diltiazem:<br>2.65<br>(2.45,
2.87)</td>
<td align="center" colspan="1" rowspan="1">2.42<br>(2.14, 2.73)<br>desacetyl-<br>diltiazem:<br>2.21<br>(2.02,
2.42)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">ethinyl estradiol &amp; norethindrone<span class="Sup">d</span>
</td>
<td align="center" colspan="1" rowspan="1">Ortho-Novum<span class="Sup">Â®</span> 7/7/7 QD, dÂ 1âˆ’29 (n=19)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 16âˆ’29 (n=19)</td>
<td align="center" colspan="1" rowspan="1">ethinyl<br>estradiol:<br>1.15<br>(0.99, 1.32)<br>norethindrone:<br>1.67<br>(1.42, 1.96)</td>
<td align="center" colspan="1" rowspan="1">ethinyl<br>estradiol:<br>1.48<br>(1.31, 1.68)<br>norethindrone:<br>2.10<br>(1.68, 2.62)</td>
<td align="center" colspan="1" rowspan="1">ethinyl<br>estradiol:<br>1.91<br>(1.57, 2.33)<br>norethindrone:<br>3.62<br>(2.57, 5.09)</td>
</tr>
<tr>
<td valign="top">ethinyl estradiol  &amp; norgestimate<span class="Sup">e</span>
</td>
<td align="center" valign="top">Ortho Tri-Cyclen<span class="Sup">Â®</span> QD, d 1â€“28 (n=18), then Ortho Tri-Cyclen<span class="Sup">Â®</span> LO QD, d 29â€“42<span class="Sup">f</span> (n=14)</td>
<td align="center" valign="top">300 mg QD/ritonavir 100 mg QD,  d 29â€“42  (n=14)</td>
<td align="center" valign="top">ethinyl<br>estradiol:<br>0.84<br>(0.74, 0.95)<br>17-deacetyl<br>norgestimate:<span class="Sup">g</span><br>1.68<br> (1.51, 1.88)</td>
<td align="center" valign="top">ethinyl<br>estradiol:<br> 0.81<br> (0.75, 0.87)<br> 17-deacetyl<br>norgestimate:<span class="Sup">g</span><br> 1.85<br> (1.67, 2.05)</td>
<td align="center" valign="top">ethinyl<br>estradiol:<br> 0.63<br> (0.55, 0.71)<br> 17-deacetyl<br>norgestimate:<span class="Sup">g</span><br> 2.02<br> (1.77, 2.31)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">fluconazole</td>
<td align="center" colspan="1" rowspan="1">200 mg QD, dÂ 1âˆ’10 (n=11) and 200 mg QD, dÂ 11âˆ’20 (n=29)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 11âˆ’20 (n=29)</td>
<td align="center" colspan="1" rowspan="1">1.05<br>(0.99, 1.10)</td>
<td align="center" colspan="1" rowspan="1">1.08<br>(1.02, 1.15)</td>
<td align="center" colspan="1" rowspan="1">1.07<br>(1.00, 1.15)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">methadone</td>
<td align="center" colspan="1" rowspan="1">Stable maintenance dose, dÂ 1âˆ’15 (n=16)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 2âˆ’15 (n=16)</td>
<td align="center" colspan="1" rowspan="1">(R)-<br>methadone<span class="Sup">h</span><br>0.91<br>(0.84, 1.0)<br>total:0.85<br>(0.78, 0.93)</td>
<td align="center" colspan="1" rowspan="1">(R)-<br>methadone<span class="Sup">h</span><br>1.03<br>(0.95, 1.10)<br>total:0.94<br>(0.87, 1.02)</td>
<td align="center" colspan="1" rowspan="1">(R)-<br>methadone<span class="Sup">h</span><br>1.11<br>(1.02, 1.20)<br>total:1.02<br>(0.93, 1.12)</td>
</tr>
<tr>
<td valign="top">nevirapine<span class="Sup">i,j</span>
</td>
<td align="center" valign="top">200 mg BID, d 1â€“23 (n=23)</td>
<td align="center" valign="top">300 mg QD/ritonavir 100 mg QD, d 4â€“13, then 400 mg QD/ritonavir 100 mg QD, d 14â€“23 (n=23)</td>
<td align="center" valign="top">1.17<br>(1.09, 1.25)<br>1.21<br>(1.11, 1.32)</td>
<td align="center" valign="top">1.25<br>(1.17, 1.34)<br>1.26<br>(1.17, 1.36)</td>
<td align="center" valign="top">1.32<br>(1.22, 1.43)<br>1.35<br>(1.25, 1.47)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">omeprazole<span class="Sup">k</span>
</td>
<td align="center" colspan="1" rowspan="1">40 mg single dose, dÂ 7 and dÂ 20 (n=16)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 1âˆ’12 (n=16)</td>
<td align="center" colspan="1" rowspan="1">1.24<br>(1.04, 1.47)</td>
<td align="center" colspan="1" rowspan="1">1.45<br>(1.20, 1.76)</td>
<td align="center" colspan="1" rowspan="1">NA</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">rifabutin</td>
<td align="center" colspan="1" rowspan="1">300 mg QD, dÂ 1âˆ’10 then 150 mg QD, dÂ 11âˆ’20 (n=3)</td>
<td align="center" colspan="1" rowspan="1">600 mg QD,<span class="Sup">l</span> dÂ 11âˆ’20 (n=3)</td>
<td align="center" colspan="1" rowspan="1">1.18<br>(0.94, 1.48)<br>25-O-<br>desacetyl-<br>rifabutin: 8.20<br>(5.90,
11.40)</td>
<td align="center" colspan="1" rowspan="1">2.10<br>(1.57, 2.79)<br>25-O-<br>desacetyl-<br>rifabutin: 22.01<br>(15.97,
30.34)</td>
<td align="center" colspan="1" rowspan="1">3.43<br>(1.98, 5.96)<br>25-O-<br>desacetyl-<br>rifabutin: 75.6<br>(30.1,
190.0)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">150 mg twice weekly, d 1âˆ’15 (n=7)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 1âˆ’17 (n=7)</td>
<td align="center" colspan="1" rowspan="1">2.49<span class="Sup">m</span><br>(2.03, 3.06)<br>25-O-<br>desacetyl-<br>rifabutin: 7.77<br>(6.13, 9.83)</td>
<td align="center" colspan="1" rowspan="1">1.48<span class="Sup">m</span><br>(1.19, 1.84)<br>25-O-<br>desacetyl-<br>rifabutin: 10.90<br>(8.14, 14.61)</td>
<td align="center" colspan="1" rowspan="1">1.40<span class="Sup">m</span><br>(1.05, 1.87)<br>25-O-<br>desacetyl-<br>rifabutin: 11.45<br>(8.15, 16.10)</td>
</tr>
<tr>
<td valign="top">rosiglitazone<span class="Sup">n</span>
</td>
<td align="center" valign="top">4 mg single dose, d 1, 7, 17 (n=14)</td>
<td align="center" valign="top">400 mg QD, d 2â€“7, then 300 mg QD/ritonavir 100 mg QD, d 8â€“17 (n=14)</td>
<td align="center" valign="top">1.08<br>(1.03, 1.13)<br>0.97<br>(0.91, 1.04)</td>
<td align="center" valign="top">1.35<br>(1.26, 1.44)<br>0.83<br>(0.77, 0.89)</td>
<td align="center" valign="top">NA<br><br><br>NA</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">saquinavir<span class="Sup">o</span> (soft gelatin capsules)</td>
<td align="center" colspan="1" rowspan="1">1200 mg QD, dÂ 1âˆ’13 (n=7)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 7âˆ’13 (n=7)</td>
<td align="center" colspan="1" rowspan="1">4.39<br>(3.24, 5.95)</td>
<td align="center" colspan="1" rowspan="1">5.49<br>(4.04, 7.47)</td>
<td align="center" colspan="1" rowspan="1">6.86<br>(5.29, 8.91)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">tenofovir<span class="Sup">p</span>
</td>
<td align="center" colspan="1" rowspan="1">300 mg QD, dÂ 9âˆ’16 (n=33) and dÂ 24âˆ’30 (n=33)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 2âˆ’16 (n=33)</td>
<td align="center" colspan="1" rowspan="1">1.14<br>(1.08, 1.20)</td>
<td align="center" colspan="1" rowspan="1">1.24<br>(1.21, 1.28)</td>
<td align="center" colspan="1" rowspan="1">1.22<br>(1.15, 1.30)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â </td>
<td align="center" colspan="1" rowspan="1">300 mg QD, dÂ 1âˆ’7 (pm) (n=14) dÂ 25âˆ’34 (pm) (n=12)</td>
<td align="center" colspan="1" rowspan="1">300 mg QD/ritonavir 100 mg QD, dÂ 25âˆ’34 (am) (n=12)<span class="Sup">q</span>
</td>
<td align="center" colspan="1" rowspan="1">1.34<br>(1.20, 1.51)</td>
<td align="center" colspan="1" rowspan="1">1.37<br>(1.30, 1.45)</td>
<td align="center" colspan="1" rowspan="1">1.29<br>(1.21, 1.36)</td>
</tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">lamivudine + zidovudine</td>
<td align="center" colspan="1" rowspan="1">150 mg lamivudine + 300 mg zidovudine BID, dÂ 1âˆ’12 (n=19)</td>
<td align="center" colspan="1" rowspan="1">400 mg QD, dÂ 7âˆ’12 (n=19)</td>
<td align="center" colspan="1" rowspan="1">lamivudine: 1.04<br>(0.92, 1.16)<br>zidovudine: 1.05<br>(0.88, 1.24)<br>zidovudine<br>glucuronide: 0.95<br>(0.88, 1.02)</td>
<td align="center" colspan="1" rowspan="1">lamivudine: 1.03<br>(0.98, 1.08)<br>zidovudine: 1.05<br>(0.96, 1.14)<br>zidovudine<br>glucuronide: 1.00<br>(0.97, 1.03)</td>
<td align="center" colspan="1" rowspan="1">lamivudine: 1.12<br>(1.04, 1.21)<br>zidovudine: 0.69<br>(0.57, 0.84)<br>zidovudine<br>glucuronide: 0.82<br>(0.62, 1.08)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.4"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4.1"></a><a name="section-11.4.1"></a><p></p>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Atazanavir (ATV) is an azapeptide HIV-1 protease inhibitor (PI). The compound selectively inhibits the virus-specific
processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, thus preventing formation of mature virions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4.2"></a><a name="section-11.4.2"></a><p></p>
<p class="First"><span class="Bold">Antiviral Activity in Cell Culture</span></p>
<p>Atazanavir exhibits anti-HIV-1 activity with a mean 50% effective concentration (EC<span class="Sub">50</span>) in the
absence of human serum of 2 to 5 nM against a variety of laboratory and clinical HIV-1 isolates grown in peripheral blood mononuclear cells, macrophages, CEM-SS cells, and MT-2 cells. ATV has activity against HIV-1 Group M subtype viruses A, B, C, D, AE, AG, F, G, and J isolates in cell culture. ATV has variable activity against HIV-2 isolates (1.9 to 32 nM), with EC<span class="Sub">50</span> values above the EC<span class="Sub">50</span> values of failure isolates. Two-drug
combination antiviral activity studies with ATV showed no antagonism in cell culture with NNRTIs (delavirdine, efavirenz, and nevirapine), PIs (amprenavir,
indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir), NRTIs (abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine, and zidovudine), the HIV-1 fusion inhibitor enfuvirtide, and two compounds used in the treatment of <span class="product-label-link" type="condition" conceptid="4291005" conceptname="Viral hepatitis">viral hepatitis</span>, adefovir and ribavirin, without enhanced cytotoxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4.3"></a><a name="section-11.4.3"></a><p></p>
<p class="First"><span class="Bold">Resistance</span></p>
<p><span class="Italics">In Cell Culture:</span> HIV-1 isolates with a decreased susceptibility to ATV have been selected in cell culture and obtained from patients treated with ATV or atazanavir/ritonavir (ATV/RTV). HIV-1 isolates with 93- to 183-fold reduced susceptibility to ATV from three different viral <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> were selected in cell culture by 5 months. The substitutions in these HIV-1 viruses that contributed to ATV resistance
include I50L, N88S, I84V, A71V, and M46I. Changes were also observed at the protease cleavage sites following drug selection. Recombinant viruses containing
the I50L substitution without other major PI substitutions were growth impaired and displayed increased susceptibility in cell culture to other PIs (amprenavir,
indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir). The I50L and I50V substitutions yielded selective resistance to ATV and amprenavir, respectively,
and did not appear to be cross-resistant.</p>
<p><span class="Italics">Clinical Studies of Treatment-Naive Patients: Comparison of Ritonavir-Boosted REYATAZ vs. Unboosted REYATAZ: </span>Study AI424-089 compared REYATAZ 300 mg once daily with ritonavir 100 mg vs. REYATAZ 400 mg once daily when administered with lamivudine and extended-release stavudine in HIV-infected treatment-naive patients. A summary of the number of virologic failures and virologic failure isolates with ATV resistance in each arm is shown in Table 19.</p>
<a name="i42d7aee2-c42d-4fbf-8b64-c3730ebbdaa3"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 19: Summary of Virologic Failures<span class="Sup">a</span> at Week 96 in Study AI424-089: Comparison of Ritonavir Boosted REYATAZ vs. Unboosted REYATAZ: Randomized Patients</span></caption>
<colgroup>
<col width="54%">
<col width="23%">
<col width="23%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" rowspan="2">Â </th>
<th class="Toprule" align="center" valign="top"><span class="Bold">REYATAZ 300 mg +<br>ritonavir 100 mg </span></th>
<th class="Toprule" align="center" valign="top"><span class="Bold">REYATAZ 400 mg</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center"><span class="Bold">(n=95)</span></th>
<th class="Botrule" align="center"><span class="Bold">(n=105) </span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="3">
<span class="Sup">a</span> Virologic failure includes patients who were never suppressed through Week 96 and on study at
Week 96, had virologic rebound or discontinued due to insufficient viral load response.</td></tr>
<tr><td colspan="3">
<span class="Sup">b</span> Percentage of Virologic Failure
Isolates with genotypic and phenotypic data. </td></tr>
<tr class="Last"><td class="Botrule" colspan="3">
<span class="Sup">c</span> Mixture of I50I/L emerged in 2 other ATV 400 mg-treated patients. Neither isolate was phenotypically resistant to ATV.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td>Virologic Failure (â‰¥50 copies/mL) at Week 96  </td>
<td align="center">15 (16%)</td>
<td align="center">34 (32%)</td>
</tr>
<tr>
<td>Virologic Failure with Genotypes and Phenotypes Data</td>
<td align="center">5</td>
<td align="center">17</td>
</tr>
<tr>
<td>Virologic Failure Isolates with ATV-resistance at Week 96 </td>
<td align="center">0/5 (0%)<span class="Sup">b</span>
</td>
<td align="center">4/17 (24%)<span class="Sup">b</span>
</td>
</tr>
<tr>
<td>Virologic Failure Isolates with I50L Emergence at Week 96<span class="Sup">c</span>
</td>
<td align="center">0/5 (0%)<span class="Sup">b</span>
</td>
<td align="center">2/17 (12%)<span class="Sup">b</span>
</td>
</tr>
<tr class="Last">
<td>Virologic Failure Isolates with Lamivudine Resistance at Week 96</td>
<td align="center">2/5 (40%)<span class="Sup">b</span>
</td>
<td align="center">11/17 (65%)<span class="Sup">b</span>
</td>
</tr>
</tbody>
</table>
<p><span class="Italics">Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 300 mg With Ritonavir 100 mg:</span> In Phase III study AI424-138, an as-treated genotypic and phenotypic analysis was conducted on samples from patients who experienced virologic failure (HIV-1 RNA â‰¥400 copies/mL) or discontinued before achieving suppression on ATV/RTV (n=39; 9%) and LPV/RTV (n=39; 9%) through 96 weeks of treatment. In the ATV/RTV arm, one of the virologic failure isolates had a 56-fold decrease in ATV susceptibility emerge on therapy with the development of PI resistance-associated substitutions  L10F, V32I, K43T, M46I, A71I, G73S, I85I/V, and L90M. The NRTI resistance-associated substitution M184V also emerged on treatment in this isolate conferring emtricitabine resistance. Two ATV/RTV-virologic failure isolates had baseline phenotypic ATV resistance and IAS-defined major PI resistance-associated substitutions at baseline. The 150L substitution emerged on study in one of these failure isolates and was associated with a 17-fold decrease in ATV susceptibility from baseline and the other failure isolate with baseline ATV resistance and PI substitutions (M46M/I and I84I/V) had additional IAS-defined major PI substitutions (V32I, M46I, and I84V) emerge on ATV treatment associated with a 3-fold decrease in ATV susceptibiity from baseline. Five of the treatment failure isolates in the ATV/RTV arm developed phenotypic emtricitabine resistance with the emergence of either the M184I (n=1) or the M184V (n=4) substitution on therapy and none developed phenotypic tenofovir disoproxil resistance. In the LPV/RTV arm, one of the virologic failure patient isolates had a 69-fold decrease in LPV susceptibility emerge on therapy with the development of PI substitutions L10V, V11I, I54V, G73S, and V82A in addition to baseline PI substitutions L10L/I, V32I, I54I/V, A71I, G73G/S, V82V/A, L89V, and L90M. Six LPV/RTV virologic failure isolates developed the M184V substitution and phenotypic emtricitabine resistance and two developed phenotypic tenofovir disoproxil resistance.</p>
<p><span class="Italics">Clinical Studies of Treatment-Naive Patients Receiving REYATAZ 400 mg Without Ritonavir: </span>ATV-resistant clinical isolates from treatment-naive patients who experienced virologic failure on REYATAZ 400 mg treatment without ritonavir often developed an I50L substitution (after an average of 50 weeks of ATV therapy), often in combination with an A71V substitution, but also developed one or more other PI substitutions (eg, V32I, L33F, G73S, V82A, I85V, or N88S) with or without the I50L substitution. In treatment-naive patients, viral isolates that developed the I50L substitution, without other major PI substitutions, showed phenotypic resistance to ATV but retained in cell culture susceptibility to other PIs (amprenavir, indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir); however, there are no clinical data available to demonstrate the effect of the I50L substitution on the efficacy of subsequently administered PIs.</p>
<p><span class="Italics">Clinical Studies of Treatment-Experienced Patients:</span> In studies of treatment-experienced
patients treated with ATV or ATV/RTV, most ATV-resistant isolates from patients who experienced virologic failure developed substitutions that were associated
with resistance to multiple PIs and displayed decreased susceptibility to multiple PIs. The most common protease substitutions to develop in the viral isolates of patients who failed treatment with ATV 300 mg once daily and RTV 100 mg once daily (together with tenofovir and an NRTI) included V32I, L33F/V/I, E35D/G, M46I/L, I50L, F53L/V, I54V, A71V/T/I, G73S/T/C, V82A/T/L, I85V, and L89V/Q/M/T. Other substitutions that developed on ATV/RTV treatment including E34K/A/Q, G48V, I84V, N88S/D/T, and L90M occurred in less than 10% of patient isolates.  Generally, if multiple PI resistance substitutions were present in the HIV-1 virus of the patient at baseline, ATV resistance developed through substitutions associated with resistance to other PIs and could include the development of the I50L substitution. The I50L substitution has been detected in treatment-experienced patients experiencing virologic failure after long-term
treatment. Protease cleavage site changes also emerged on ATV treatment but their presence did not correlate with the level of ATV resistance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4.4"></a><a name="section-11.4.4"></a><p></p>
<p class="First"><span class="Bold">Cross-Resistance</span></p>
<p>Cross-resistance among PIs has been observed. Baseline phenotypic and genotypic analyses of clinical isolates from ATV clinical trials of PI-experienced patients showed that isolates cross-resistant to multiple PIs were cross-resistant to ATV.  Greater than 90% of the isolates
with substitutions that included I84V or G48V were resistant to ATV.  Greater than 60% of isolates containing L90M, G73S/T/C, A71V/T, I54V, M46I/L, or a change at V82 were resistant to ATV, and 38% of isolates containing a D30N substitution in addition to other changes were resistant to ATV. Isolates
resistant to ATV were also cross-resistant to other PIs with &gt;90% of the isolates resistant to indinavir, lopinavir, nelfinavir, ritonavir, and saquinavir,
and 80% resistant to amprenavir.  In treatment-experienced patients, PI-resistant viral isolates that developed the I50L substitution in addition to other PI
resistance-associated substitution were also cross-resistant to other PIs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_12.4.5"></a><a name="section-11.4.5"></a><p></p>
<p class="First"><span class="Bold">Baseline Genotype/Phenotype and Virologic Outcome Analyses</span></p>
<p>Genotypic and/or phenotypic analysis of baseline virus may aid in determining ATV susceptibility before initiation 
of ATV/RTV therapy. An association between virologic response at 48 weeks and the number and type of primary PI resistance-associated substitutions
detected in baseline HIV-1 isolates from antiretroviral-experienced patients receiving ATV/RTV once daily or lopinavir (LPV)/RTV twice daily in Study AI424-045
is shown in Table 20.</p>
<p>Overall, both the number and type of baseline PI substitutions affected response rates in treatment-experienced
patients. In the ATV/RTV group, patients had lower response rates when 3 or more baseline PI substitutions, including a substitution at position 36, 71,
77, 82, or 90, were present compared to patients with 1â€“2 PI substitutions, including one of these substitutions.</p>
<a name="i8a6e2da3-a9c2-4163-8246-6a387bf10e30"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 20: HIV RNA Response by Number and Type of Baseline PI Substitution, Antiretroviral-Experienced Patients in Study AI424-045, As-Treated Analysis</span></caption>
<colgroup>
<col width="36%">
<col width="32%">
<col width="32%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="center" rowspan="2"><span class="Bold">Number and Type of Baseline PI Substitutions<span class="Sup">a</span></span></th>
<th class="Toprule" align="center" colspan="2" rowspan="1"><span class="Bold">Virologic Response = HIV RNA &lt;400 copies/mL<span class="Sup">b</span></span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">ATV/RTV<br>(n=110)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">LPV/RTV<br>(n=113)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1">
<span class="Sup">a</span> Primary substitutions include any change at D30, V32, M36, M46, I47, G48, I50, I54,
A71, G73, V77, V82, I84, N88, and L90. </td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">b</span> Results should be interpreted with caution because the subgroups were small.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" rowspan="1">
<span class="Sup">c</span> There were insufficient data (n&lt;3) for PI substitutions V32I, I47V, G48V, I50V,
and F53L.</td></tr>
</tfoot>
<tbody>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1"><span class="Bold">3 or more primary PI substitutions including:<span class="Sup">c</span></span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â D30N</td>
<td align="center" colspan="1" rowspan="1">75% (6/8)</td>
<td align="center" colspan="1" rowspan="1">50% (3/6)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â M36I/V</td>
<td align="center" colspan="1" rowspan="1">19% (3/16)</td>
<td align="center" colspan="1" rowspan="1">33% (6/18)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â M46I/L/T</td>
<td align="center" colspan="1" rowspan="1">24% (4/17)</td>
<td align="center" colspan="1" rowspan="1">23% (5/22)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â I54V/L/T/M/A</td>
<td align="center" colspan="1" rowspan="1">31% (5/16)</td>
<td align="center" colspan="1" rowspan="1">31% (5/16)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â A71V/T/I/G</td>
<td align="center" colspan="1" rowspan="1">34% (10/29)</td>
<td align="center" colspan="1" rowspan="1">39% (12/31)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â G73S/A/C/T</td>
<td align="center" colspan="1" rowspan="1">14% (1/7)</td>
<td align="center" colspan="1" rowspan="1">38% (3/8)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â V77I</td>
<td align="center" colspan="1" rowspan="1">47% (7/15)</td>
<td align="center" colspan="1" rowspan="1">44% (7/16)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â V82A/F/T/S/I</td>
<td align="center" colspan="1" rowspan="1">29% (6/21)</td>
<td align="center" colspan="1" rowspan="1">27% (7/26)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â I84V/A</td>
<td align="center" colspan="1" rowspan="1">11% (1/9)</td>
<td align="center" colspan="1" rowspan="1">33% (2/6)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â N88D</td>
<td align="center" colspan="1" rowspan="1">63% (5/8)</td>
<td align="center" colspan="1" rowspan="1">67% (4/6)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â L90M</td>
<td align="center" colspan="1" rowspan="1">10% (2/21)</td>
<td align="center" colspan="1" rowspan="1">44% (11/25)</td>
</tr>
<tr valign="top"><td align="left" colspan="3" rowspan="1"><span class="Bold">Number of baseline primary PI substitutions<span class="Sup">a</span></span></td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">All patients, as-treated</td>
<td align="center" colspan="1" rowspan="1">58% (64/110)</td>
<td align="center" colspan="1" rowspan="1">59% (67/113)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">0â€“2 PI substitutions</td>
<td align="center" colspan="1" rowspan="1">75% (50/67)</td>
<td align="center" colspan="1" rowspan="1">75% (50/67)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">3â€“4 PI substitutions</td>
<td align="center" colspan="1" rowspan="1">41% (14/34)</td>
<td align="center" colspan="1" rowspan="1">43% (12/28)</td>
</tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">5 or more PI substitutions</td>
<td align="center" colspan="1" rowspan="1">0% (0/9)</td>
<td align="center" colspan="1" rowspan="1">28% (5/18)</td>
</tr>
</tbody>
</table>
<p>The response rates of antiretroviral-experienced patients in Study AI424-045 were analyzed by baseline phenotype (shift in susceptibility in cell culture relative to reference, Table 21). The analyses are based on a select patient population with 62% of patients receiving an NNRTI-based regimen before study entry compared to 35% receiving a PI-based regimen. Additional data are needed to determine clinically relevant break points for REYATAZ.</p>
<a name="idb20a95e-3239-433e-817c-fffa2d992665"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 21: Baseline Phenotype by Outcome, Antiretroviral-Experienced Patients in Study AI424-045, As-Treated Analysis</span></caption>
<colgroup>
<col width="30%">
<col width="35%">
<col width="35%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="center" rowspan="2"><span class="Bold">Baseline Phenotype<span class="Sup">a</span></span></th>
<th class="Toprule" align="center" colspan="2" rowspan="1"><span class="Bold">Virologic Response = HIV RNA &lt;400 copies/mL<span class="Sup">b</span></span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">ATV/RTV<br>(n=111)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">LPV/RTV<br>(n=111)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1">
<span class="Sup">a</span> Fold change susceptibility in cell culture relative to the wild-type reference.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" rowspan="1">
<span class="Sup">b</span> Results should be interpreted with caution because the subgroups were small.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="center" colspan="1" rowspan="1">0â€“2</td>
<td align="center" colspan="1" rowspan="1">71% (55/78)</td>
<td align="center" colspan="1" rowspan="1">70% (56/80)</td>
</tr>
<tr valign="top">
<td align="center" colspan="1" rowspan="1">&gt;2â€“5</td>
<td align="center" colspan="1" rowspan="1">53% (8/15)</td>
<td align="center" colspan="1" rowspan="1">44% (4/9)</td>
</tr>
<tr valign="top">
<td align="center" colspan="1" rowspan="1">&gt;5â€“10</td>
<td align="center" colspan="1" rowspan="1">13% (1/8)</td>
<td align="center" colspan="1" rowspan="1">33% (3/9)</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule" align="center" colspan="1" rowspan="1">&gt;10</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">10% (1/10)</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">23% (3/13)</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_13.1.1"></a><a name="section-12.1.1"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis</span></p>
<p>Long-term carcinogenicity studies in mice and rats were carried out with atazanavir for two years. In the mouse study, drug-related increases in <span class="product-label-link" type="condition" conceptid="4301500" conceptname="Liver cell adenoma">hepatocellular adenomas</span> were found in females at 360 mg/kg/day. The systemic drug exposure (AUC) at the NOAEL (no observable adverse effect level) in females, (120 mg/kg/day) was 2.8 times and in males (80 mg/kg/day) was 2.9 times higher than those in humans at the clinical dose (300 mg/day atazanavir boosted with 100 mg/day ritonavir, non-pregnant patients). In the rat study, no drug-related increases in tumor incidence were observed at doses up to 1200 mg/kg/day, for which AUCs were 1.1 (males) or 3.9 (females) times those measured in humans at the clinical dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_13.1.2"></a><a name="section-12.1.2"></a><p></p>
<p class="First"><span class="Bold">Mutagenesis</span></p>
<p>Atazanavir tested positive in an <span class="Italics">in vitro</span> clastogenicity test using primary human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, in the absence and presence of metabolic activation. Atazanavir tested negative in the <span class="Italics">in vitro</span> Ames reverse-mutation assay, <span class="Italics">in vivo</span>  micronucleus and DNA repair tests in rats, and <span class="Italics">in vivo</span> DNA damage test in rat duodenum (comet assay).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_13.1.3"></a><a name="section-12.1.3"></a><p></p>
<p class="First"><span class="Bold">Impairment of Fertility</span></p>
<p>At the systemic drug exposure levels (AUC) 0.9 (in male rats) or 2.3 (in female rats) times that of the human
clinical dose, (300 mg/day atazanavir boosted with 100 mg/day ritonavir) significant effects on mating, fertility, or early embryonic development were not observed.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Adult Patients Without Prior Antiretroviral Therapy</h2>
<p class="First"><span class="Italics">Study AI424-138: a 96-week study comparing the antiviral efficacy and safety of atazanavir/ritonavir with lopinavir/ritonavir, each in combination with fixed-dose tenofovir-emtricitabine in HIV-1 infected treatment-naive subjects. </span>Study AI424-138 is a 96-week open-label, randomized, multicenter study, comparing REYATAZ (300 mg once daily) with ritonavir (100 mg once daily) to lopinavir with ritonavir (400/100 mg twice daily), each in combination with fixed-dose tenofovir with emtricitabine (300/200 mg once daily), in 878 antiretroviral treatment-naive treated patients. Patients had a mean age of 36 years (range: 19â€“72), 49% were Caucasian, 18% Black, 9% Asian, 23% Hispanic/Mestizo/mixed race, and 68% were male. The median baseline plasma CD4+ cell count was 204 cells/mm<span class="Sup">3</span> (range: 2 to 810 cells/mm<span class="Sup">3</span>) and the mean baseline plasma HIV-1 RNA level was 4.94 log<span class="Sub">10</span> copies/mL (range: 2.60 to 5.88 log<span class="Sub">10 </span>copies/mL). Treatment response and outcomes through Week 96 are presented in Table 22.</p>
<a name="i054fe763-46de-498e-8361-d6773c37df5e"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 22: Outcomes of Treatment Through Week 96 (Study AI424-138)</span></caption>
<colgroup>
<col width="36%">
<col width="32%">
<col width="32%">
</colgroup>
<thead>
<tr class="First">
<th class="Botrule Toprule" align="center" rowspan="2" valign="bottom"><span class="Bold">Outcome</span></th>
<th class="Toprule" align="center"><span class="Bold">REYATAZ<br>300 mg + ritonavir 100 mg<br>(once daily) with<br>tenofovir/emtricitabine<br>(once daily)<span class="Sup">a</span><br>(n=441)
												</span></th>
<th class="Toprule" align="center"><span class="Bold">lopinavir<br>400 mg + ritonavir 100 mg<br>(twice daily) with<br>tenofovir/emtricitabine<br>(once daily)<span class="Sup">a</span><br>(n=437)
												</span></th>
</tr>
<tr class="Last">
<th class="Botrule" align="center" valign="bottom"><span class="Bold">96 Weeks</span></th>
<th class="Botrule" align=" center" valign="bottom"><span class="Bold">96 Weeks</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" colspan="3">
<span class="Sup">a</span>	As a fixed-dose combination: 300 mg tenofovir, 200 mg emtricitabine once daily. </td></tr>
<tr><td colspan="3">
<span class="Sup">b</span>	Patients achieved HIV RNA &lt;50 copies/mL at Week 96.  Roche Amplicor<span class="Sup">Â®</span>,
v1.5 ultra-sensitive assay.</td></tr>
<tr><td colspan="3">
<span class="Sup">c</span>	Pre-specified ITT analysis at Week 48 using as-randomized cohort: ATV/RTV 78% and LPV/RTV 76% [difference estimate: 1.7% (95% confidence interval: âˆ’3.8%, 7.1%)]. </td></tr>
<tr><td colspan="3">
<span class="Sup">d</span>	Pre-specified ITT analysis at Week 96 using as-randomized cohort: ATV/RTV 74% and LPV/RTV 68% [difference estimate: 6.1% (95% confidence interval: 0.3%, 12.0%)].</td></tr>
<tr><td colspan="3">
<span class="Sup">e</span>	Includes viral rebound and failure to achieve confirmed HIV RNA &lt;50 copies/mL through Week 96.</td></tr>
<tr class="Last"><td class="Botrule" colspan="3">
<span class="Sup">f</span>	Includes lost to follow-up, patientâ€™s withdrawal, noncompliance, protocol violation, and other reasons.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td>Responder<span class="Sup">b,c,d</span>
</td>
<td align="center">75%</td>
<td align="center">68%</td>
</tr>
<tr>
<td>Virologic failure<span class="Sup">e</span>
</td>
<td align="center">17%</td>
<td align="center">19%</td>
</tr>
<tr>
<td>Â Â Â Rebound</td>
<td align="center">8%</td>
<td align="center">10%</td>
</tr>
<tr>
<td>Â Â Â Never suppressed through Week 96</td>
<td align="center">9%</td>
<td align="center">9%</td>
</tr>
<tr>
<td><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">1%</td>
<td align="center">1%</td>
</tr>
<tr>
<td>Discontinued due to adverse event</td>
<td align="center">3%</td>
<td align="center">5%</td>
</tr>
<tr class="Last">
<td>Discontinued for other reasons<span class="Sup">f</span>
</td>
<td align="center">4%</td>
<td align="center">7%</td>
</tr>
</tbody>
</table>
<p>Through 96 weeks of therapy, the proportion of responders among patients with high viral loads (ie, baseline HIV RNA â‰¥100,000 copies/mL) was comparable for the REYATAZ/ritonavir (165 of 223 patients, 74%) and lopinavir/ritonavir (148 of 222 patients, 67%) arms. At 96 weeks, the median increase from baseline in CD4+ cell count was 261 cells/mm<span class="Sup">3</span> for the REYATAZ/ritonavir arm and 273 cells/mm<span class="Sup">3</span> for the lopinavir/ritonavir arm.</p>
<p><span class="Italics">Study AI424-034: REYATAZ once daily compared to efavirenz once daily, each in combination with fixed-dose lamivudine + zidovudine twice daily.</span>  Study AI424-034 was a randomized, double-blind, multicenter trial comparing REYATAZ (400 mg once daily) to efavirenz (600 mg once daily), each in combination with a fixed-dose combination of lamivudine (3TC) (150 mg) and zidovudine (ZDV) (300 mg) given twice daily, in 810 antiretroviral treatment-naive patients.  Patients had a mean age of 34 years (range: 18 to 73), 36% were Hispanic, 33% were Caucasian, and 65% were male. The mean baseline CD4+ cell count was 321 cells/mm<span class="Sup">3</span> (range: 64 to 1424 cells/mm<span class="Sup">3</span>) and the mean baseline plasma HIV-1 RNA level was 4.8 log<span class="Sub">10</span> copies/mL (range: 2.2 to 5.9 log<span class="Sub">10</span> copies/mL). Treatment response and outcomes through Week 48 are presented in Table 23.</p>
<a name="i76ebec13-dabf-42f2-8e42-fc7c908cd59b"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 23: Outcomes of Randomized Treatment Through Week 48 (Study AI424-034)</span></caption>
<colgroup>
<col width="36%">
<col width="32%">
<col width="32%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="center" rowspan="2"><span class="Bold">Outcome</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">REYATAZ<br>400 mg once daily <br>+ lamivudine<br>+ zidovudine<span class="Sup">d</span></span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">efavirenz<br> 600 mg once daily <br>+ lamivudine<br> + zidovudine<span class="Sup">d</span></span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=405)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=405)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1">
<span class="Sup">a</span> Patients achieved and maintained confirmed HIV RNA &lt;400 copies/mL (&lt;50 copies/mL) through Week 48. Roche Amplicor<span class="Sup">Â®</span> HIV-1 Monitor<span class="Sup">â„¢</span> Assay, test version 1.0 or 1.5 as geographically appropriate.</td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">b</span> Includes viral rebound and failure to achieve confirmed HIV RNA &lt;400 copies/mL through Week 48. </td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">c</span> Includes lost to follow-up, patientâ€™s withdrawal, noncompliance, protocol violation, and other reasons.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" rowspan="1">
<span class="Sup">d</span> As a fixed-dose combination: 150 mg lamivudine, 300 mg zidovudine twice daily.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">Responder<span class="Sup">a</span>
</td>
<td align="center" colspan="1" rowspan="1">67% (32%)</td>
<td align="center" colspan="1" rowspan="1">62% (37%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Virologic failure<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">20%</td>
<td align="center" colspan="1" rowspan="1">21%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Rebound</td>
<td align="center" colspan="1" rowspan="1">17%</td>
<td align="center" colspan="1" rowspan="1">16%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Never suppressed through Week 48</td>
<td align="center" colspan="1" rowspan="1">3%</td>
<td align="center" colspan="1" rowspan="1">5%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center" colspan="1" rowspan="1">â€“</td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Discontinued due to adverse event</td>
<td align="center" colspan="1" rowspan="1">5%</td>
<td align="center" colspan="1" rowspan="1">7%</td>
</tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">Discontinued for other reasons<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">8%</td>
<td align="center" colspan="1" rowspan="1">10%</td>
</tr>
</tbody>
</table>
<p>Through 48 weeks of therapy, the proportion of responders among patients with high viral loads (ie, baseline HIV RNA â‰¥100,000 copies/mL) was comparable for the REYATAZ and efavirenz arms. The mean increase from baseline in CD4+ cell count was 176 cells/mm<span class="Sup">3</span> for the REYATAZ arm and 160 cells/mm<span class="Sup">3</span> for the efavirenz arm. </p>
<p><span class="Italics">Study AI424-008: REYATAZ 400 mg once daily compared to REYATAZ 600 mg once daily, and compared to nelfinavir 1250 mg twice daily, each in combination with stavudine and lamivudine twice daily</span>. Study AI424-008 was a 48-week, randomized, multicenter trial, blinded to dose of REYATAZ, comparing REYATAZ at two dose levels (400 mg and 600 mg once daily) to nelfinavir (1250 mg twice daily), each in combination with stavudine (40 mg) and lamivudine (150 mg) given twice daily, in 467 antiretroviral treatment-naive patients. Patients had a mean age of 35 years (range: 18 to 69), 55% were Caucasian, and 63% were male. The mean baseline CD4+ cell count was 295 cells/mm<span class="Sup">3</span> (range: 4 to 1003 cells/mm<span class="Sup">3</span>) and the mean baseline plasma HIV-1 RNA level was 4.7 log<span class="Sub">10</span> copies/mL (range: 1.8 to 5.9 log<span class="Sub">10</span> copies/mL). Treatment response and outcomes through Week 48 are presented in Table 24.</p>
<a name="ia2b278d9-6426-47b9-85bd-008313121da5"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 24: Outcomes of Randomized Treatment Through Week 48 (Study AI424-008)</span></caption>
<colgroup>
<col width="36%">
<col width="32%">
<col width="32%">
</colgroup>
<thead><tr class="First Last" valign="bottom">
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">Outcome</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">REYATAZ<br>400 mg once daily<br>+ lamivudine + stavudine<br>(n=181)</span></th>
<th class="Botrule Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">nelfinavir<br>1250 mg twice daily<br>+ lamivudine + stavudine<br>(n=91)</span></th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="3" rowspan="1">
<span class="Sup">a</span> Patients achieved and maintained confirmed HIV RNA &lt;400 copies/mL (&lt;50 copies/mL)
through Week 48. Roche Amplicor<span class="Sup">Â®</span> HIV-1 Monitor<span class="Sup">â„¢</span> Assay, test version 1.0 or 1.5 as geographically appropriate.</td></tr>
<tr><td align="left" colspan="3" rowspan="1">
<span class="Sup">b</span> Includes viral rebound and failure to achieve confirmed HIV RNA &lt;400 copies/mL through Week 48.</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="3" rowspan="1">
<span class="Sup">c</span> Includes lost to follow-up, patientâ€™s withdrawal, noncompliance, protocol violation,
and other reasons.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">Responder<span class="Sup">a</span>
</td>
<td align="center" colspan="1" rowspan="1">67% (33%)</td>
<td align="center" colspan="1" rowspan="1">59% (38%)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Virologic failure<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">24%</td>
<td align="center" colspan="1" rowspan="1">27%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Rebound</td>
<td align="center" colspan="1" rowspan="1">14%</td>
<td align="center" colspan="1" rowspan="1">14%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â Never suppressed through Week 48</td>
<td align="center" colspan="1" rowspan="1">10%</td>
<td align="center" colspan="1" rowspan="1">13%</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center" colspan="1" rowspan="1">&lt;1%</td>
<td align="center" colspan="1" rowspan="1">â€“</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Discontinued due to adverse event</td>
<td align="center" colspan="1" rowspan="1">1%</td>
<td align="center" colspan="1" rowspan="1">3%</td>
</tr>
<tr class="Last" valign="top">
<td align="left" colspan="1" rowspan="1">Discontinued for other reasons<span class="Sup">c</span>
</td>
<td align="center" colspan="1" rowspan="1">7%</td>
<td align="center" colspan="1" rowspan="1">10%</td>
</tr>
</tbody>
</table>
<p>Through 48 weeks of therapy, the mean increase from baseline in CD4+ cell count was 234 cells/mm<span class="Sup">3</span> for the REYATAZ 400-mg arm and 211 cells/mm<span class="Sup">3</span> for the nelfinavir arm. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Adult Patients With Prior Antiretroviral Therapy</h2>
<p class="First"><span class="Italics">Study AI424-045: REYATAZ once daily + ritonavir once daily compared to REYATAZ once daily + saquinavir (soft gelatin capsules) once daily, and compared to lopinavir + ritonavir twice daily, each in combination with tenofovir + one NRTI</span>.  Study AI424-045 is an ongoing, randomized, multicenter trial comparing REYATAZ (300 mg once daily) with ritonavir (100 mg once daily) to REYATAZ (400 mg once daily) with saquinavir soft gelatin capsules (1200 mg once daily), and to lopinavir + ritonavir (400/100 mg twice daily), each in combination with tenofovir and
one NRTI, in 347 (of 358 randomized) patients who experienced virologic failure on HAART regimens containing PIs, NRTIs, and NNRTIs. The mean time of prior
exposure to antiretrovirals was 139 weeks for PIs, 283 weeks for NRTIs, and 85 weeks for NNRTIs. The mean age was 41 years (range: 24 to 74); 60% were
Caucasian, and 78% were male. The mean baseline CD4+ cell count was 338 cells/mm<span class="Sup">3</span> (range: 14 to 1543 cells/mm<span class="Sup">3</span>) and the mean baseline plasma HIV-1 RNA level was 4.4 log<span class="Sub">10</span> copies/mL (range: 2.6 to 5.88 log<span class="Sub">10</span> copies/mL). </p>
<p>Treatment outcomes through Week 48 for the REYATAZ/ritonavir and lopinavir/ritonavir treatment arms are presented in Table 25. REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. Study AI424-045 was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection.  [See <span class="Italics">Clinical Pharmacology,
Tables 20</span> and <span class="Italics">21 <a href="#Section_12.4">(12.4)</a></span>.]</p>
<a name="i9d109765-b4a0-4a84-8ed8-c7c4f6856d1f"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<caption><span>Table 25: Outcomes of Treatment Through Week 48 in Study AI424-045 (Patients with Prior Antiretroviral Experience)</span></caption>
<colgroup>
<col width="27%">
<col width="27%">
<col width="24%">
<col width="22%">
</colgroup>
<thead>
<tr class="First" valign="bottom">
<th class="Botrule Toprule" align="center" rowspan="2"><span class="Bold">Outcome</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">REYATAZ 300 mg +<br>ritonavir 100 mg once<br>daily + tenofovir +<br>1 NRTI</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1"><span class="Bold">lopinavir/ritonavir<br>(400/100 mg) twice<br>daily + tenofovir +<br>1 NRTI</span></th>
<th class="Toprule" align="center" colspan="1" rowspan="1" valign="middle"><span class="Bold">Difference<span class="Sup">a</span><br>(REYATAZ-lopinavir/ritonavir)</span></th>
</tr>
<tr class="Last" valign="bottom">
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=119)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(n=118)</span></th>
<th class="Botrule" align="center" colspan="1" rowspan="1"><span class="Bold">(CI)</span></th>
</tr>
</thead>
<tfoot>
<tr class="First"><td class="Toprule" align="left" colspan="4" rowspan="1">
<span class="Sup">a</span> Time-averaged difference through Week 48 for HIV RNA; Week 48 difference in HIV RNA percentages and CD4+ mean changes, REYATAZ/ritonavir vs lopinavir/ritonavir; CI = 97.5% confidence interval for change in HIV RNA; 95% confidence interval otherwise.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">b</span> Roche Amplicor<span class="Sup">Â®</span> HIV-1 Monitor<span class="Sup">â„¢</span> Assay, test version 1.5.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">c</span> Protocol-defined primary efficacy outcome measure.</td></tr>
<tr><td align="left" colspan="4" rowspan="1">
<span class="Sup">d</span> Based on patients with baseline and Week 48 CD4+ cell count measurements (REYATAZ/ritonavir,
n=85; lopinavir/ritonavir, n=93).</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" rowspan="1">
<span class="Sup">e</span> Patients achieved and maintained confirmed HIV-1 RNA &lt;400 copies/mL (&lt;50 copies/mL) through Week 48.</td></tr>
</tfoot>
<tbody>
<tr class="First" valign="top">
<td align="left" colspan="1" rowspan="1">HIV RNA Change from<br>Â Â Â BaselineÂ (log<span class="Sub">10</span> copies/mL)<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">âˆ’1.58</td>
<td align="center" colspan="1" rowspan="1">âˆ’1.70</td>
<td align="center" colspan="1" rowspan="1">+0.12<span class="Sup">c</span><br>(âˆ’0.17, 0.41)</td>
</tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">CD4+ Change from<br>Â Â Â BaselineÂ (cells/mm<span class="Sup">3</span>)<span class="Sup">d</span>
</td>
<td align="center" colspan="1" rowspan="1">116</td>
<td align="center" colspan="1" rowspan="1">123</td>
<td align="center" colspan="1" rowspan="1">âˆ’7<br>(âˆ’67, 52)</td>
</tr>
<tr valign="top"><td align="left" colspan="4" rowspan="1">Percent of Patients Responding<span class="Sup">e</span>
</td></tr>
<tr valign="top">
<td align="left" colspan="1" rowspan="1">Â Â Â HIV RNA &lt;400 copies/mL<span class="Sup">b</span>
</td>
<td align="center" colspan="1" rowspan="1">55%</td>
<td align="center" colspan="1" rowspan="1">57%</td>
<td align="center" colspan="1" rowspan="1">-2.2%<br>(âˆ’14.8%, 10.5%)</td>
</tr>
<tr class="Last" valign="top">
<td class="Botrule" align="left" colspan="1" rowspan="1">Â Â Â HIV RNA &lt;50 copies/mL<span class="Sup">b</span>
</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">38%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">45%</td>
<td class="Botrule" align="center" colspan="1" rowspan="1">âˆ’7.1%<br>(âˆ’19.6%, 5.4%)</td>
</tr>
</tbody>
</table>
<p>No patients in the REYATAZ/ritonavir treatment arm and three patients in the lopinavir/ritonavir treatment arm experienced a new-onset CDC Category C event during the study.</p>
<p>In Study AI424-045, the mean change from baseline in plasma HIV-1 RNA for REYATAZ 400 mg with saquinavir (n=115) was âˆ’1.55 log<span class="Sub">10</span> copies/mL, and the time-averaged difference in change in HIV-1 RNA levels versus lopinavir/ritonavir was 0.33. The corresponding mean increase in CD4+ cell count was 72 cells/mm<span class="Sup">3</span>. Through 48 weeks of treatment, the proportion of patients in this treatment
arm with plasma HIV-1 RNA &lt;400 (&lt;50) copies/mL was 38% (26%). In this study, coadministration of REYATAZ and saquinavir did not provide adequate
efficacy [see <span class="Italics">Drug Interactions <a href="#Section_7">(7)</a></span>].</p>
<p>Study AI424-045 also compared changes from baseline in lipid values. [See <span class="Italics">Adverse
Reactions <a href="#Section_6.1">(6.1)</a>.</span>]</p>
<p><span class="Italics">Study AI424-043:</span> Study AI424-043 was a randomized, open-label, multicenter
trial comparing REYATAZ (400 mg once daily) to lopinavir/ritonavir (400/100 mg twice daily), each in combination with two NRTIs, in 300 patients who experienced virologic failure to only one prior PI-containing regimen. Through 48 weeks, the proportion of patients with plasma HIV-1 RNA &lt;400 (&lt;50) copies/mL was 49% (35%) for patients randomized to REYATAZ (n=144) and 69% (53%) for patients randomized to lopinavir/ritonavir (n=146). The mean change from baseline was âˆ’1.59 log<span class="Sub">10</span> copies/mL in the REYATAZ treatment arm and âˆ’2.02 log<span class="Sub">10</span> copies/mL in the lopinavir/ritonavir arm. Based on the results of this study, REYATAZ without ritonavir is inferior to lopinavir/ritonavir in PI-experienced patients with prior virologic failure and is not recommended for such patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Pediatric Patients</h2>
<p class="First">Assessment of the pharmacokinetics, safety, tolerability, and efficacy of REYATAZ is based on data from the open-label,
multicenter clinical trial PACTG 1020A conducted in patients from 3 months to 21 years of age.  In this study, 193 patients (86 antiretroviral-naive and 107 antiretroviral-experienced) received once daily REYATAZ, with or without ritonavir, in combination with two NRTIs.</p>
<p>One-hundred and five patients (6 to less than 18 years of age) treated with the REYATAZ capsule formulation, with or without ritonavir, were evaluated. Using an ITT analysis, the overall proportions of antiretroviral-naive and -experienced patients with HIV RNA &lt;400 copies/mL at Week 96 were 51% (22/43) and 34% (21/62), respectively. The overall proportions of antiretroviral-naive and -experienced patients with HIV RNA &lt;50 copies/mL at Week 96 were 47% (20/43) and 24% (15/62), respectively. The median increase from baseline in absolute CD4 count at 96 weeks of therapy was 335 cells/mm<span class="Sup">3</span> in antiretroviral-naive patients and 220 cells/mm<span class="Sup">3</span> in antiretroviral-experienced patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">REYATAZ<span class="Sup">Â®</span> (atazanavir sulfate) Capsules are available in the following strengths and configurations of plastic bottles with child-resistant closures.</p>
<a name="i39f937e2-481a-4a0e-855f-7006de3dd322"></a><table border="0" cellpadding="2" cellspacing="1" width="100%">
<col width="14%">
<col width="20%">
<col width="16%">
<col width="16%">
<col width="14%">
<col width="20%">
<thead>
<tr class="First">
<th colspan="1"><span class="Bold">Product Strength*</span></th>
<th colspan="1"><span class="Bold">Capsule Shell Color (cap/body)</span></th>
<th colspan="2"><span class="Bold">Markings on Capsule<br>(ink color)</span></th>
<th colspan="1"><span class="Bold">Capsules per Bottle</span></th>
<th colspan="1"><span class="Bold">NDC Number</span></th>
</tr>
<tr class="Last">
<th colspan="1"><span class="Bold">cap</span></th>
<th colspan="1"><span class="Bold">body</span></th>
</tr>
</thead>
<tbody>
<tr class="First">
<td>150 mg</td>
<td>blue/powder blue</td>
<td>BMS 150 mg<br>(white)</td>
<td>3624<br>(blue)</td>
<td>60</td>
<td>54868-4857-0</td>
</tr>
<tr class="Last">
<td>300 mg</td>
<td>red/blue</td>
<td>BMS 300 mg<br>(white)</td>
<td>3622<br>(white)</td>
<td>30</td>
<td>54868-5838-0</td>
</tr>
</tbody>
</table>
<p>* atazanavir equivalent as atazanavir sulfate.<br></p>
<p>REYATAZ (atazanavir sulfate) Capsules should be stored at 25Â° C (77Â° F); excursions permitted to 15â€“30Â° C (59â€“86Â° F) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <span class="Italics">FDA-approved patient labeling (Patient Information)</span>.</p>
<p>A statement to patients and healthcare providers is included on the productâ€™s bottle label: <span class="Bold">ALERT: Find out about medicines that should NOT be taken with REYATAZ</span>.</p>
<p>Patients should be informed that REYATAZ is not a cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> and that they may continue to develop <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> and other complications associated with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV disease</span>. Patients should be told that there are currently no data demonstrating that therapy with REYATAZ can reduce the risk of transmitting HIV to others through sexual contact.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.1"></a><a name="section-15.1"></a><p></p>
<h2>17.1 Dosing Instructions</h2>
<p class="First">Patients should be told that sustained decreases in plasma HIV RNA have been associated with a reduced risk of progression to AIDS and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Patients should remain under the care of a physician while using REYATAZ. Patients should be advised to take REYATAZ with food every day and take other concomitant antiretroviral therapy as prescribed.  REYATAZ must always be used in combination with other antiretroviral drugs.  Patients should not alter the dose or discontinue therapy without consulting with their doctor. If a dose of REYATAZ is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped the patient should not double the next dose.</p>
</div>
<div class="Section">
<a name="Section_17.2"></a><a name="section-15.2"></a><p></p>
<h2>17.2 Drug Interactions </h2>
<p class="First">REYATAZ may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other
prescription, nonprescription medication, or herbal products, particularly St. Johnâ€™s wort.</p>
<p>Patients receiving a PDE5 inhibitor and atazanavir should be advised that they may be at an increased risk of PDE5 inhibitor-associated adverse events including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, and <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span>, and should promptly report any symptoms to
their doctor.</p>
<p>Patients should be informed that REVATIO<span class="Sup">Â®</span> (used to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>) is contraindicated with REYATAZ and that dose adjustments are necessary when REYATAZ is used with CIALIS<span class="Sup">Â®</span>, LEVITRA<span class="Sup">Â®</span> or VIAGRA<span class="Sup">Â®</span> (used to treat <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>), or ADCIRCA<span class="Sup">Â®</span> (used to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.3"></a><a name="section-15.3"></a><p></p>
<h2>17.3 Cardiac Conduction Abnormalities</h2>
<p class="First">Patients should be informed that atazanavir may produce changes in the electrocardiogram (eg, PR prolongation).  Patients
should consult their physician if they are experiencing symptoms such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.4"></a><a name="section-15.4"></a><p></p>
<h2>17.4 <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></h2>
<p class="First">Patients should be informed that mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> without other symptoms have been reported with REYATAZ use. These <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span> go away within two weeks with no change in treatment. However, there have been a few reports of severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (eg, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="141370" conceptname="Toxic erythema">toxic skin eruptions</span>) with REYATAZ use. Patients developing signs or symptoms of severe <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (including, but not limited to, severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> accompanied by one or more of the following: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>, muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">oral lesions</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, and renal dysfunction) must discontinue REYATAZ and seek medical evaluation immediately.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.5"></a><a name="section-15.5"></a><p></p>
<h2>17.5 <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span></h2>
<p class="First">Patients should be informed that asymptomatic elevations in indirect bilirubin have occurred in patients receiving REYATAZ.
This may be accompanied by yellowing of the skin or whites of the eyes and alternative antiretroviral therapy may be considered if the patient has cosmetic
concerns. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_17.6"></a><a name="section-15.6"></a><p></p>
<h2>17.6 Fat Redistribution</h2>
<p class="First">Patients should be informed that redistribution or accumulation of body fat may occur in patients receiving antiretroviral
therapy including protease inhibitors and that the cause and long-term health effects of these conditions are not known at this time. It is unknown whether
long-term use of REYATAZ will result in a lower incidence of <span class="product-label-link" type="condition" conceptid="134324" conceptname="Lipodystrophy">lipodystrophy</span> than with other protease inhibitors.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="Section_18.0"></a><a name="section-16"></a><p></p>
<h1></h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_18.1"></a><a name="section-16.1"></a><p></p>
<p class="First"><span class="Bold">Patient Information</span></p>
<p><span class="Bold">REYATAZ</span><span class="Sup">Â®</span> (RAY-ah-taz)</p>
<p>(generic name = <span class="Bold">atazanavir sulfate</span>)</p>
<p><span class="Bold">Capsules</span></p>
<p><span class="Bold">ALERT: Find out about medicines that should NOT be taken with REYATAZ.</span> Read
the section â€œWhat important information should I know about taking REYATAZ with other medicines?â€?</p>
<p>Read the Patient Information that comes with REYATAZ before you start using it and each time you get a refill. There may be new information. This leaflet provides a summary about REYATAZ and does not include everything there is to know about your medicine. This information does not take the place of talking with your healthcare provider about your medical condition or treatment. </p>
<p><span class="Bold">What is REYATAZ?</span></p>
<p>REYATAZ is a prescription medicine used with other anti-HIV medicines to treat people 6 years of age and older who are infected with the human <span class="product-label-link" type="condition" conceptid="433740" conceptname="Immunodeficiency disorder">immunodeficiency</span> virus (HIV). HIV is the virus that causes <span class="product-label-link" type="condition" conceptid="4267414" conceptname="AIDS">acquired immune deficiency syndrome</span> (AIDS). REYATAZ is a type of anti-HIV medicine
called a protease inhibitor. <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> destroys CD4+ (T) cells, which are important to the immune system.  The immune system helps fight <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. After a large number of (T) cells are destroyed, AIDS develops. REYATAZ helps to block HIV protease, an enzyme that is needed for the HIV virus to multiply.  REYATAZ may lower the amount of HIV in your blood, help your body keep its supply of CD4+ (T) cells, and reduce the risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> and illness associated
with HIV.</p>
<p><span class="Bold">Does REYATAZ cure HIV or AIDS?</span></p>
<p><span class="Bold">REYATAZ does not cure <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> or AIDS.</span>  At present there is no cure for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>.  People taking REYATAZ may still get <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infections</span> or other conditions that happen with <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">Opportunistic infections</span> are <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that develop because the immune system is weak.  Some of these conditions are <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="435463" conceptname="Herpesvirus infection">herpes virus infections</span>, and <span class="Italics">Mycobacterium avium</span> complex (MAC) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="Bold">It is very important that you see your healthcare provider regularly while taking REYATAZ.</span></p>
<p><span class="Bold">REYATAZ does not lower your chance of passing HIV to other people through sexual contact,
sharing needles, or being exposed to your blood.</span> For your health and the health of others, it is important to always practice safer sex by using
a latex or polyurethane condom or other barrier to lower the chance of sexual contact with semen, vaginal secretions, or blood. Never use or share dirty
needles.</p>
<p><span class="Bold">Who should not take REYATAZ?</span></p>
<p><span class="Bold">Do not take REYATAZ if you:</span></p>
<ul class="Disc">
<li>
<span class="Bold">are taking certain medicines.</span> (See â€œWhat important information should I know about taking REYATAZ with other medicines?â€?) Serious life-threatening side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may happen. Before you take REYATAZ, tell your healthcare provider about all medicines you are taking or planning to take. These include other prescription and nonprescription medicines, vitamins, and herbal supplements.</li>
<li>
<span class="Bold">are allergic to REYATAZ or to any of its ingredients.</span> The active ingredient is atazanavir sulfate. See the end of this leaflet for a complete list of ingredients in REYATAZ. Tell your healthcare provider if you think you have had an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to any of these ingredients.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before I take REYATAZ?</span></p>
<p><span class="Bold">Tell your healthcare provider:</span></p>
<ul class="Disc">
<li>
<span class="Bold">If you are pregnant or plan to become pregnant.</span> REYATAZ use during pregnancy has not been associated with an increase in <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>. Pregnant women have experienced serious side effects when taking REYATAZ with other HIV medicines called nucleoside analogues. You and your healthcare provider will need to decide if REYATAZ is right for you.  If you use REYATAZ while you are pregnant, talk to your
healthcare provider about the Antiretroviral Pregnancy Registry.
<ul><li>
<span class="Bold">After your baby is born</span>, tell your healthcare provider if your babyâ€™s skin or the white part of his/her eyes turns yellow.</li></ul>
</li>
<li>
<span class="Bold">If you are breast-feeding.</span> You should not breast-feed if you are HIV-positive because of the chance of passing HIV to your baby. Also, it is not known if REYATAZ can pass into your breast milk and if it can harm your baby. If you are a woman who has or will have a baby, talk with your healthcare provider about the best way to feed your baby. </li>
<li>
<span class="Bold">If you have liver problems or are infected with the <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C virus.</span> See â€œWhat are the possible side effects of REYATAZ?â€?</li>
<li>
<span class="Bold">If you have end stage kidney disease</span> managed with hemodialysis.</li>
<li>
<span class="Bold">If you have <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>.</span> See â€œWhat are the possible side effects of REYATAZ?â€?</li>
<li>
<span class="Bold">If you have <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>.</span> See â€œWhat are the possible side effects of REYATAZ?â€?</li>
<li>
<span class="Bold">About all the medicines you take</span> including prescription and nonprescription medicines, vitamins, and herbal supplements. Keep a list of your medicines with you to show your healthcare provider. For more information, see â€œWhat important information should I know about taking REYATAZ with other medicines?â€? and â€œWho should not take REYATAZ?â€?  Some medicines can cause serious
side effects if taken with REYATAZ.</li>
</ul>
<p><span class="Bold">How should I take REYATAZ?</span></p>
<ul class="Disc">
<li>
<span class="Bold">Take REYATAZ once every day exactly as instructed by your healthcare provider.</span><br> Your healthcare provider will prescribe the amount of REYATAZ that is right for you.   
									</li>
<li>
<span class="Bold">Always take REYATAZ with food</span> (a meal or snack) to help it work better. Swallow the capsules whole. <span class="Bold">Do not open the capsules. </span> Take REYATAZ at the same time each day.</li>
<li>
<span class="Bold">If you are taking antacids or didanosine (VIDEX</span><span class="Sup">Â®</span><span class="Bold"> or VIDEX</span><span class="Sup">Â® </span><span class="Bold"> EC)</span>, take REYATAZ 2 hours before or 1 hour after these medicines.</li>
<li>
<span class="Bold">If you are taking medicines for <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> such as AXID</span><span class="Sup">Â®</span><span class="Bold"> (nizatidine)</span>, <span class="Bold">PEPCID AC</span><span class="Sup">Â®</span><span class="Bold"> (famotidine)</span>, <span class="Bold">TAGAMET</span><span class="Sup">Â®</span><span class="Bold"> (cimetidine)</span>, <span class="Bold">ZANTAC</span><span class="Sup">Â®</span><span class="Bold"> (ranitidine)</span>, <span class="Bold">AcipHex</span><span class="Sup">Â®</span><span class="Bold"> (rabeprazole)</span>, <span class="Bold">NEXIUM</span><span class="Sup">Â®</span><span class="Bold"> (esomeprazole)</span>, <span class="Bold">PREVACID</span><span class="Sup">Â®</span><span class="Bold"> (lansoprazole)</span>, <span class="Bold">PRILOSEC</span><span class="Sup">Â®</span><span class="Bold"> (omeprazole)</span>, <span class="Bold"> or PROTONIX</span><span class="Sup">Â®</span><span class="Bold"> (pantoprazole)</span>, talk to your healthcare provider.</li>
<li>
<span class="Bold">Do not change your dose or stop taking REYATAZ without first talking with your healthcare provider.</span> It is important to stay under a healthcare providerâ€™s care while taking REYATAZ.</li>
<li>
<span class="Bold">When your supply of REYATAZ starts to run low</span>, get more from your healthcare provider or pharmacy.  It is important not to run out of REYATAZ. The amount of HIV in your blood may increase if the medicine is stopped for even a short time.</li>
<li>
<span class="Bold">If you miss a dose of REYATAZ</span>, take it as soon as possible and then take your next scheduled dose at its regular time.  If, however, it is within 6 hours of your next dose, do not take the missed dose. Wait and take the next dose at the regular time.  Do not double the next dose. <span class="Bold">It is important that you do not miss any doses of REYATAZ or your other anti-HIV medicines.</span>
</li>
<li>
<span class="Bold">If you take more than the prescribed dose of REYATAZ</span>, call your healthcare provider or poison control center right away. </li>
</ul>
<p><span class="Bold">What are the possible side effects of REYATAZ?</span></p>
<p>The following list of side effects is <span class="Bold">not</span> complete. Report any new or continuing symptoms to your healthcare provider. If you have questions about side effects, ask your healthcare provider. Your healthcare provider may be able to help you manage these side effects.</p>
<p><span class="Bold">The following side effects have been reported with REYATAZ:</span></p>
<ul class="Disc">
<li>
<span class="Bold">mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span> and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>) without other symptoms sometimes occurs in patients taking REYATAZ, most often in the first few weeks after the medicine is started. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rashes</span> usually go away within 2 weeks with no change in treatment.  Tell your healthcare provider if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> occurs.</li>
<li>
<span class="Bold">severe <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> may develop in association with other symptoms which could be serious and potentially cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  <p class="First"><span class="Bold">If you develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with any of the following symptoms stop using REYATAZ and call your healthcare provider right away:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span></li>
<li>general ill feeling or â€œflu-likeâ€? symptoms</li>
<li><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span></li>
<li>muscle or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint aches</span></li>
<li><span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> (red or inflamed eyes, like â€œpink eyeâ€?)</li>
<li><span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span></li>
<li>mouth sores</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face</li>
</ul>
</li>
<li>
<span class="Bold">yellowing of the skin or eyes.</span> These effects may be due to increases in bilirubin levels in the blood (bilirubin is made by the liver). Although these effects may not be damaging to your liver, skin, or eyes, call your healthcare provider promptly if your skin or the white part of your eyes turn yellow.</li>
<li>
<span class="Bold">a change in the way your heart beats (heart rhythm change).</span> Call your healthcare provider right away if you get dizzy or lightheaded. These could be symptoms of a heart problem.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and high blood sugar (<span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>)</span> sometimes happen in patients taking protease inhibitor medicines like REYATAZ. Some patients had <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> before taking protease inhibitors while others did not. Some patients may need changes in their <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> medicine.</li>
<li>
<span class="Bold">if you have liver disease</span> including <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> B or C, your liver disease may get worse when you take anti-HIV medicines like REYATAZ.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span></span> have been reported in patients taking REYATAZ. If you develop signs or symptoms of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your side, blood in your urine, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> when you urinate) tell your healthcare provider promptly. </li>
<li>
<span class="Bold">some patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span></span> have increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems with protease inhibitors like REYATAZ.</li>
<li>
<span class="Bold">changes in body fat.</span> These changes may include an increased amount of fat in the upper back and neck (â€œbuffalo humpâ€?), breast, and around the trunk. Loss of fat from the legs, arms, and face may also happen. The cause and long-term health effects of these conditions are not known at this time.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4139034" conceptname="Immune reconstitution syndrome">immune reconstitution syndrome</span>.</span> In some patients with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span> (AIDS) and a history of <span class="product-label-link" type="condition" conceptid="4247535" conceptname="Opportunistic infectious disease">opportunistic infection</span>, signs and symptoms of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> from previous <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may occur soon after anti-HIV treatment, including REYATAZ, is started. </li>
</ul>
<p>Other common side effects of REYATAZ taken with other anti-HIV medicines include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; trouble sleeping; <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, or burning of hands or feet; and <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>. </p>
<p><span class="Bold">Gallbladder disorders </span>(which may include <span class="product-label-link" type="condition" conceptid="196456" conceptname="Gallstone">gallstones</span> and gallbladder <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>) have been reported in patients taking REYATAZ. </p>
<p><span class="Bold">What important information should I know about taking REYATAZ with other medicines?</span></p>
<p><span class="Bold">Do not take REYATAZ if you take the following medicines (not all brands may be listed; tell your healthcare provider about all the medicines you take). REYATAZ may cause serious, life-threatening side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when used with these medicines. </span></p>
<ul class="Disc">
<li>Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine such as CAFERGOT<span class="Sup">Â®</span>, MIGRANAL<span class="Sup">Â®</span>, D.H.E. 45<span class="Sup">Â®</span>, ergotrate maleate, METHERGINE<span class="Sup">Â®</span>, and others (used for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>).</li>
<li>ORAP<span class="Sup">Â®</span> (pimozide, used for Touretteâ€™s disorder).</li>
<li>PROPULSID<span class="Sup">Â®</span> (cisapride, used for certain stomach problems).</li>
<li>Triazolam, also known as HALCION<span class="Sup">Â®</span> (used for <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>). </li>
<li>Midazolam, also known as VERSED<span class="Sup">Â®</span> (used for sedation), when taken by mouth.</li>
</ul>
<p><span class="Bold">Do not take the following medicines with REYATAZ because of possible serious side effects:</span></p>
<ul class="Disc">
<li>CAMPTOSAR<span class="Sup">Â®</span> (irinotecan, used for cancer).</li>
<li>CRIXIVAN<span class="Sup">Â®</span> (indinavir, used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>). Both REYATAZ and CRIXIVAN sometimes cause increased levels of bilirubin in the blood. </li>
<li><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>-lowering medicines MEVACOR<span class="Sup">Â®</span> (lovastatin) or ZOCOR<span class="Sup">Â®</span> (simvastatin).</li>
<li>UROXATRAL<span class="Sup">Â®</span> (alfuzosin, used to treat benign enlargement of the prostate).</li>
<li>REVATIO<span class="Sup">Â®</span> (sildenafil, used to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>).</li>
</ul>
<p><span class="Bold">Do not take the following medicines with REYATAZ because they may lower the amount of REYATAZ in your blood. </span>This may lead to an increased <span class="product-label-link" type="condition" conceptid="4201046" conceptname="HIV viral load">HIV viral load</span>. Resistance to REYATAZ or cross-resistance to other HIV medicines may develop:</p>
<ul class="Disc">
<li>Rifampin (also known as RIMACTANE<span class="Sup">Â®</span>, RIFADIN<span class="Sup">Â®</span>, RIFATER<span class="Sup">Â®</span>, or RIFAMATE<span class="Sup">Â®</span>, used for <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>).</li>
<li>St. Johnâ€™s wort (<span class="Italics">Hypericum perforatum</span>), an herbal product sold as a dietary supplement, or products containing St. Johnâ€™s wort.</li>
<li>VIRAMUNE<span class="Sup">Â®</span> (nevirapine, used for <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>).</li>
</ul>
<p><span class="Bold">The following medicines are not recommended with REYATAZ:</span></p>
<ul><li>SEREVENT DISKUS<span class="Sup">Â®</span> (salmeterol) and ADVAIR<span class="Sup">Â®</span> (salmeterol with fluticasone), used to treat <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>/<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> also known as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>.</li></ul>
<p><span class="Bold">Do not take the following medicine if you are taking REYATAZ and NORVIR<span class="Sup">Â®</span> together:</span></p>
<ul class="Disc"><li>VFEND<span class="Sup">Â®</span> (voriconazole).</li></ul>
<p><span class="Bold">The following medicines may require your healthcare provider to monitor your therapy more closely (for some medicines a change in the dose or dose schedule may be needed):</span></p>
<ul class="Disc">
<li>CIALIS<span class="Sup">Â®</span> (tadalafil), LEVITRA<span class="Sup">Â®</span> (vardenafil), or VIAGRA<span class="Sup">Â®</span> (sildenafil), used to treat <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>. REYATAZ may increase the chances of serious side effects that can happen with CIALIS, LEVITRA, or VIAGRA. Do not use CIALIS, LEVITRA, or VIAGRA while you are taking REYATAZ unless your healthcare provider tells you it is okay.</li>
<li>ADCIRCA<span class="Sup">Â®</span> (tadalafil) or TRACLEER<span class="Sup">Â®</span> (bosentan), used to treat <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>.</li>
<li>LIPITOR<span class="Sup">Â®</span> (atorvastatin) or CRESTOR<span class="Sup">Â®</span> (rosuvastatin). There is an increased chance of serious side effects if you take REYATAZ with
this <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medicine.</li>
<li>Medicines for abnormal heart rhythm: CORDARONE<span class="Sup">Â®</span> (amiodarone), lidocaine, quinidine (also known as CARDIOQUIN<span class="Sup">Â®</span>, QUINIDEX<span class="Sup">Â®</span>, and others). </li>
<li>MYCOBUTIN<span class="Sup">Â®</span> (rifabutin, an antibiotic used to treat <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span>).</li>
<li>BUPRENEX<span class="Sup">Â®</span>, SUBUTEX<span class="Sup">Â®</span>, SUBOXONE<span class="Sup">Â®</span> (buprenorphine or buprenorphine/naloxone, used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and addiction to narcotic painkillers).</li>
<li>VASCOR<span class="Sup">Â®</span> (bepridil, used for <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>).</li>
<li>COUMADIN<span class="Sup">Â®</span> (warfarin).</li>
<li>Tricyclic antidepressants such as ELAVIL<span class="Sup">Â®</span> (amitriptyline), NORPRAMIN<span class="Sup">Â®</span> (desipramine), SINEQUAN<span class="Sup">Â®</span> (doxepin), SURMONTIL<span class="Sup">Â®</span> (trimipramine), TOFRANIL<span class="Sup">Â®</span> (imipramine),
or VIVACTIL<span class="Sup">Â®</span> (protriptyline).</li>
<li>Medicines to prevent organ <span class="product-label-link" type="condition" conceptid="4248020" conceptname="Graft rejection">transplant rejection</span>: SANDIMMUNE<span class="Sup">Â®</span> or NEORAL<span class="Sup">Â®</span> (cyclosporin), RAPAMUNE<span class="Sup">Â®</span> (sirolimus), or PROGRAF<span class="Sup">Â®</span> (tacrolimus). </li>
<li>The antidepressant trazodone (DESYREL<span class="Sup">Â®</span> and others).</li>
<li>Fluticasone propionate (FLONASE<span class="Sup">Â®</span>, FLOVENT<span class="Sup">Â®</span>), given by nose or inhaled to treat allergic symptoms or <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. Your doctor may choose not to keep you on fluticasone,
especially if you are also taking NORVIR<span class="Sup">Â®</span>.</li>
<li>Colchicine (COLCRYS<span class="Sup">Â®</span>), used to prevent or treat <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> or treat familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</li>
</ul>
<p><span class="Bold">The following medicines may require a change in the dose or dose schedule of either REYATAZ or the other medicine:</span></p>
<ul class="Disc">
<li>INVIRASE<span class="Sup">Â®</span> (saquinavir).</li>
<li>NORVIR<span class="Sup">Â®</span> (ritonavir).</li>
<li>SUSTIVA<span class="Sup">Â®</span> (efavirenz).</li>
<li>Antacids or buffered medicines.</li>
<li>VIDEX<span class="Sup">Â®</span> (didanosine).</li>
<li>VIREAD<span class="Sup">Â®</span> (tenofovir disoproxil fumarate).</li>
<li>MYCOBUTIN<span class="Sup">Â®</span> (rifabutin).</li>
<li>Calcium channel blockers such as CARDIZEM<span class="Sup">Â®</span> or
TIAZAC<span class="Sup">Â®</span> (diltiazem), COVERA-HS<span class="Sup">Â®</span> or
ISOPTIN SR<span class="Sup">Â®</span> (verapamil) and others.</li>
<li>BIAXIN<span class="Sup">Â®</span> (clarithromycin).</li>
<li>Medicines for <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">indigestion</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, or <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> such as AXID<span class="Sup">Â®</span> (nizatidine), PEPCID AC<span class="Sup">Â®</span> (famotidine), TAGAMET<span class="Sup">Â®</span> (cimetidine), or ZANTAC<span class="Sup">Â®</span> (ranitidine).</li>
</ul>
<p><span class="Bold">Talk to your healthcare provider about choosing an effective method of contraception.</span> REYATAZ may affect the safety and effectiveness of hormonal contraceptives such as birth control pills or the contraceptive patch. Hormonal contraceptives do not prevent the spread of HIV to others.</p>
<p><span class="Bold">Remember:</span></p>
<ol class="Arabic">
<li><span class="Bold">Know all the medicines you take.</span></li>
<li><span class="Bold">Tell your healthcare provider about all the medicines you take.</span></li>
<li><span class="Bold">Do not start a new medicine without talking to your healthcare provider.</span></li>
</ol>
<p><span class="Bold">How should I store REYATAZ?</span></p>
<ul class="Disc">
<li>Store REYATAZ Capsules at room temperature, 59Â° to 86Â° F (15Â° to 30Â° C). Do <span class="Bold">not</span> store this medicine in a damp place such as a bathroom medicine cabinet or near the kitchen sink. </li>
<li>Keep your medicine in a tightly closed container.</li>
<li>Keep all medicines out of the reach of children and pets at all times. Do not keep medicine that is out of date or that you no longer need. Dispose of unused medicines through community take-back disposal programs when available or place REYATAZ in an unrecognizable, closed container in the household trash.</li>
</ul>
<p><span class="Bold">General information about REYATAZ</span></p>
<p>This medicine was prescribed for your particular condition. Do not use REYATAZ for another condition.  Do not give REYATAZ to other people, even if they have the same symptoms you have.  It may harm them. <span class="Bold">Keep REYATAZ and all medicines out of the reach of children and pets.</span></p>
<p>This summary does not include everything there is to know about REYATAZ. Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Remember no written summary can replace careful discussion with your healthcare provider. If you would like more information, talk with your healthcare provider or you can call 1-800-321-1335.</p>
<p><span class="Bold">What are the ingredients in REYATAZ?</span></p>
<p><span class="Bold">Active Ingredient: </span> atazanavir sulfate</p>
<p><span class="Bold">Inactive Ingredients:</span> Crospovidone, lactose monohydrate (milk sugar), magnesium stearate, gelatin, FD&amp;C Blue #2, and titanium dioxide.</p>
<p>VIDEX<span class="Sup">Â®</span> and REYATAZ<span class="Sup">Â®</span> are registered trademarks of Bristol-Myers Squibb Company.  COUMADIN<span class="Sup">Â®</span> and SUSTIVA<span class="Sup">Â®</span> are registered trademarks of Bristol-Myers Squibb Pharma Company. DESYREL<span class="Sup">Â®</span> is a registered trademark of Mead Johnson and Company. Other brands listed are the trademarks of their respective owners and are not trademarks of Bristol-Myers Squibb Company. </p>
<p></p>
<p></p>
<p>Bristol-Myers Squibb Company<br>Princeton, NJ 08543  USA</p>
<p></p>
<p>1246226B0<br>Rev October 2011</p>
<p>Additional barcode labeling by:</p>
<p>Physicians Total Care, Inc.</p>
<p>Tulsa, Oklahoima  74146</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">REPRESENTATIVE PACKAGING</span></p>
<p><span>NDC 54868-4857-0<br>60 Capsules<br></span></p>
<p><span>REYATAZ<span class="Sup">Â®</span><br>(atazanavir sulfate)<br>150 mg<br></span></p>
<p><span>Rx only<br></span></p>
<p><span>Note to pharmacist: Do not cover ALERT box with pharmacy label.<br>ALERT: Find out about medicines that<br>should NOT be taken with REYATAZ<span class="Sup">Â®</span></span></p>
<div class="Figure"><img alt="REYATAZ 150-mg Capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=025876b6-f031-43ea-967a-b1d95b4685a6&amp;name=4857.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">REPRESENTATIVE PACKAGING</span></p>
<p><span>NDC 54868-5838-0<br>30 Capsules<br></span></p>
<p><span>REYATAZ<span class="Sup">Â®</span><br>(atazanavir sulfate)<br>300 mg<br></span></p>
<p><span>Rx only<br></span></p>
<p><span>Note to pharmacist: Do not cover ALERT box with pharmacy label.<br>ALERT: Find out about medicines that<br>should NOT be taken with REYATAZ<span class="Sup">Â®</span></span></p>
<div class="Figure"><img alt="REYATAZ 300-mg Capsules" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=025876b6-f031-43ea-967a-b1d95b4685a6&amp;name=5838.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REYATAZÂ 		
					</strong><br><span class="contentTableReg">atazanavir sulfate capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4857(NDC:0003-3624)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATAZANAVIR SULFATE</strong> (ATAZANAVIR) </td>
<td class="formItem">ATAZANAVIR</td>
<td class="formItem">150Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (BLUE/POWDER BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BMS;150;mg;3624</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4857-0</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021567</td>
<td class="formItem">07/16/2003</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REYATAZÂ 		
					</strong><br><span class="contentTableReg">atazanavir sulfate capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4854(NDC:0003-3631)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATAZANAVIR SULFATE</strong> (ATAZANAVIR) </td>
<td class="formItem">ATAZANAVIR</td>
<td class="formItem">200Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (BLUE/BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BMS;200;mg;3631</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4854-0</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021567</td>
<td class="formItem">07/10/2003</td>
<td class="formItem">06/30/2011</td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REYATAZÂ 		
					</strong><br><span class="contentTableReg">atazanavir sulfate capsule, gelatin coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5838(NDC:0003-3622)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ATAZANAVIR SULFATE</strong> (ATAZANAVIR) </td>
<td class="formItem">ATAZANAVIR</td>
<td class="formItem">300Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C BLUE NO. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FERRIC OXIDE RED</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong><span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">AMMONIA</span></strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>BUTYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SHELLAC</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE</td>
<td class="formLabel">Size</td>
<td class="formItem">23mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">BMS;300;mg;3622</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5838-0</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021567</td>
<td class="formItem">12/04/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e59e8cfa-c250-483e-b545-d37e1b4baf8b</div>
<div>Set id: 025876b6-f031-43ea-967a-b1d95b4685a6</div>
<div>Version: 2</div>
<div>Effective Time: 20120217</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
